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Abstract 
The work reported in this thesis aims to develop and apply new assays for high content analysis (HCA) 
based on novel automated fluorescence lifetime imaging microscopy (FLIM) technology adapted for 
multiwell plate readers and evaluate their potential for drug discovery. Two such FLIM multiwell plate 
readers were investigated, one based on a custom-modified commercially available plate reader (GE 
Healthcare In Cell 1000) and the other based on an Olympus IX-81 wide-field microscope adapted for use as 
an automated multiwell plate imaging system.  
To evaluate the potential for drug discovery, an exemplar assay of HIV-1 Gag protein aggregation was 
developed and used to evaluate the performance of the multiwell plate readers. HIV-1 Gag is the major 
structural protein within HIV-1 virions and is thought to interact with other viral proteins, the viral genome 
and with a large number of host cell factors to orchestrate the formation of new virions. HIV-1 Gag protein 
oligomerisation is a precursor to virion production at the plasma membrane of the target cell during the HIV 
virus life cycle and so represents a potential readout for testing the efficacy of anti HIV drugs. The 
expression of HIV-1 Gag alone within living cells leads to the formation of virus-like particles (VLPs), 
which provide a convenient and safe means to study this late stage of the HIV cycle. 
This exemplar assay is based on Förster Resonance Energy Transfer (FRET) between appropriately 
(fluorescently) labelled HIV-1 Gag proteins. By tagging HIV-1 Gag proteins with either a donor fluorophore 
or an acceptor fluorophore, a FRET signal can be utilised to indicate when the oligomerisation brings the 
donor and acceptor within close (<~10 nm) proximity and this can be read out and mapped using FLIM to 
observe the decrease in donor fluorescence lifetime that is a consequence of FRET. In the first instance the 
Gag proteins were stochastically labelled with either CFP or YFP and FRET was mapped by imaging the 
CFP lifetime. The assay could also be implemented by labelling the Gag protein with CFP only and detecting 
the small change in lifetime that occurs during homo-FRET of CFP. 
To evaluate and validate the assay, biological controls were developed using mutants of the Gag protein that 
lacked the ability to be myristoylated, a pre-requisite for the Gag protein to assemble at the cell plasma 
membrane where the VLP are formed. Comparisons were made using both myristoylated (WT) and non- 
myristoylated (mutated) HIV-1 Gag proteins to demonstrate each plate reader‘s ability to read out levels of 
HIV-1 Gag protein aggregation.  
To further characterise the performance of the assay and the plate readers, a dose response study was 
undertaken using an inhibitor of the enzyme responsible for myristoylation in eukaryotic cells and the assay 
was fully characterised following standard pharmaceutical industry guidelines. Accounting for experimental 
factors such as pipetting errors, plate edge effects, spatial uniformity and drift over time, these 
characterisations and dose response studies yielded Z‘ factors to reflect the practical quality of the assays and 
thereby provided a robust means to compare different approaches, including different labelling strategies 
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(e.g. hetero-FRET v. homo-FRET), imaging strategies (e.g. wide-field v. optically sectioned) and data 
analysis strategies (e.g. fitting models, image segmentation). To my knowledge this represents the first such 
robust and systematic evaluation of FLIM assays, e.g. using Z‘ from dose response curves, and is therefore 
of value to the pharmaceutical industry and other potential users of FLIM HCA. 
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Figure 2.1: Jabloński Diagram showing the processes associated with fluorescence and 
phosphorescence. Here the ground state is denoted S0 and the first excited singlet 
and triplet states are denoted S1 and T1 respectively. Each level also illustrates the 
vibrational levels, denoted 0,1,2. Rotational levels reside within these vibrational 
levels (not shown). Transitions between all of these finely spaced levels result in the 
observed broad absorption/emission curves. 
Figure 2.2: Example absorption and emission spectra illustrating stokes shift and mirror image 
concepts 
Figure 2.3: (a) Primary antibody labelling; (b) Secondary antibody labelling. 
Figure 2.4: Crystal structure of the Aequorea Victoria green fluorescent protein [8]. 
Figure 2.5: Inverted epifluorescence microscope, with illumination pathway in blue and detection 
pathway in green. 
Figure 2.6: Confocal microscope. The sample is illuminated by a point of laser light (blue rays) and 
imaged onto a point detector (green rays). Light from out of focus planes (red rays) is 
block from reaching the detector by inserting a detection pinhole in front of the PMT. 
Figure 2.7: (a) Jabloński diagram illustrating excitation using one-, two-, and three-photon 
absorption; (b) Schematic comparison of one photon (top) and two photon absorption 
(bottom).Adapted from [1]. 
Figure 2.8: Frequency domain FLIM. The sample is excited by a modulated light source and the 
lifetime may then be extracted by measurement of the induced phase and the change in 
modulation depth 
Figure 2.9: TCSPC schematic set up (Stop-Start) 
Figure 2.10: Time-gated widefield FLIM schematic 
Figure 2.11: Simplified time gating scheme. After excitation with short pulse of light (blue), the 
intensities in gates 1 and 2 are measured and used to determine the lifetime. 
Figure 2.12: Time gated, time domain FLIM where a short excitation pulse (blue) is used and the 
resultant fluorescence decay (purple) is sampled at different delay points after excitation 
(green time gates). 
Figure 2.13: Förster Resonance Energy Transfer between donor and acceptor 
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Figure 2.14: (a) Angles involved in the determination of the κ2 value; (b) example values of κ2 where 
D represents the donor and A represents the acceptor. Adapted from [4]. 
Figure 2.15: FRET efficiency curve as a function of donor-acceptor distance (R) for arbitrary 
value of R0. 
Figure 2.16: Intramolecular FRET. Attachment of a FRET pair to a chemically sensitive protein linker 
allows the user to monitor protein activation or ligand binding through changes in FRET 
Figure 2.17: Intermolecular FRET. Attachment of donor and acceptor fluorophores to separate 
proteins of interest allows the user to monitor protein-protein interactions through 
changes in FRET 
Figure 2.18: Concept of sensitised emission. FRET is measured as a decrease in donor intensity and a 
corresponding increase in acceptor intensity. 
Figure 2.19:  Example fluorescence lifetime decays in the presence (green) and absence (purple) of 
FRET. 
Figure 3.1: Schematic representation of a mature HIV virion. 
Figure 3.2: Schematic representation of the linear organisation of HIV-1 Gag protein. Myristoylated 
matrix (MA), Capsid (CA), nucleocapsid (NC) and p6 domains are indicated along with 
spacer proteins 1 and 2 (SP1 and SP2). 
Figure 3.3: Viral maturation. The viral protease cleaves the Gag protein into it‘s constituent parts 
leading to a morphological change and resulting in the virion becoming fully infectious. 
Figure 3.4: (a) Myristic moiety is sequestered within the MA region of Gag and PI(4,5)P2 is found 
embedded in the inner leaflet of the plasma membrane: (b) Upon membrane binding, the 
myristic acid moiety is inserted into the plasma membrane and the 2‘ chain of PI(4,5)P2 
is sequestered within the MA domain of Gag. 
Figure 4.1: Schematic of the yeast two-hybrid screening system. (a)Binding domain (BD) and 
activating domain (AD) of transcription factor in their natural state bind to upstream 
activating sequence leading to transcription of the fluorescent reporter gene; (b) Protein 1 
(P1) and Protein 2 (P2) are connected to BD and AD respectively. If P1 and P2 interact, 
the reporter gene is transcribed and the resultant fluorescence is read out. 
Figure 4.2: Schematic of LANCE TR-FRET assay (adapted from [174]). B: Biotin; E: Europium; P: 
Phosphate group; SA: Streptavidin. 
Figure 4.3: Schematic of automated FLIM plate reader. FSCS: Fianium supercontinuum source; FW: 
Filter wheel; PD: Photodiode; GOI: Gated optical intensifier. 
Figure 4.4: Schematic diagram illustrating the workings of a Nipkow disk. (a) the pinholes within the 
Nipkow disk are arranged in a series of nested Archimedean spirals (here only three such 
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spirals are shown for clarity); (b) a zoomed in area from the Nipkow disk illustrating how 
the pinholes rotate from the current position (green) to the new position (purple) as the 
disk spins. 
Figure 4.5: The microlens array placed before the pinhole array focuses the collimated excitation 
light through pinholes. The fluorescence emission passes back through the pinhole array 
and is separated from the excitation light through use of a dichroic mirror place in 
between the microlens and the pinhole arrays. 
Figure 4.6: Schematic diagram of gated optical intensifier. Fluorescence photons are converted to 
photoelectrons at the photocathode and accelerated into the micro-channel plate (MCP) 
upon application of a negative voltage to the photocathode (gating voltage). These 
photoelectrons are amplified within the MCP and converted back to photons at the 
phosphor screen. 
Figure 4.7: Typical arrangement of time gates for time-gated FLIM experiments 
Figure 4.8: Optimisation plating scheme. (a) number of HeLa cells seeded per well; (b) total amount 
of DNA applied per well; (c) DNA to Lipid ratio, with white squares on the bottom row 
being lipid only toxicity test. 
Figure 4.9: Schematic illustrating the differences between: (a) aggregating wild type HIV-1 Gag 
proteins and (b) non-aggregating Myr(-)Gag proteins. 
Figure 4.10: (a) Background image of well containing PBS with laser illumination off taken at the 
peak of the fluorescence decay; (b) same well as (a) with laser illumination on taken 6 ns 
from the peak of the fluorescence decay; (c) same well as (a) with laser illumination on 
taken at the peak of the fluorescence decay; (d) Sample image from the same plate taken 
at the peak of fluorescence decay. Colour scale indicates intensity from 193 to 4095. 
Figure 4.11: (a) Plot illustrating signal (purple), background (green) and signal to background ratio 
(grey) for 16 cells selected from 4 plates; (b) example FOV used in signal to background 
calculations, where scale indicates signal to background ratio. (Scale runs from 0, 
black/blue to 18, white.) 
Figure 4.12: Schematic set up of single exponential decay simulation. Green area indicated the time 
varying background region and purple area indicates the signal region. The simulation 
adds together the fluorescence decays of the overlapping areas. 
Figure 4.13: Normalised histograms illustrating the effects of a background contribution to the fitted 
fluorescence lifetime and how the use of a measured TVB can correct the fitted lifetimes 
for (a)2.5% TVB contribution; (b) 5% TVB contribution; (c) 10% TVB contribution and 
(d) 20% TVB contribution. In all cases, the black curve shows the lifetime histogram for 
a single exponential decay containing no time varying background, the blue curve shows 
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the lifetime histogram when a time varying background component is present but not 
accounted for and the red curve shows the same region when the TVB correction is used. 
Figure 4.14: Schematic set up of the multi-exponential decay simulations.(a)The two component 
simulation; Green area (region 1)indicated the time varying background region and purple 
area (region2) indicates the signal region. The simulation adds together the fluorescence 
decays of the overlapping area in region 3. (b) The four component simulation; Green 
area indicated the time varying background region (region 1). Region 2 contains a 
exponential decay with four components and region 3 contains an exponential with the 
same four components as region 2 added to the TVB from region 1. 
Figure 4.15: Normalised histograms illustrating the effects of a background contribution to the fitted 
fluorescence lifetime and how the use of a measured TVB can correct the fitted lifetimes 
for (a) a two component exponential decay containing 5% TVB contribution; (b) a four 
component exponential decay containing 5% TVB contribution; In all cases, the black 
curve shows the lifetime histogram for a single exponential decay containing no time 
varying background, the blue curve shows the lifetime histogram when a time varying 
background component is present but not accounted for and the red curve shows the same 
region (as the red curve) when the TVB correction is used. 
Figure 4.16: (a) Plating scheme for plate containing HeLa cell control samples transfected with 
varying combinations of fluorescently tagged Myr(-)Gag and wild-type Gag;(b) 
Fluorescence lifetime platemap showing the average lifetime value per well resultant 
from fitting a single exponential decay model, pixel-wise, across all four repeat FOV 
within each well. Colour scale ranges from 2000 ps (blue) to 3200 ps (red). 
Figure 4.17: (a) FLIM image of FOV containing HeLa cells transfected with Myr(-)Gag-CFP; (b) FLIM 
image of FOV containing cells transfected with Gag-CFP; (c) composite fluorescence 
lifetime histograms (from all pixels above the set intensity threshold, from all four FOV, 
across all repeat wells) for each plasmid preparation in the control plate (see plate map in 
Figure 4.16). 
Figure 4.18: Arrangement of Gag protein lattice within VLPs 
Figure 4.19: Comparison of different image segmentation methods. (a) Application of simple intensity 
threshold vs application of cell segmentation algorithm to select whole cells; (b) whole 
cell segmentation fitted either pixel wise or by binning all pixels to a single decay for 
each cell; (c) binning all pixels to a single decay for either the whole cell, or just the cell 
plasma membrane; (d) a comparison of approaches outlined in (a-c).In all cases, error 
bars show the standard deviation between the eight repeat wells. 
Figure 4.20: Example field of view from cells expressing Gag-CFP, either with (a) application of an 
intensity threshold; (b) application of image segmentation. The white box on both (a) and 
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(b) indicates an example region which is selected for analysis when an intensity threshold 
is applied, but not selected when image segmentation is applied. Areas selected for fitting 
are shown in red. 
Figure 4.21: (a) Example of image segmentation algorithm selecting cell membrane regions; (b) box 
plots showing average lifetime ( SD) for each plasmid combination. 
Figure 4.22: Comparison between two control plates. (a) Plate 1, as described previously (Section 4.5); 
(b) Plate 2, control plate containing HeLa cells transfected with Myr(-)Gag-CFP (column 4,) 
Myr(-)Gag-CFP + Myr(-)Gag-YFP (columns 6 & 7), Gag-CFP (columns 8 & 9) and Gag-CFP 
+ Gag-YFP (columns 10 & 11). No cells were transfected in column 5. In both cases the 
colour scale runs from 2000 ps (blue) to 3200 ps (red). 
Figure 4.23: Comparison of the mean lifetimes ( standard deviation between repeat wells) per 
condition for the four positive and negative control plasmids. 
Figure 5.1: Schematic representation of the NMT catalytic cycle (adapted from [195]). 
Figure 5.2: Matrix domain. (a) top view of MA. (b) side view of MA showing association with 
plasma membrane [198] 
Figure 5.3: Chemical structure of NMT inhibitor DDD85646 
Figure 5.4: Emission spectra of PBS and 10 µM NMT inhibitor DD85646 
Figure 5.5: (a) Lifetime platemap of HeLa cells transfected with Myr(-)Gag-CFP and incubated with 
either 10 µM (column 1), 1 µM(column 2), 0.1 µM (column 3) or non-treated control 
(column 4); (b) Mean lifetimes ( Standard deviation between wells) for each column 
shown in (a) N.B. due to plotting on a semi-log scale, the non-treated control is shown as 
a 1 x 10-4 µM dose, rather than 0. 
Figure 5.6: Plating scheme for hetero-FRET assay characterization. HeLa cells were plated as shown, 
transfected with Gag-CFP + Gag-YFP and incubated with either 2 μM, 0.2 μM or 0.02 
μM inhibitor. 
Figure 5.7: Plate variability and signal uniformity assessment. (a) & (b) plate map of mean well 
lifetimes (averaged over 4 FOV per well) from pixel-wise fitting to single exponential 
decay model and mean lifetimes plotted column-wise for each condition and row-wise for 
each condition for plate 1. (c) & (d) plate map and mean lifetime plots (column-wise and 
row-wise) for plate 2. (e) & (f) plate map and mean lifetime plots (column-wise and row-
wise) for plate 3. White wells indicate that no cells were found by the auto find routine. 
Wells D6 and D7 were used for background and IRF. Error bars refer to standard 
deviations between repeat wells for each column or row. 
Figure 5.8: (a), (c) & (e) mean well lifetimes (averaged over 4 FOV per well) from pixel-wise fitting 
to single exponential decay model plotted per condition column-wise for plates 1, 2 and 
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3; (b), (d) & (f) mean well lifetimes (averaged over 4 FOV per well) from pixel-wise 
fitting to single exponential decay model plotted per condition row-wise for plates 1, 2 
and 3. 
Figure 5.9: Plate variability and signal uniformity assessment. Plate variation between replicate plates 
described previously (section 5.3.3). Error bars represent the standard deviation between 
all repeat wells for a particular condition. 
Figure 5.10: An ideal dose response curve where purple points represent data and green points 
represent the control measurements. Here the positive and negative control measurements 
are shown at 2 and -4 on a log scale. This is for display purposes only. Typically these 
measurements are taken using a positive control for inhibition and vehicle only (i.e. no 
inhibitor) respectively. 
Figure 5.11: Defining the difference between relative and absolute IC50 values. An example of a partial 
inhibitor where the purple points represent the data and the green points represent the 
measured controls. 
Figure 5.12: (a) plating scheme for dose response. Top half of plate (purple) was used for the homo-
FRET assay and bottom half of the plate (green) was used for the hetero-FRET assay. 
Positive controls for both assays were plated in column 1 and negative controls for both 
assay were plated in column 11. The dose range spanned from 0.001 µM (column 10) up 
to 10 µM (column 2), as indicated; (b) fluorescence lifetime plate map showing the mean 
lifetime value per well when averaged over all pixels above the intensity threshold and 
across all four repeat FOV within each well, scale runs from 2000 ps (blue) to 3000 ps 
(red); (c) Extracted dose response curves obtained from taking the average of the four 
repeat wells and standard deviation between repeat wells for each dose condition. Purple 
points represent data from the homo-FRET assay and green points represent data from the 
hetero-FRET assay. Data was fitted with a four parameter logistic model in Origin 8.5; 
(d) Same data as part (c) shown plotted as a percentage relative to the highest and lowest 
dosed wells. 
Figure 5.13: Comparison of 4 parameter logistic fit (Black) vs a 3 parameter logistic fit (red, p=1) for 
data shown in Figure 5.12. Error bars show standard deviation between the four repeat 
wells for each condition. 
Figure 5.14:  Comparison of dose response curves with and without the application of plasma 
membrane segmentation. Purple points show Gag-CFP with an intensity threshold 
applied. Green points show Gag-CFP data with membrane segmentation applied. Orange 
points show Gag-CFP + Gag-YFP data with an intensity threshold applied. Blue points 
show Gag-CFP + Gag-YFP data with membrane segmentation applied. All data is shown 
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with error bars representing the standard deviation between repeat wells and a 
corresponding three parameter logistic fit (red lines). 
Figure 6.1: Testing different NMT inhibitors. (a) Fluorescence lifetime plate map showing average 
lifetime per well when averaged over 8 repeat FOVs. Column 1 contains HeLa cells 
transfected with Myr(-)Gag-CFP as a positive control for inhibition. Column 11 contains 
vehicle only Gag-CFP transfected HeLa cells as a negative control for inhibition. Dashed 
coloured squares indicate the four different inhibitors used from high dose column 2 to 
low dose column 10, scale runs from 2200 ps (blue) to 3100 ps (red). (b) Plots of 
percentage inhibition for each inhibitor relative to the average 10 μM dose of ICL13, 15 
and 16 and the and negative control column (column11). Points in black at 2 and -4 on 
the horizontal axis are the positive and negative control points respectively. Error bars 
refer to the standard deviation between the 16 repeat FOVs. 
Figure 6.2: Fluorescence lifetime plate maps for the NMT inhibitor screen of HeLa cells transfected 
with Myr(-)Gag-CFP (Column 1) and Gag-CFP (columns 2-11) obtained from a single 
exponential fit for (a) 1 FOV per well; (b) 2 FOV per well & (c) 7 FOV per well; (d) the 
effects observed when different numbers of FOV were used when processing the data. 
The purple points indicate the Myr(-)Gag-CFP positive controls (column 1 in (a), (b) & (c)), 
the green points indicate the Gag-CFP negative controls (column 11 in (a), (b) & (c)) with 
the values being shown on the left hand (purple) axis and the error bars displaying the 
standard deviation between repeat wells. The blue points indicate the calculated Z‘ values 
for each plate, with the values shown on the right hand (blue) axis. 
Figure 6.3: NMT inhibitor screen performed with (a) widefield illumination and (b) Nipkow disk 
based optical sectioning. 
Figure 6.4: Dose response curves showing the differences observed between widefield illumination 
(green) and Nipkow disk based illumination (purple) for four NMT inhibitors; (a) ICL13; 
(b)ICL14; (c)ICL15; (d) ICL16.Error bars refer to the standard deviation between repeat 
wells. 
Figure 6.5: (a) Fluorescence lifetime plate map showing the average fluorescence lifetime over 8 
repeat FOVs per well for HeLa cells transfected with varying (1:1 to 1:7) ratios of Gag-
CFP to Gag-YFP; (b) Mean lifetime ( SD between wells) of varying ratios of Gag-CFP 
to Gag-YFP taken from (a). 
Figure 6.6: (a) Fluorescence intensity of three different DMEM preparations and PBS control; (b) 
Zoomed in region of (a) corresponding to the emission filter used in imaging experiments 
(483/35 nm, blue box in (a)). 
Figure 6.7: (a) Intensity image of well containing DMEM media used for live cell assay, yellow 
region indicates area of measurement; (b) intensity image of cells containing 
xviii 
 
Myr(-)Gag-CFP from live cell assay plate. Region 1 indicates background measurement 
from plate and region 2 indicates measurement of cell intensity. In both parts (a) and (b) 
scale runs from 193 DN to 4095 DN. 
Figure 6.8: Live cell Gag aggregation assay within HeLa cells. (a) Plating scheme for dose response. 
The top half of plate (purple) was used for the homo-FRET assay (Gag-CFP) and the 
bottom half of the plate (green) was used for the hetero-FRET assay (Gag-CFP + 
Gag-YFP). Positive controls for both assays were plated in column 1 and negative 
controls for both assay were plated in column 11. The dose range spanned from 0.001 µM 
(column 10) up to 10 µM (column 2); (b) Fluorescence lifetime plate map showing the 
mean lifetime value per well when averaged over all pixels above the intensity threshold 
and across all 8 repeat FOV within each well. Scale runs from 1200 ps (blue) to 2200 ps 
(red). 
Figure 6.9: Live cell assay dose response fits from the data outlined in Figure 6.8. Purple data points 
represent the homo-FRET assay and green points represent the hetero-FRET assay, with 
3PL fits shown in red and 4PL fits shown in black. Error bars show standard deviation 
between repeat wells. 
Figure 6.10: Population histograms for (a) Homo-FRET and (b) Hetero-FRET assays. Each cell 
membrane was segmented and individually fitted to a single exponential decay model to 
result in a single fluorescence lifetime per cell membrane. The purple overlay indicates 
the approximate distribution of the negative control data from the homo-FRET assay in 
(a), an identical region is shown on (b), highlighting the effects of the unknown 
stoichiometry of the hetero-FRET assay. 
Figure 6.11: Fluorescence lifetime plate maps for the HIV-1 Gag aggregation assay showing the mean 
lifetime value per well when averaged over all pixels above the intensity threshold and 
across all four repeat FOV within each well for (a) Modified InCell 1000; (b) IX-81 Plate 
reading microscope. In both (a) and (b) 4 FOV were acquired per well with the top half of 
each plate being used for the homo-FRET assay and bottom half of the plate being used 
for the hetero-FRET assay. Positive controls for both assays were plated in column 1 and 
negative controls for both assays were plated in column 11. The dose range spanned from 
0.001 µM (column 10) up to 10 µM (column 2), scale runs from 2200 ps (blue) to 
3000 ps (red). 
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Chapter 1: Thesis Outline 
This thesis describes the development, testing and application of an automated fluorescence lifetime imaging 
(FLIM) plate reader and aims to showcase the potential of such automated microscope technology for both 
drug discovery/development and basic research. The FLIM plate reader was applied to an exemplar FRET 
assay that was developed for this project and was based on the aggregation of human immunodeficiency 
virus type 1 (HIV-1) Gag proteins. This assay was used to investigate the performance of the FLIM plate 
reader in three distinct stages: firstly, to explore the extent and robustness of differences between the 
fluorescence lifetimes of positive and negative control samples measured using the FLIM plate reader; 
secondly, to investigate the action of an inhibitor of Gag protein aggregation and characterise the 
performance of this FLIM-based assay following standardised pharmaceutical guidelines and thirdly, to 
demonstrate further applications of the HIV-1 Gag aggregation FLIM assay including extending its use to 
live cells and to ―screening‖ multiple inhibitors.  
The initial two chapters aim to introduce the topics of fluorescence microscopy and HIV-1 Gag protein 
aggregation. Chapter 2 outlines the basic principles of fluorescence metrology, introducing the underlying 
physics of fluorescence, describing the various approaches to quantitative fluorescence microscopy and 
discussing the theoretical background and practical implementations of Förster resonant energy transfer 
(FRET) measurements. Chapter 3 discusses HIV-1 with a specific emphasis placed on the HIV-1 Gag 
protein, around which the exemplar FLIM assay was developed. The constituent parts of the Gag protein are 
described and the mechanism of the interaction of the Gag protein with the cell plasma membrane — 
paramount for the formation of higher order aggregates — is highlighted. Current and potential future drug 
targets are outlined along with the practical issues of investigating Gag protein interactions and an overview 
of previous work utilising fluorescence microscopy, particularly with FRET readouts is given.  
Chapter 4 describes the automated FLIM plate reader and its ability to discriminate differences in the 
fluorescence lifetime of the positive and negative control samples for the HIV-1 assay. The various 
components of the FLIM plate reader are discussed and the development of a reproducible assay protocol is 
described with measurements made on a plate containing control samples. Chapter 5 then extends the 
groundwork of chapter 4 by exploring the perturbation of the aggregation of the Gag proteins through 
addition of an inhibitor. An assay of Gag protein aggregation is described and is characterised following 
standardised assay development protocols to ensure reproducibility and robustness. The generation of dose 
response curves using a known inhibitor of Gag protein aggregation is then reported along with an 
investigation of the relative merits of different fitting and segmentation methods.  
Chapter 6 further extends this work, encompassing the application of this assay to live cells, the evaluation 
of its ability to discriminate inhibitors of different potencies, a study of the optimum donor -acceptor 
expression ratio for this assay, an investigation of different illumination methods and a comparison of two 
different FLIM plate readers. Finally, Chapter 7 concludes the thesis, summarising the experiments 
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performed and presenting conclusions regarding the major results presented. Additionally, future directions 
of possible research based upon the results of this thesis are explored and discussed.  
  
3 
 
Chapter 2: Introduction to fluorescence 
microscopy 
This chapter introduces the basic concepts of fluorescence, specifically its use in conjunction with different 
microscopy techniques. The process of Förster resonance energy transfer (FRET) is introduced and a 
selection of techniques to monitor changes in FRET are discussed. Topics covered include: 
 Physical properties of fluorescence 
 Fluorescent probes 
 Common fluorescence microscopy techniques and methods of imaging 
 FRET; in theory and practice 
2.1. Fluorescence and phosphorescence 
Fluorescence refers to a process whereby a photon is emitted following the relaxation of a molecular (or 
atomic) orbital electron from a higher to lower energy level of the same angular momentum i.e. singlet to 
singlet or triplet to triplet. There are a large number of processes involved in fluorescence which may be 
visualised through use of a Jabloński diagram (Figure 2.1).  
 
Figure 2.1: Jabloński Diagram showing the processes associated with fluorescence and 
phosphorescence. Here the ground state is denoted S0 and the first excited singlet and triplet states are 
denoted S1 and T1 respectively. Each level also illustrates the vibrational levels, denoted 0,1,2. Rotational 
levels reside within these vibrational levels (not shown). Transitions between all of these finely spaced 
levels result in the observed broad absorption/emission curves. 
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The Jabloński diagram shows a simplified view of the different energy levels within an atom or molecule. 
The levels S0, S1, and S2 represent the ground, first and second excited singlet states respectively and the 
level T1 represents the first excited triplet state. Within each available electronic level resides vibrational and 
rotational sub-levels. For simplicity, only the first three (0,1,2) vibrational levels are shown for each 
electronic level.  
From Boltzmann statistics, at standard room temperature and pressure it can be considered that almost all 
molecules will be found in the ground state. Upon absorption of a photon whose energy is greater than or 
equal to the size of the energy gap, a valence electron from the electronic ground state (S0) is pushed into a 
higher energy level, creating an excited state (Sn) [1]. 
Once excited, the fluorophore will then rapidly relax to the lowest vibrational level within the S1 level on a 
picosecond time scale, a process known as internal conversion. The rate of internal conversion generally 
increases as the separation of the energy levels decreases. This is due to the increase in the overlap of the 
vibrational wavefunctions as described by the Frank Condon factors for vibrational transitions. Higher 
energy levels tend to be more closely spaced, which results in the rapid de-excitation to the S1 level. 
However, the energy gap between the S1 and S0 levels is larger and as such, it is from the lowest vibrational 
level of the S1state that fluorescence typically originates (Kasha‘s rule). 
Once the electron is within the lowest vibrational level of the S1 excited state it may give up its remaining 
energy by a number of possible means. One route is through the emission of a photon — a process termed 
fluorescence — of a longer wavelength (relative to the excitation wavelength) due to the loss of energy 
involved in internal conversion. This difference between excitation and emission wavelengths is referred to 
as the Stokes shift. Alternatively, various quenching mechanisms may come into play, for example, 
collisions with surrounding molecules, leading to a non-radiative release of energy and transfer back to the 
ground state. Finally, the excited electron may undergo spin conversion (i.e. a flip in spin from -1/2 to +1/2 
or vice versa) and populate a triplet state, a process known as intersystem crossing. Radiative transfer from 
an excited triplet to the ground state is known as phosphorescence. For de-excitation to occur from a triplet 
state, it requires the electron to undergo spin conversion which is a slow process, and thus phosphorescence 
occurs on a timescale of seconds to microseconds compared to the typical fluorescence timescale of a few 
nanoseconds. 
2.2. Useful properties of fluorescence 
There are a number of properties of fluorescence that can be measured including the intensity, wavelength 
and lifetime. Each one of these properties is dependent on the underlying electronic configuration of the 
atom or molecule which may be perturbed by changes in the local environment. Therefore, through 
measurement of one (or more) of the properties of fluorescence it is possible to probe the local environment 
of the fluorescent species. 
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2.2.1. Intensity and quantum yield 
The fluorescence intensity (I) refers to the number of emitted photons, in essence, how bright the sample is. 
As such it is inherently linked to the quantum yield () of the sample under investigation. The quantum yield 
is a relative measure of the efficiency with which a given sample emits fluorescence photons. It is defined as 
the ratio of emitted (Ne) to absorbed (Na) photons, which may also be expressed in terms of radiative (Γ) and 
non-radiative (knr) decay rates as shown below: 
 
    
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The non-radiative decay rates include (but are not limited to) the rate of intersystem crossing and internal 
conversion described above. Measurements of fluorescence intensity are the most common form of 
measurement made on fluorescence microscopes, however, as generally the concentration of the fluorophore 
is unknown, problems can occur when attempting to make quantitative measurements. Intensity based 
measurements are also sensitive to the effects of scattering and absorption of both excitation light and 
emitted fluorescence as well as background signal.  
2.2.2. Absorption and emission spectra 
The wavelength of the emitted fluorescence will depend directly on the energy gap between the initial and 
final energy levels as described by Plank‘s law: 
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As many rotational and vibrational levels reside within each electronic level, excitation from the ground state 
may occur to a number of excited levels, leading to a spread of allowed energies and consequently, a broad 
fluorescence absorption spectra typically a few 10 s of nm wide. Conversely, emission occurs from the 
lowest vibrational level of the S1 state (Kasha‘s rule, as discussed previously) to one of a number of 
vibrational levels within the ground state yielding the emission spectra. In many fluorophores the rotational 
and vibrational levels are the same in the ground and excited (S1) states and so the measured spectra are often 
mirror images of each other (Figure 2.2). 
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Figure 2.2: Example absorption and emission spectra illustrating stokes shift and mirror image concepts  
It can be generally said that fluorescence emission occurs at longer wavelengths than the wavelength used 
for excitation, with the shift in wavelength known as the ‗Stokes shift‘. Stokes shifts in emission occur due to 
the internal relaxation to the lowest vibrational energy level prior to fluorescence emission, leading to a 
lower energy and hence, longer wavelength of emission. The Stokes shift of fluorophores is crucial for 
fluorescence imaging to be possible, enabling the separation of excitation light from emitted fluorescence. 
The magnitude of the Stokes shift may also be used to make measurements of local fluorophore environment 
for example, probing the solvent polarity [2]. 
2.2.3. Fluorescence lifetime 
The fluorescence lifetime defines the average time a molecule spends in an excited state, prior to decaying 
back to the ground state. This excited state lifetime is governed by the reciprocal of the sum of rates that 
depopulate it (equation 2-3). 
 
 
Here Γ is the radiative decay rate and knr is the non-radiative decay rate, which in turn is given by the sum of 
rate constants for internal conversion, kic, and intersystem crossing to the triplet state kisc, and if there is 
quenching due to interactions with other molecules kq[q], where [q] is the concentration of quenchers [3] so 
that in total the non-radiative decay rate is given by equation 2-4. 
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Considering a single fluorescent species which has undergone excitation via a -function pulse of light, the 
population of the excited state has a decay rate given by the sum of radiative () and non-radiative (knr) 
decay rates [4]. The excited state population will then decay according to equation 2-5. 
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Where n(t) is the number of molecules in the excited state at a time t. The population of the excited state is 
proportional to the rate of photon emission and hence, the observed fluorescence intensity. The intensity of 
fluorescence emitted from this population of fluorophores will decay exponentially over time from its initial 
intensity of I0 to the value I(t) at time t (equation 2-6). 
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From this equation the fluorescence lifetime may also be said to be the time it takes the emitted fluorescence 
intensity to decay to 1/e of its original value (I0). The text above describes a single exponential decay 
process. In practice however, samples may exhibit multi-exponential decay profiles. Where this is the case, 
typically a linear sum of exponentials is used to fit the data. In this multi-exponential case, each decay 
constant, τi, has its own pre-exponential amplitude, ai. The pre-exponential amplitudes represent the fractional 
contribution of each decay constant to the total decay profile and are normalised to be equal to the initial 
intensity I0. The intensity profile of a sample with N species follows a multi-exponential decay given by 
equation 2-7.  
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Once a multi-exponential decay has been recorded and the values of the different lifetime (τi) and 
pre-exponential factors (ai) have been determined, it is often desirable to report a single value to describe the 
decay. This typically takes the form of the weighted mean fluorescence lifetime defined by equation 2-8. 
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As the fluorescence lifetime is an inherently ratiometric quantity, determined by the intensity decay over 
time and not by the absolute intensity value, it is less susceptible to artefacts introduced by varying 
fluorophore concentrations, sample heterogeneity or fluctuations in the power of the excitation source [1]. 
2.3. Fluorescent probes 
As changes in the molecular environment alter the observed fluorescence properties outlined above, 
fluorescence has the ability to report on molecular interactions and local microenvironments. Available 
fluorophores consist of those termed to be endogenous (naturally occurring within the sample) and those 
termed to be exogenous (artificially introduced to the sample as a means of generating contrast). Most 
molecules are able to fluoresce, however, the energy gap between the S0 and S1 states for these molecules is 
usually large, which necessitates the use of high energy photons (UV wavelengths) that are not always 
desirable for biological applications due to the associated photo-toxicity effects.  
The sharing of ‗delocalised‘ electrons between atoms in some molecules results in the energy gap between 
the S0 and S1 states being lowered to a level where excitation and emission occur within the visible range of 
the electromagnetic spectrum. Therefore, most fluorophores used within biological/biomedical imaging 
experiments contain a number of aromatic ring structures that allow for a large number of delocalised 
electrons. What follows is a brief review of some of the most common methods of exogenous labelling 
techniques used in biological imaging. 
2.3.1. Fluorescent dyes 
Fluorescent dye molecules have been used in biology and medicine since the 19th century in the form of 
fluorescent stains — still widely used, particularly within the field of histology — but it was not until the 
advent of antibody labelling in 1942 that these dyes were able to be targeted to specific proteins of interest 
through conjugating them to antibodies [5]. This use of antibodies forms the basis of the technique of 
immunofluorescence microscopy which is still widely used today in two basic forms. Firstly, primary 
(direct) antibody labelling uses a dye molecule that is directly attached to an antibody. This antibody is then 
introduced to the cell where it recognises and binds to its target antigen, thus enabling localisation of the 
protein of interest by visualising the fluorescence signal from the conjugated dye. Alternatively, secondary 
(indirect) antibody labelling employs two antibodies. The first recognises the antigen of interest and binds to 
it as with primary labelling. Then, a secondary antibody is introduced which is conjugated to a fluorescent 
dye and recognises the primary antibody. The decision to use either primary or secondary labelling depends 
on the situation at hand. Primary labelling is simpler and more specific and the antibody directly binds to the 
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target of interest, however secondary labelling allows for multiple labelled secondary antibodies to bind to 
the primary antibody, thus providing signal amplification as shown in Figure 2.3.  
 
Figure 2.3: (a) Primary antibody labelling; (b) Secondary antibody labelling. 
In both cases, if the target proteins are not located on the cell surface, antibody labelling can only be 
performed in fixed (and therefore, dead) cells whose plasma membranes have been permeablised though 
exposure to an appropriate detergent, as the antibodies are too large to enter living cells. Also, non-specific 
labelling or background fluorescence may also occur, particularly when multiple labelling steps are used. 
2.3.2. Genetically expressed fluorescent proteins 
To avoid multiple labelling steps and achieve 100% specific labelling, recombinant proteins containing 
fluorescent domains derived from the green fluorescent protein (GFP) can be used. In this way, when the 
protein of interest is transcribed, the fluorescent protein tag is also transcribed leading to fluorescently 
labelled proteins of interest in live cells. 
The gene that encodes GFP was first isolated and cloned from the jellyfish Aequorea Victoria in 1992 [6] 
and subsequently its potential use as a fluorescent tag for in vivo labelling was demonstrated in 1994 [7]. 
GFP, and the proteins derived from it, allow for fully genetically encoded labelling of proteins of interest 
providing the ability for direct visualisation of interactions in living cells and whole organisms.  
(a) (b)
Antigen
Primary Antibody
Secondary Antibody
Fluorescent label
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Figure 2.4: Crystal structure of the Aequorea Victoria green fluorescent protein [8]. 
GFP and its derivatives are formed of ~220-240 amino acids that fold and mature to form a beta barrel 
formed of 11 beta sheets, inside which resides the chromophore helix (~27 kDa in total). Within the native 
form of GFP the chromophore is formed from residues 65-67 (Ser-Thy-Gly) [9]. The currently accepted 
mechanism of chromophore maturation is that the GFP folds into a nearly native organisation, then 
nucleophilic attack of the amide of Gly67 on the carbonyl of residue 65 forms the imidazolinone which is 
then dehydrated. Finally molecular oxygen causes dehydrogenation of the a-β bond of residue 66 leading to 
the aromatic group being placed in conjunction with the imidazolinone. Once this is achieved, the 
chromophore is then able to fluoresce [9]. 
Since the initial work to clone and express native GFP within live cells, a body of research has concentrated 
on improving its fluorescent properties, increasing the quantum yield [10], [11] and improving its folding 
efficiency [12], with the resultant protein being called enhanced green fluorescent protein (EGFP). 
Once this was achieved, work began on generating spectrally distinct varieties of EGFP. It was established 
that substitution of the Tyr66 of the GFP chromophore with either phenylalanine (Phe), histidine (His) or 
tryptophan (Trp) results in a blue shifted chromophore. Use of Phe at position 66 results in the shortest 
wavelength GFP like fluorescent protein (Sirius) [13], an ultraviolet FP with its excitation peak at 355 nm 
and emission occurring at 424 nm. If instead a His is inserted at position 66 it results in the range of blue 
fluorescent proteins, EBFP [14], SBFP2 [15] and EBFP2[16], with excitation/emission wavelengths of 
around 383/448 nm. Finally, most cyan FPs are derived from GFP through switching the Tyr66 for Trp66 
resulting in excitation occurring around 435 nm and emission around 480 nm, which is the case for ECFP 
[10], Cerulean [17] and mTurquoise [18]. Another cyan FP has recently been published (mTFP1) which is 
developed from the tetrameric protein cFP484 found in the soft coral Clavilaria [19], which when compared 
with ECFP and Cerulean appears to have a higher brightness and improved photostability, although its 
emission is slightly red shifted (emission at 492 nm) and so there is a greater degree of cross talk between 
channels when performing multi-colour experiments with yellow or green FPs or dyes.  
These blue shifted proteins are often used as ‗donor‘ fluorophores in Förster resonance energy transfer 
(FRET) experiments in conjunction with a yellow derivative of GFP to act as an acceptor. The yellow 
variants of GFP were developed by performing a Thr203Tyr substitution which resulted in a red-shifted 
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version of GFP [8] with excitation/emission maxim around 514/525 nm . Subsequently, a variety of other 
mutated yellow FPs have become available, with improved tolerances to pH and greater photostability 
(Citrine [20], Topaz [21], mVenus [22]).  
As well as the blue, green and yellow versions of FPs which are discussed above, a range of orange (mKO 
[23] and mOrange [24]), red (mCherry [24], DsRed [25] and TagRFP [26]) and far-red FPs (mKate2 [27]) 
have been developed, which have resulted in FPs spanning the entirety of the visible spectrum, allowing 
multi-parameter imaging within live samples. 
2.3.3. Biarsenical labelling  
Biarsenical labelling was originally published in 1998 as one of the first methods of labelling recombinant 
proteins with small dye molecules [28]. This labelling system relies on the genetic expression of a 
tetracysteine handle (Cys-Cys-Xaa-Xaa-Cys-Cys; where Xaa is any other amino acid other than cysteine) 
that serves as the genetically encoded targeting mechanism for subsequent labelling with a biarsenical dye. 
The most commonly used dye is FLAsH, which consists of a membrane permeable fluorescein molecule 
with As(III) substitutions on the 4‘- and 5‘- positions [29]. The tetracysteine handle is sufficiently 
uncommon in naturally occurring proteins to allow for relatively specific labelling of the target cells and 
labelling in the presence of 1,2 ethanedithiol (EDT) reduces non-specific binding and toxicity issues as EDT 
forms more stable bonds with arsenic than pairs of cysteines. Moreover, FLAsH in complex with two EDT 
molecules is cell permeable and non-fluorescent until bound to the tetracysteine handle, which results in a 
increase in fluorescence and thus reduces the background signal from unbound dye [30]. 
2.4. Fluorescence microscopy 
Fluorescence can provide a highly specific, localised signal to report on the interaction of molecules and 
their surrounding environment. There are a variety of methods that may be employed to measure 
fluorescence signals from samples of interest. Combining the use of fluorescence within the context of a 
microscope allows the spatial localisation of the fluorescent signals to be monitored within living organisms 
in a non-invasive and non-destructive manner, which is of particular interest within the area of biomedical 
research where it allows the monitoring of protein and molecular functions.  
Fluorescence microscopes rely on the phenomenon of fluorescence to generate images, rather than making 
use of absorption or reflection. All fluorescence microscopes work on the same basic principle: the sample is 
illuminated with light of one (or more) wavelengths, fluorescent species within the sample absorb this energy 
and release photons of a longer wavelength in the form of fluorescence or phosphorescence which is detected 
by the user. What follows below is an outline of the basics of some of the fluorescence microscopy 
techniques available. 
12 
 
2.4.1. Wide-field fluorescence microscopy 
The simplest implementation of a fluorescence microscope comes in the form of the widefield 
epifluorescence microscope, which is traditionally used in an upright configuration, but may also be inverted, 
the configuration for which is shown in Figure 2.5. The sample is illuminated (blue rays) from a light source, 
typically a mercury vapour or xenon arc lamp source (although a laser may also be used), and the 
fluorescence (green rays) is collected either using a CCD camera or viewed by the user through the eyepieces 
of the microscope. Use of an appropriate dichroic beamsplitter and excitation and emission filters allows for 
separation of sample fluorescence and excitation light.  
 
Figure 2.5: Inverted epifluorescence microscope, with illumination pathway in blue and detection 
pathway in green. 
2.4.2. Confocal laser scanning microscopy 
Widefield imaging suffers from the effects of out of focus light (and potentially, stray excitation light) 
reaching the detector and reducing the contrast of the in-focus image. It is therefore often desirable to 
employ optical sectioning, whereby out of focus light is prevented from reaching the detector. Confocal laser 
scanning microscopy (CLSM) achieves optical sectioning through the use of a point illumination source 
(typically a laser) that is raster scanned across the sample, in conjunction with a detection pinhole. The 
pinhole is placed in a conjugate plane to the focal spot in the sample, giving rise to the term ‗confocal‘, and it 
is this use of point illumination and point detection that leads to the rejection of out of focus light. 
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Figure 2.6: Confocal microscope. The sample is illuminated by a point of laser light (blue rays) and 
imaged onto a point detector (green rays). Light from out of focus planes (red rays) is block from reaching 
the detector by inserting a detection pinhole in front of the PMT. 
2.4.3. Multi-photon microscopy 
Typically, the term ‗multi-photon microscopy‘ refers to two-photon (2P) microscopy [31] although higher 
non-linear effects are also possible [32]. Multi-photon microscopy is a process whereby two or more photons 
are simultaneously (within 10-18s) absorbed. Since energy is inversely proportional to the wavelength of 
light, for a two photon transition to occur from the S0 to S1 state two photons of double the wavelength (half 
the energy) must be absorbed together. The efficiency of two-photon absorption scales with the square of the 
intensity. This requirement necessitates the use of pulsed lasers that achieve high enough intensities within 
the focal volume for multi-photon excitation to occur, while the average power remains reasonably low to 
avoid photodamage to the sample [33].  
The selection rules for one-, two-, and three-photon excitation are different and therefore the use of different 
imaging modes will lead to the population of different excited states. However, as fluorescence emission 
occurs from the lowest excited singlet state, the fluorescence emission is independent of excitation 
wavelength (Kasha‘s rule; see section 2.1). Therefore, it is still possible to use a simplified Jabloński diagram 
consisting of just the S0 and S1 states to depict the processes of multi-photon absorption (Figure 2.7 (a)). 
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Figure 2.7: (a) Jabloński diagram illustrating excitation using one-, two-, and three-photon absorption; 
(b) Schematic comparison of one photon (top) and two photon absorption (bottom).Adapted from [1]. 
Multi-photon techniques are of interest in biological imaging as they are intrinsically optically sectioning and 
consequently cause low out-of-plane photo-bleaching and photo-damage to the sample. To illustrate this 
consider a (hypothetical) example shown in Figure 2.7 (b) where two cuvettes are filled with a fluorescent 
dye. When one-photon excitation is used (top) the total amount of light absorbed in any plane is proportional 
to the optical power incident at this plane. Using a lens to focus the light through the cuvette does not change 
the amount of light passing through the cuvette, but merely the size of the beam at different axial positions. 
Therefore the emission power is constant across the cuvette (under the assumption that the inner filter effect 
does not apply). For the two-photon case (bottom) the amount of light emitted is proportional to the square of 
the excitation intensity and therefore, when the light is focussed the increase in intensity at the focal point 
leads to preferential excitation, resulting in a maximum excitation at the focal point. The optical set up for a 
typical multi-photon microscope is therefore almost identical to that of a standard one photon confocal, but 
without the need for the detection pinhole to achieve optical sectioning.  
2.4.4. Multipoint illumination 
Splitting the light available from a typical laser source into multiple points provides a means of allowing 
more light to arrive at the sample whilst limiting the peak intensity at each point and consequently speeds up 
imaging. The most common way of achieving this is through implementation of a spinning disk [34]. 
Spinning (or Nipkow) disks are comprised of a disk of pinholes arranged in an Archimedean spiral of 
constant pitch. Light is passed through the rotating pinhole disk onto the sample and this arrangement results 
in an equal amount of light being used to illuminate every position of the field of view for every rotation of 
the disk. The spinning disk unit is placed in an image plane of the objective such that each illumination point 
is imaged back through the pinhole disk, which then act like a series of parallel confocal microscopes. The 
fluorescence throughput and resolution is determined entirely by the size of the pinholes and the density of 
focal spots in the sample plane. There is therefore a trade off that needs to be made in the design of the 
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pinhole disks as moving the pinholes closer increases the throughput, but at a cost of increased cross talk 
[35].  
2.5. Fluorescence imaging techniques 
2.5.1. Intensity imaging 
Measuring the intensity of the signal is the simplest implementation of fluorescence microscopy. The image 
is formed by recording the fluorescence signal emitted from each point within the sample, which allows a 
map of fluorophore density to be created. Intensity based imaging may also be employed to perform single 
molecule imaging allowing the tracking of individual molecules within cells and permitting measurements to 
be made on the binding kinetics of molecular interactions or diffusion properties of molecules of interest 
[36], [37]. 
2.5.2. Spectral imaging 
Through use of a dichroic mirror and appropriate emission filters it is possible to separate out fluorescence 
into two separate channels which allows the monitoring of co-localisation of two independent labels which 
have spectrally separate emission spectra. Use of more than two emission channels is known as 
multi-spectral imaging. However, due to cross talk caused by the broad fluorophore emission spectra and 
imperfect filters it is sometimes necessary to employ spectral unmixing where, within each pixel, data from 
multiple spectral channels is acquired and then, through comparison with reference spectra, the main 
contributions per pixel can be unmixed to provide a concentration map of the different fluorophores [38]. 
Alternatively, multiple emission channels may be ratioed to provide a quantitative measure of a probe‘s 
activity whose spectral properties change due to environmental changes, for example a change in ion 
concentration [39] or lipid order [40]. 
2.5.3. Anisotropy/polarisation imaging 
If a fluorescent sample is excited with linearly polarised light, those fluorophores whose transition dipole 
moments have a component aligned parallel to the polarised excitation will be preferentially excited in a 
process known as ‗photoselection‘. If, during the excited state lifetime of the fluorophore, the dipole changes 
its orientation, either through naturally occurring rotation or through interactions with its surroundings, it 
leads to a depolarisation of the emitted fluorescence. Making measurements of the intensity at orientations 
perpendicular (I) and parallel (I) to the incident excitation light allows a quantity termed the fluorescence 
anisotropy (r) to be calculated which is defined as: 
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Measuring the fluorescence anisotropy allows the rotational kinetics of a population of molecules to be 
studied and may also be applied to probe interactions with other molecules by using it to infer FRET [41]. 
When FRET is present within a system, the transfer of energy from a first molecule to a second leads to a 
depolarisation of the emitted fluorescence if the emission dipole of the first is at an angle to the absorption 
dipole of the second. 
2.5.4. Fluorescence lifetime imaging microscopy (FLIM) 
As already discussed, the fluorescence lifetime defines the average time a fluorophore spends in an excited 
state. Fluorescence lifetime imaging microscopy (FLIM) then uses measured differences in the excited state 
lifetimes as a method to generate contrast, providing information on a molecule‘s local environment, 
reporting on changes in pH, ion concentration, temperature and quenching (most notably FRET). 
Alternatively, the fluorescence lifetime can be used to map the relative concentrations of a number of 
fluorophores in tissue samples with similar emission spectra. There are several methods which can be 
employed to measure the lifetime of a fluorophore, whether it is making measurements of bulk solutions 
[42], performing fluorescence lifetime microscopy [43] or integrating fluorescence lifetime resolution into an 
endoscope [44]. A more detailed description of the different techniques used to make fluorescence lifetime 
measurements can be found in the next section. 
2.6. Equipment used to perform FLIM 
FLIM may be performed in both the time and frequency domain. What follows below is an outline of both 
methods and the most common forms of their implementation. 
2.6.1. Wide-field frequency-domain FLIM 
Frequency domain FLIM uses a sinusoidally modulated laser (typically in the MHz range) excitation source 
to illuminate the sample and an image intensifier in front of a CCD to collect the resultant (modulated) 
emission. The sensitivity of this intensifier is modulated with the same frequency as the source, but with a 
phase shift relative to the excitation and several images are then acquired at different phase shifts.  
Modulation of the excitation source results in modulated fluorescence emission at the same frequency but 
with a phase shift relative to the excitation source due to the finite fluorescence lifetime of the fluorophore 
under investigation, as shown in Figure 2.8. The lifetime (for a single exponential decay) may therefore be 
calculated from measurements of this induced phase shift (equation 2-10). 
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Where    is the phase lifetime,    is the induced phase shift and ω is the circular frequency (=2*frequency 
in Hz).  
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The fluorescence decay also causes a reduction in the modulation depth (peak to trough height as a fraction 
of the mean) of the emission as those fluorophore excited at the peak of the excitation signal continue to emit 
through the minimum of the excitation signal, an effect that is mirrored, but to a lesser degree (due to the 
lower initial excitation intensity) when fluorophores are excited at the minimum of the excitation period and 
emitting through the maximum, leading to the observed reduction in modulation depth. Measurement of the 
change in modulation depth then provides another method to calculate the fluorescence lifetime (for a single 
exponential decay) given by: 
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Where    is the modulation lifetime, ω is is as defined previously and m is given by: 
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With the values A, a, B and b defined in Figure 2.8.  
 
Figure 2.8: Frequency domain FLIM. The sample is excited by a modulated light source and the lifetime 
may then be extracted by measurement of the induced phase and the change in modulation depth 
2.6.2. Time-domain FLIM: Time-correlated single photon counting 
Time correlated single photon counting (TCSPC) is the most common implementation of time domain FLIM 
and, as its name suggests, works by measuring the arrival times of single photons. A photodiode is linked to 
Phase Shift (∆φ)
A
B
a
b
Intensity
Time
18 
 
a pulsed excitation source (typically MHz) such that each pulse produces a start signal. This start signal 
triggers the initiation of a linear voltage ramp in the time to amplitude convertor (TAC) which is then 
stopped upon the detection of a fluorescence photon emitted by the sample, with the voltage generated being 
proportional to the time between start and stop signals. This is then converted to a time signal through an 
analogue to digital convertor (ADC) and a multi-channel analyzer (MCA) places this in the correct time 
channel. A histogram of time channels is then built up over repeated pulses of the excitation source and from 
this histogram the fluorescence decay may be extracted [1].  
As TCSPC is a point excitation, point detection method that detects single photons, it can be readily 
combined with confocal microscopy. The well defined signal to noise characteristics associated from 
detecting single photons make TCSPC an attractive option for making lifetime measurements. However, the 
main drawbacks are the speed of acquisition and the high peak powers in confocal imaging. TCSPC 
necessitates the scanning of the excitation beam across the sample through use of galvanometric mirrors to 
acquire data pixel by pixel, which is inherently slow (although use of resonant scanners can enable 
considerably faster scanning speeds), and increasing the laser power in an attempt to compensate for this can 
result in increased photobleaching and in an effect called ‗pulse pile up‘, where multiple photons are emitted 
for a single excitation pulse. As TCSPC requires the detection of, at most, a single photon per excitation 
pulse, pulse pile up results in a bias of the measured lifetimes to shorter values. A second factor to consider 
is the ‘TCSPC dead time’ which refers to the time taken for the TAC to reset ready for the next detection 
period. During this dead time, any other photons emitted are not recorded (although they are detected) 
reducing the photon efficiency.  
 
 
Figure 2.9: TCSPC schematic set up (Stop-Start) 
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The requirement of keeping the probability of detecting more than one photon in a detection period 
negligible results in there being many detection periods where no photons are recorded and consequently, 
there is no stop signal. Therefore the TAC is equipped with an out of range condition that automatically 
resets the TAC before the next detection period. This situation is not desirable in high repetition systems 
with laser repetition rates of 50-100 MHz, therefore TCSPC cards often work in a reversed stop-start mode. 
Here, the detection of a fluorescence photon is used as the start signal thus avoiding the TAC having to be 
constantly reset 
2.6.3. Time-domain FLIM: Wide-field time gated FLIM 
Time gated measurements of fluorescence lifetime make use of gated optical intensifiers (GOIs) as a means 
of temporally gating the fluorescence onto the CCD camera for detection. The GOI acts as a fast shutter in 
front of the CCD, only passing photoelectrons when an accelerating voltage is applied to the GOI. Through 
combination with a delay generator, the time gates may be shifted relative to the excitation pulse and the 
fluorescence decay profile sampled, allowing the extraction of the fluorescence lifetime. A schematic of a 
typical time-gated FLIM set-up is shown below in Figure 2.10. 
 
Figure 2.10: Time-gated widefield FLIM schematic 
In the simplest case of a single exponential decay shown in Figure 2.11, measurement of ratio of the intensity 
acquired in two gates placed at different delays can yield the fluorescence lifetime given by equation 2-13. 
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where ∆T is the time offset between the start of the two gates and I1 and I2 are the accumulated intensities in 
gates 1 and 2 respectively. This form of data collection and analysis forms the basis of rapid lifetime 
determination (RLD) and is made under the assumption that the two gates are of equal width [45]. 
 
Figure 2.11: Simplified time gating scheme. After excitation with short pulse of light (blue), the intensities 
in gates 1 and 2 are measured and used to determine the lifetime.  
If this approach is used to measure complex exponential fluorescence decay profiles, it yields an ‗average‘ 
lifetime value, sufficient to view changes in fluorescence lifetimes but not quantitative information of the 
relative fractional contributions. Making quantitative time gated FLIM measurements of complex decay 
profiles necessitates the use of more than two time gates, as shown in Figure 2.12. 
 
Figure 2.12: Time gated, time domain FLIM where a short excitation pulse (blue) is used and the 
resultant fluorescence decay (purple) is sampled at different delay points after excitation (green time gates). 
The data may then be fitted to multi-exponential decay models to yield the lifetime components and their 
relative fractions, enabling a more quantitative analysis of the sample. Time gated FLIM may also be 
employed in a wide-field illumination geometry or in conjunction with multipoint confocal scanning as 
provided by the use of a Nipkow disk, which allows the collection of data to be sped up considerably with 
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respect to confocal imaging while maintaining a low peak power. More details on the workings of the GOI 
and technical implementation of time gated FLIM can be found in section 4.3.3. 
2.6.4. Fitting fluorescence lifetime data 
Once the fluorescence lifetime data has been acquired, the data must be analysed to extract the lifetime 
information. This is typically done by fitting the acquired data (yi) to a particular model (f(xi)) which in the 
case of time domain data follows the form of an exponential decay as outlined in equation 2-7. The degree to 
which the model and the data agree is normally determined by the goodness-of-fit parameter defined by χ2 as 
shown in equation 2-14. The parameters of the model are then adjusted until the value of χ2 reaches a 
minimum. 
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As what is actually measured is not the pure fluorescence decay profile of the fluorophore, but the 
fluorescence decay of the fluorophore convolved with the instrument response function (IRF), a measure of 
the IRF must be taken with all data to recover the true fluorescence signal. The IRF is the response of the 
system to a delta function input and measurements are typically made using a scattering solution or short 
lifetime (< 100 ps) dye. Once the IRF is acquired, it can be used to deconvolve the true fluorescence signal 
from the measured data or it can be convolved with the decay model prior to fitting. The later of these 
methods is simpler and less susceptible to noise in the IRF. 
2.7. Förster resonance energy transfer (FRET) 
Förster Resonance Energy Transfer (FRET) is a photo-physical process by which energy is non-radiatively 
transferred from an excited state of one fluorophore (termed the donor (D*)) to another fluorophore (the 
acceptor (A)) via a dipole-dipole interaction [46]. For the transfer of energy to occur a number of criteria 
must be satisfied [47]: 
 The absorption spectra of the acceptor must have sufficient overlap with the emission spectra of the 
donor. 
 The transition dipole moments of the donor and acceptor must be favourably aligned.  
 The donor and acceptor must be close enough for energy transfer to occur. 
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Figure 2.13: Förster Resonance Energy Transfer between donor and acceptor 
Förster [46], and later Kuhn [48], showed that the rate of energy transfer (    was given by equation 2-15. 
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Here, R is the distance between the donor and acceptor, τD is the fluorescence lifetime of the donor (without 
the acceptor present) and R0 is the Förster radius which characterises the distance at which the efficiency of 
energy transfer between donor and acceptor is 50%. The Förster radius is a parameter that can be (relatively) 
easily determined for any pair of fluorophores through the use of well known properties [47] and is defined 
according to equation 2-16. 
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As before R0 is the Förster radius given in nm, n is the refractive index of the medium, NA is Avogadro's 
number, ηD is the quantum yield of the donor in the absence of the acceptor, εA is the molar absorption 
coefficient of the acceptor, FD is the fluorescence intensity of emission spectrum of the donor (with      
being the overlap integral of the donor emission and acceptor absorption spectra) and κ2 is determined by the 
relative orientations of the donor and acceptor. The value of κ2 is defined by equation 2-17. 
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Where the angles are defined in Figure 2.14 (a). In theory, κ2 may take values from 0 to 4 as shown in Figure 
2.14 (b), where perpendicular alignment of the transition dipoles results in a κ2 value of 0 and therefore no 
Acceptor EmissionExcitation FRET
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energy transfer, parallel alignment results in a κ2 value of 1 and collinear alignment results in a maximum 
κ2of 4. Ordinarily the value for κ2 is normally assumed to be 2/3, which represents the average value 
integrated over all angles i.e. assuming a random distribution of donor and acceptor orientations. This 
assumption only holds if the fluorophores are able to freely rotate at a rate that is faster than the rate of de-
excitation of the donor, although in practice it is more widely assumed to be valid. 
 
Figure 2.14: (a) Angles involved in the determination of the κ2 value; (b) example values of κ2 where D 
represents the donor and A represents the acceptor. Adapted from [4]. 
The efficiency of energy transfer (E), also known as the FRET efficiency, can be defined as the fraction of 
photons the donor absorbs that are sub-sequentially transferred to, and absorbed by, the acceptor [1]: 
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Recalling equation 2-15 this easily becomes the equation for FRET efficiency, E: 
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At a donor-acceptor separation equal to that of the Förster radius the FRET efficiency will be 50%, as the 
separation increases the FRET efficiency quickly drops off to approach 0. For example, when the separation 
between donor and acceptor is twice that of the Förster radius, the FRET efficiency is 1.54% (as shown in 
Figure 2.15) 
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Figure 2.15: FRET efficiency curve as a function of donor-acceptor distance (R) for arbitrary value 
of R0. 
FRET became known as a spectroscopic ruler due to its sensitivity to changes in distance between the donor 
and acceptor around the value of R0 [49]. From equation 2-15 it can be seen that this sensitivity stems from 
the rate of energy transfer varying with an inverse sixth power relationship with regards to the donor-
acceptor separation. This was first demonstrated through experiments with tryptophyl peptides by Edelhoch 
et al. in 1967 [50]. The distance dependence of FRET makes it appealing for use in biomedical applications 
to monitor the interaction of proteins or probe signalling pathways. The next two sections discuss the ways in 
which FRET is implemented within a biological/biomedical context and how changes in FRET are measured 
within the field of microscopy.  
2.8. Using FRET within biological experiments; Intramolecular vs. 
Intermolecular FRET 
The use of FRET for biological applications has expanded greatly, making use of the nanometer sensitivity 
in distance between the donor and acceptor necessary to achieve energy transfer. Two general 
implementations of FRET are used; intermolecular and intramolecular. 
2.8.1. Intramolecular FRET 
Intramolecular FRET usually takes the form of protein biosensors, where two fluorescent probes (typically 
fluorescent proteins) are attached to different points of the same chemically sensitive protein. The biosensor 
will start in either a state of high FRET (where the fluorescent proteins are close together) and, upon 
activation, change to a state of low FRET (where the fluorescent proteins are far apart) or vice versa, 
allowing the observer to monitor the changes and location of FRET occurring within live cells.  
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Figure 2.16: Intramolecular FRET. Attachment of a FRET pair to a chemically sensitive protein linker 
allows the user to monitor protein activation or ligand binding through changes in FRET 
Changes in the FRET state of biosensors are normally achieved in one of three ways: 
 Conformational change in the chemically sensitive protein due to post-translational modification e.g. 
phosphorylation [51]. 
 Conformational change in the chemically sensitive protein due to a change in environment e.g. 
changes in calcium concentration [43]. 
 Cleavage of the chemically sensitive protein leading to a abolition of FRET [52]. 
2.8.2. Intermolecular FRET 
Intermolecular FRET involves the attachment of fluorescent probes to different proteins that, when brought 
together, result in FRET. Typically this is used to monitor protein-protein interactions (PPIs) [53], [54], with 
a good example being imaging the activation of protein kinase Cα [55]. Intermolecular FRET has also been 
used to investigate the effectiveness of cancer therapies in inducing cell apoptosis [56], to monitor signalling 
mechanisms within cells [57] and to determine oligomerization states [58]. 
 
Figure 2.17: Intermolecular FRET. Attachment of donor and acceptor fluorophores to separate proteins 
of interest allows the user to monitor protein-protein interactions through changes in FRET 
2.9. Measuring FRET 
As discussed above, the use of FRET has wide ranging applications within biological systems. Measuring the 
transfer of energy indicative of FRET may be achieved in a variety of ways.  
Low FRET High FRET
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2.9.1. Intensity measurements  
One of the simplest methods of measuring FRET is to observe the fluorescence intensity of the donor 
fluorophore. If FRET is present, a reduction in the observed fluorescence intensity of the donor will occur 
due to the extra non-radiative decay pathway afforded by the presence of FRET. However, it is difficult to 
make quantitative intensity measurements due to the spectral bleed through and concentration artefacts, and 
even with the use of ‘donor only’ and ‘FRET’ samples prepared independently it is still difficult to achieve 
quantification of FRET due to the unknown concentration of fluorophore in each sample. One solution to this 
problem is the use of acceptor photobleaching where a FRET sample is used, containing both donor and 
acceptor, to measure the fluorescence intensity of the donor in the presence of FRET. Then, the acceptor is 
photo-bleached to induce photochemical destruction of the fluorophore, preventing energy transfer, and the 
sample is reimaged to provide the intensity of the donor without the acceptor [59]. The FRET efficiency at 
any pixel may then be calculated by using equation 
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Where IDA and ID are the fluorescence intensities of the donor measured in the presence and absence of the 
acceptor (i.e. pre- and post-bleach) respectively. As this method involves the photo-bleaching of the acceptor 
it may be applied only once and therefore prevents its use in timelapse experiments. Moreover, exposure of 
the sample to high laser powers necessary to bleach the acceptor may also affect the donor fluorophore 
fluorescence, create cytotoxic species or not result in the destruction of the acceptor but instead create FP 
variants that possess similar spectral properties to the donor [60]. 
2.9.2. Spectral measurements 
A more sophisticated method comes in the form of measurement of the ‘sensitised emission’, where images 
are acquired at both the donor and acceptor emission wavelengths. As discussed previously, the presence of 
FRET leads to a decrease in the fluorescence intensity of the donor. Use of a second spectral window to 
measure acceptor fluorescence allows the measurement of the corresponding increase in acceptor 
fluorescence (sensitised fluorescence) due to FRET. Taking the ratio of the two spectral channels then offers 
a method of monitoring changes in FRET. 
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Figure 2.18: Concept of sensitised emission. FRET is measured as a decrease in donor intensity and a 
corresponding increase in acceptor intensity. 
Problems may still arise due to cross talk or bleed through between the two spectral channels, which can 
have severe effects on the accuracy of FRET detection. Therefore it is necessary to perform a number of 
control experiments in samples labelled with donor only and acceptor only to measure the extent of these 
effects and eliminate any cross talk contribution [61]. Sensitized emission methods are ideally suited to 
experiments where the expected FRET is high and the stoichiometry is known, for example, FRET bio-
sensors [62], which removes one of the unknown parameters compared to intermolecular FRET. This is 
because in the case of intermolecular FRET experiments, the relative concentration of donor to acceptor will 
vary from pixel to pixel, making changes in FRET difficult to separate from local diffusion of fluorophore 
into the focal volume. Ratiometric methods can be used to extract an ‗effective FRET efficiency‘ provided 
donor only, sensitised emission and directly excited acceptor images are also acquired for calibration [63]. 
2.9.3. Fluorescence polarization microscopy 
As previously discussed, preferential excitation (photoselection) of those molecules whose transition 
moments are aligned parallel to the exciting electric field occurs [4]. If the excited fluorescent species has a 
large rotational correlation time in comparison to its fluorescent lifetime (an assumption that is valid with the 
use of fluorescent proteins which typically have rotational correlation times that are approximately one order 
of magnitude larger than their fluorescent lifetimes [64]) then the presence of FRET results in an overall 
depolarisation (a short component in the measured anisotropy decay) if these excited donors transfer energy 
to acceptors whose dipole moments have a component aligned perpendicular to the polarised excitation field 
[41]. 
Detection of FRET through fluorescence polarization microscopy also allows for the possibility of measuring 
energy migration resonance energy transfer (EM-RET, also called homo-FRET). Whereas in the traditional 
hetro-FRET measurements where two spectroscopically distinct fluorophores are utilized, EM-RET requires 
the use of only one fluorophore. This approach is obviously more spectrally efficient, allowing the possibility 
of multiplexing measurements with other tagged proteins to allow the probing of more than one part of a 
signalling pathway. EM-RET measurements have been used to measure oligomer formation [65], quantify 
protein cluster size [66] as well as the association of receptor tyrosine kinases [67]. Traditionally it was 
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thought that energy migration has no effect on the measured fluorescence lifetime of the donor. As the donor 
and acceptor are chemically identical, the rates of forward and backward energy transfer are the same and 
thus any change in the fluorescence of the donor molecule (within a FRET pair) is reciprocated by an equal 
and opposite change in the acceptor fluorescence [68]. 
Recently however, Koushik et al have shown that within the cyan fluorescent protein family, measured 
energy migration correlates to drops in the observed fluorescent lifetime [68].This drop in the observed 
fluorescent lifetime is thought to be due to the complex fluorescence decay profile of CFP and CFP derived 
fluorescent proteins. Within the paper, Koushik et al. postulated that if a fluorescent protein has multiple 
conformations and hence multiple lifetime states, then there is the possibility that one of these conformations 
may be more efficiently populated by direct laser excitation and the other may be efficiently populated by 
energy transfer, leading to an overall reduction in the observed average fluorescent lifetime This correlation 
was not found for yellow or green fluorescent proteins. The paper therefore highlights an issue with the use 
of CFP and Cerulean as donors for FRET experiments, especially when used in environments where many 
donors will be forced to be in close proximity, for example membrane binding FRET experiments. In these 
cases, the use of the isolated fluorescent protein lifetime as the reference for the ―donor only lifetime‖ 
becomes invalid. Instead, the donor-only reference lifetime should be obtained when the donor fluorescent 
protein is attached to the protein of interest. This then takes into account any energy migration and avoids 
biasing fluorescence lifetime measurements to lower values, which may lead to inaccurate reporting of FRET 
efficiencies.  
2.9.4. Fluorescence Lifetime Imaging (FLIM) 
Fluorescence lifetime imaging, or FLIM, uses FRET induced changes in the fluorescence lifetime of a donor 
molecule to gain a measure of energy transfer occurring. As shown in equation 2-3 the fluorescence lifetime 
defines the average time a molecule spends in the excited state after excitation and this, in turn, is determined 
by the rate constants that depopulate the state. FRET provides an extra de-excitation pathway (equation 2-21) 
and therefore results in the shortening of the fluorescence lifetime of the donor as shown in Figure 2.19. 
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Figure 2.19:  Example fluorescence lifetime decays in the presence (green) and absence (purple) of FRET. 
As FLIM is only concerned with measurements of the donor lifetime, it is less prone to cross-talk compared 
to intensity based measurements. Moreover, unlike intensity measurements, the fluorescence lifetime of a 
sample is independent of the concentration of fluorophores. Therefore, FLIM-FRET may be applied in both 
intramolecular- and intermolecular-FRET experiments. This has led to FLIM being a popular method of 
FRET imaging with papers in the literature covering a wide range of topics, from microarray analysis of 
protein-protein interactions [53] to investigating the recruitment of signal adapters [69]. 
Fluorescence lifetime measurements also have the potential to be more quantitative than intensity based 
measurements [70]. As shown is equation 2-7, if more than one fluorescent species is present, data may be 
fitted to an exponential decay model with more than one exponential decay component. In the case of a 
FRET system containing a mono-exponential donor with only one fixed orientation of donor and acceptor 
when undergoing FRET, leading to a single FRET efficiency, fitting of a double exponential decay may 
directly yield the fractions of bound (donors undergoing FRET) and not bound (donors not undergoing 
FRET).Fitting of such models on a pixel-by-pixel basis then allows the fraction of donors in complex with 
acceptors (α2) to be mapped, as described by equation 2-22. 
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2.10. Chapter conclusions 
This chapter has provided an introduction to the concept of fluorescence and described the main properties 
that may be measured. The main thrust of the chapter was to outline how fluorescence is utilised as a means 
of measurement in biological samples. To that end, a number of the most common implementations of 
fluorescence microscopy were described which all provide a non-invasive, non-destructive methods of 
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imaging biological samples. Specific attention was paid to the technique of FRET which, due to its highly 
sensitive dependence on the donor to acceptor distance, allows information on the binding of appropriately 
labelled proteins to be obtained. Several methods of measuring FRET in biological systems were presented 
and the potential advantages of FLIM were highlighted.  
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Chapter 3: Studying HIV-1 using fluorescence 
techniques 
The limited genetic makeup of HIV-1 results in an intimate association with the infected host cell, with HIV 
relying on the host cell machinery for the production of progeny virions. The small size of HIV (~145nm) is 
smaller than the resolution limit of conventional optical microscopy techniques, therefore simply ‗watching‘ 
the virus is not an option. Electron microscopy (EM), immune-EM and cryo-EM techniques allow the 
visualization of snap shots of the virus lifecycle and have been widely used in the study of HIV, however, 
they cannot be extended to live cell imaging which enables the study of virus dynamics. Moreover, the virus 
lifecycle contains a phase where the virion no longer exists in any recognisable form. This occurs post entry 
as the virus uncoats, prior to integration with the host cell genome, and does not exist in a morphological 
identifiable state again until the composite parts of the virion are individually transcribed in the infected cell 
and trafficked to the site of assembly forming the progeny virion. The use of fluorescently tagged proteins 
therefore opens the possibility of monitoring virus-cell protein interactions and probing trafficking pathways 
for virus infection and assembly. 
3.1. Human immunodeficiency virus type I (HIV-1) 
Human immunodeficiency virus (HIV) is the retrovirus responsible for acquired immunodeficiency 
syndrome (AIDS). It is comprised of just 15 mature proteins, two copies of positive single stranded RNA and 
a lipid bilayer. A schematic of a mature HIV virion is shown below [71].  
 
Figure 3.1: Schematic representation of a mature HIV virion. 
At the centre of each virion is the capsid core, a conical shape protein shell within which resides all that is 
necessary to replicate within a host cell. This capsid shell contains the viral RNA genome and the enzymes 
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protease (responsible for the process of maturation through cleavage of the HIV polyproteins into their 
constituent parts), reverse transcriptase (responsible for transforming the single stranded RNA genome into a 
double stranded DNA genome) and integrase (responsible for integrating this double stranded DNA into the 
host cell). Also present are the so called ‗accessory‘ proteins Vpr, Vif and Nef as well as a number of cellular 
proteins. Outside this conical capsid core is a spherical shell of matrix protein attached to a lipid envelope 
through an N-terminal myristoyl anchor and electrostatic interactions. Studded within the lipid envelope are 
the viral envelope proteins (Env) which are presented on the surface of virions as a complex of three gp120 
outer subunits non-covalently associated with three gp41 inner subunits, anchored in the lipid bilayer via a 
transmembrane domain (TM). 
3.2. HIV-1 Lifecycle 
The lifecycle of the mature HIV-1 virion begins with its attachment to a target cell (specifically CD4+ T-
cells, macrophages and dendritic cells) through binding of the gp120 protein to the CD4+ receptor of the 
target cell. This binding event results in an initial conformational change that exposes a binding site within 
gp120 to allow the gp120:CD4 complex to further interact with a host co-receptor - usually CCR5 or CXCR4 
[72]. Co-receptor binding triggers the extrusion of the N-terminal fusion peptide (FPep) of gp41 away from 
the Env trimer and into the host cell membrane. At this stage (termed the pre-fusion intermediate) the FPep 
and TM of gp41 are engaged in the host membrane and viral envelope respectively, forming a physical link 
or protein bridge. The metastable extended conformation of the gp41 trimer exposes two helical coiled-coil 
regions (HR1 and HR2) which undergo a further conformational change to a hairpin structure, with the 
alignment of the HR1 and HR2 regions allowing the formation of a very stable 6-helical bundle [73]. This 
favourable energy change drives the fusion of the virion envelope with the host membrane and the HIV 
capsid gains entry into the host cell, but likely remains attached to the inner lipid bilayer via the association 
of the viral capsid with the membrane embedded matrix protein. 
Once virion and target cell are fused, the virion core enters the target cell. The virion core is composed of a 
capsid protein shell encompassing the necessary proteins, enzymes and viral RNA needed for translocation 
to the nucleus and subsequent infection. Once the virion core is inside the target cell, a process known as 
‗uncoating‘ begins, releasing the contents of the core and leading to the formation of the reverse transcription 
complex (RTC). The RTC is a nucleoprotein complex containing the viral RNA, matrix protein (MA), viral 
protein r (Vpr) along with the viral enzymes reverse transcriptase (RT) and integrase (IN). It is within the 
RTC that reverse transcription occurs, converting the viral RNA genome to DNA. The viral DNA is then 
trafficked to the nucleus of the cell in the pre-integration complex (PIC) and once inside the nucleus the 
integrase enzyme (IN) then inserts the viral DNA into the host cell genome [74].  
The final stage in the HIV lifecycle is often called the ‗late stage‘ of the virion lifecycle and involves the 
production and assembly of new proteins to form progeny virions. The late stage of the virus lifecycle is 
orchestrated by the HIV Gag protein, which interacts with other viral proteins, the viral genome and with a 
large number of host cell factors, to facilitate the formation of new virions at the plasma membrane of the 
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host cell [75],[76]. The Gag proteins are translated as polyproteins containing a number of different sub-
domains (see section 3.3). During translation, HIV makes use of a process termed ‗ribosomal frameshifting‘ 
[77] where a stem-loop structure is used to impede the movement of the ribosome along the RNA and causes 
a -1 shift to a new frame. This allows the translation of Pr160Gag-Pol in approximately 5% of cases which 
facilitates the production of the integrase (IN), reverse transcriptase (RT) and protease (PR) enzymes at the 
correct levels. 
Two copies of the viral RNA are encapsidated during the assembly of a new virion through interaction with 
the NC domain of Gag. This interaction of NC and RNA is also thought to promote Gag multimerization, 
acting as a scaffold. Once assembled at the host membrane, the newly formed virion undergoes budding 
from the plasma membrane through interplay with components of the cell‘s own endosomal machinery, 
specifically the endosomal sorting complex required for transport (ESCRT) [78]. During release from the 
cell, the PR cleaves the Gag and Gag-Pol proteins into their constituent parts in a process called viral 
maturation, which is essential for the production of infectious virions [79]. Viral maturation results in a 
morphological change in the virus from its immature state to that of a mature state containing the 
characteristic conical core. In its unprocessed, immature form, Gag forms a doughnut like shell in the 
immature virion and this shell is thought to be too stable for disassembly and thus release of the RTC into the 
target cell cannot occur. The process of maturation through the cleavage of Gag then provides a way of 
producing a metastable capsid core which can readily disassemble when it enters into a new host cell.  
3.3. HIV-1 Gag protein 
HIV-1 Gag (Pr55Gag) is part of the molecular machine responsible for orchestrating the assembly of nascent 
HIV-1 virions. HIV-1 uses an efficient strategy to produce new virions whereby Gag is initially synthesised 
as a precursor protein that is subsequently cleaved into its constituent parts only once assembly is completed, 
allowing the individual domains to efficiently act in concert together to achieve assembly as well as reducing 
the number of components that need to be trafficked to the site of assembly. 
HIV-1 Gag provides the structural components of progeny HIV-1 virions, as well as being responsible for 
incorporating all necessary accessory proteins, enzymes and viral RNA in to the virion. It is composed of 
four major domains: Matrix (MA), Capsid (CA), Nucleocapsid (NC), and P6, along with two spacer proteins 
(SP1 and SP2).  
 
Figure 3.2: Schematic representation of the linear organisation of HIV-1 Gag protein. Myristoylated 
matrix (MA), Capsid (CA), nucleocapsid (NC) and p6 domains are indicated along with spacer proteins 1 
and 2 (SP1 and SP2).  
Immature virus particles are composed of ~5000 Gag proteins formed into a spherical shell, with the N-
terminus of Gag associated with the plasma membrane envelope and the C-terminus at the centre. To become 
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fully infectious, the immature virus particles must undergo a morphological change to the mature form. 
During the process of maturation, the viral protease cleaves the Gag protein into its constituent parts, with 
the capsid domain forming the conical viral core, whilst the matrix region remains plasma membrane 
associated.  
 
Figure 3.3: Viral maturation. The viral protease cleaves the Gag protein into it’s constituent parts 
leading to a morphological change and resulting in the virion becoming fully infectious. 
Even in the absence of other viral proteins and enzymes, expression of HIV-1 Gag alone results in the 
production of virus like particles (VLPs). VLPs are similar to an immature HIV-1 virion, being of a 
comparable size and undergoing the same assembly and budding processes [80]. As there is no viral 
protease, the VLPs remain in the immature ‗doughnut shape‘ form. Therefore, they are often used as a model 
system to study late stage HIV-1 lifecycle [81].  
3.3.1. Matrix 
The Matrix (MA) region is found at the N-terminal region of Gag and is responsible for membrane 
interactions through two entities, the N-terminal myristoyl moiety and a highly basic region (HBR). The MA 
domain is co-translationally modified with the addition of a myristate which is attached to a glycine and 
plays an important role in the association of Gag with the plasma membrane. Mutations within this region 
that prevent the myristoylation of Gag have been shown to have marked effects on the ability of the virus to 
assemble correctly through the prevention of membrane binding [82]. It was proposed that the ability of Gag 
to bind to membranes was regulated by a ‗myristyl switch‘ mechanism [83] whereby the myristate is 
normally sequestered within the globular head of the MA region, but upon Gag dimerisation or interactions 
with Phosphatidylinositol (4,5) bisphosphate (PI(4,5)P2) [84] a structural change within the MA occurs 
forcing the myristate to become exposed to the surrounding solvent. This exposure of the myristate causes an 
increase in hydrophobicity, driving Gag molecules to the plasma membrane.  
As well as the addition of an N-terminal myristate, Gag targeting to the plasma membrane is also regulated 
by a region of highly basic amino acids (HBR) [85] that form a region of positive charge [86]. This positive 
charge has been shown to interact with a specific class of negatively charged lipids called phosphoinositides. 
These lipids are comprised of an inositol head group and two fatty-acid tails and differ from each other by 
the position and number of phosphate groups on the head group. Different phosphoinositides are found to be 
PR Cleavage 
35 
 
enriched within different membrane regions of the cell, with PI(4,5)P2 found within the inner leaflet of the 
plasma membrane [87]. A number of in vitro assays have shown that the association of the HBR of MA with 
RNA competitively regulates interactions with certain membrane lipids, but allows Gag interactions with 
PI(4,5)P2. This regulation results in a preferential selection of the plasma membrane as a site of assembly 
and an enhancement in the plasma membrane binding of Gag [88],[89]. 
 
Figure 3.4: (a) Myristic moiety is sequestered within the MA region of Gag and PI(4,5)P2 is found 
embedded in the inner leaflet of the plasma membrane: (b) Upon membrane binding, the myristic acid 
moiety is inserted into the plasma membrane and the 2’ chain of PI(4,5)P2 is sequestered within the MA 
domain of Gag. 
Functional genomic screens have implicated a vast number of host cell proteins in the assembly of new 
virions at various stages of the HIV lifecycle [90]. These screens are backed up by experimental evidence 
which have shown that a number of host cell proteins are important in the trafficking and assembly of Gag 
proteins at the plasma membrane of infected cells [91],[92],[93],[94],[95], all of which have the potential to 
be therapeutic targets if the nature of the association of these proteins with Gag can be elucidated.   
3.3.2. Capsid 
The mature capsid (CA) protein is comprised of two functionally structural domains joined by a flexible 
linker, the C-terminal domain (CACTD) and the N-terminal domain (CANTD). Within Gag the CACTD is 
thought to play the more important role in virion assembly as deletion of the CANTD does not seem to disrupt 
particle production [96]. Interestingly though if, instead of entire deletion, point mutations in the CANTD are 
made, then particle assembly is seen to be impaired [97]. This suggests that if the CANTD is present it 
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interacts weakly with the CACTD to facilitate particle assembly, but this interaction is not crucial, or that 
CANTD mutations impair CA folding [96-97].  
The CACTD plays an important role in the mulitmerization of Gag precursors through its ability to form 
dimers via an interactive interface [96-98]. It is thought that the CACTD forms two dimer conformations, the 
side by side [99] and the domain swapped [100]. This ability of Gag proteins to interact via CA has 
important implications, allowing the Gag proteins to aggregate and assemble within the infected cell, with 
dimerisation of Gag proteins being a pre-requisite for myristoyl switch mediated membrane binding, as 
discussed previously. The CACTD also contains an area called the major homology region (MHR), a sequence 
of 20 amino acids that is highly conserved within all known retroviruses. Therefore it would be expected that 
this region plays an important role within the virus lifecycle and indeed, mutations within the MHR lead to 
impairments of assembly [97]. It has been shown through crystal structure investigations that the MHR is 
distinct from the CACTD dimer interface [99], although the exact function of the MHR within the virus 
lifecycle is, as yet, unknown. 
3.3.3. Nucleocapsid 
The nucleocapsid (NC) incorporates and packages the viral RNA genome. As a consequence of the binding 
of nucleic acid, NC acts as a scaffold to increase Gag multimerisation [101],[102]. NC can bind RNA non-
specifically, however to form an infectious virion two copies of the viral RNA genome are required to be 
incorporated from the milieu of non-viral RNAs. This is achieved through the interaction of the NC Zinc 
finger motifs (of Cys-X2-Cys-X4-His-X4-Cys type [103]) and the 5‘ end of the viral genome (the Ψ site) 
[104]. In the context of a fully mature virion, NC remains associated with the nucleic acid, serving as a 
scaffold or chaperone to enhance reverse transcription and integration efficiency [102].  
3.3.4. p6 domain 
The p6 domain is important in the effective budding of the newly formed immature virions. Deletion of the 
p6 does not cause any impairment in assembly, but virions remain attached to the cell membrane [105]. The 
budding activity of HIV-1 has been localised to a highly conserved Pro-Thr/Ser-Ala-Pro [P(T/S)AP] region, 
with any mutations made in this region giving the same results as complete deletion of the p6 domain [106]. 
Moreover, the p6 region of Gag is thought to contain multiple ―late-domains‖ which interact with the host 
cell machinery to facilitate budding and release from the infected cell. Three broad classes of late domains 
have been identified [107] and it has been shown that many retroviral Gag proteins contain multiple late 
domains. The HIV-1 Gag protein, for example, contains two late domains within the p6 region of Gag. These 
late domains have been heavily implicated in interactions with the family of proteins know as the endosomal 
sorting complex required for transport (ESCRT) proteins [78]. The ESCRT protein complexes play an 
important role in transporting and sorting cargo proteins, with the complexes ESCRT-0, ESCRT-1, 
ESCRT-2 and ESCRT-3 sequentially handing the cargo from one to the other until budding into internal 
vesicles of multivesicular bodies (MVBs). It is this ability of the ESCRT complexes to drive budding and 
membrane scission that HIV and many other viruses usurp to help achieve budding into the extracellular 
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space [108]. It has also been demonstrated that the binding of TSG101 to a proline-rich sequence within the 
p6 is important for virus release with experiments in which the levels of TSG101 were reduced through the 
use of small interfering RNA resulting in the prevention of virion budding from the plasma membrane [109].  
3.4. HIV-1 Gag trafficking and assembly 
Once synthesised the myristoylated Gag proteins have been shown to target membranes, specifically the 
plasma membrane for assembly [110]. However there are a number of other possible sites for virion 
assembly, and while it is currently accepted that assembly takes place at the plasma membrane in most cell 
lines, almost all the work undertaken has focused on monoculture systems (i.e. a single cell line in isolation) 
and therefore the situation may differ substantially within an in vivo context where multiple cell types are 
present. HIV Gag has also been observed within intracellular compartments rich in late endosomal markers 
in a number of cell lines [111],[112],[113]. This raises the possibility that either Gag assembly takes place at 
these sites before relocation to the plasma membrane for budding or that the assembled virion buds into the 
lumen of late endosomes/multivesicular bodies and release from the cell is achieved through usurping the 
cellular exosome machinery. 
It is important to note that in an attempt to answer the question of the site of assembly, many groups turned 
to live cell imaging, making use of genetically encoded fluorescent proteins [113-114],[115],[116], however 
Gag is known to bind membranes within 10 minutes of being synthesised and such fluorescent proteins often 
have long maturation times, requiring correct folding of the beta-barrel structure before the chromophore 
becomes fluorescent (section 2.3.2). This, in combination with the variety of cell types and experimental 
methods used led to conflicting conclusions as to the site of functional virion assembly. For example, GFP 
tagged Gag in COS cells showed internal localisations [114] whereas Gag-GFP in 293T cells demonstrated 
Gag localisation initially at the plasma membrane [115] and then subsequent relocation to intracellular 
compartments. In HeLa cells similar contradictions exist, with biarsenic-based dyes used to visualise initial 
Gag aggregation taking place at the plasma membrane [117] or intracellular compartments prior to arriving 
at the plasma membrane [113]. More light has been shed on the kinetics of Gag assembly in HeLa cells 
recently by a study that employed a combination of Förster resonance energy transfer (FRET), total internal 
reflection fluorescence microscopy (TIRF) and fluorescence recovery after photo-bleaching (FRAP) 
microscopy to monitor the biogenesis of individual HIV virions in live cells [118]. In this paper, the authors 
identified two populations of Gag puncta; a slowly appearing population and a rapidly appearing population. 
Through use of dual colour TIRF, expression of the rapidly appearing population (Gag-GFP) was shown to 
coincide with fluorescently tagged markers of endosomes (CD63-mCherry or clathrin-dsRed) and therefore 
it was concluded that the slowly appearing population represented the assembly of genuinely new VLPs. 
FRAP was then used to bleach the fluorescence of these assembling VLPs to demonstrate the recruitment of 
new Gag proteins to the VLP from the cytosolic pool of Gag.  
Similar contradictions were previously observed in studies which use natural HIV target cells, for example, 
macrophages, CD4+ T-cells and dendritic cells. It was originally thought that within macrophages, virion 
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assembly took place at late endosomes or multi-vesicular bodies [119],[120], however it was later shown that 
these apparent intracellular accumulations were actually deep invaginations of the plasma membrane, which 
have now been named virus containing compartments (VCCs) [121]. The current state of thinking is that, for 
the majority of cell lines, the productive site of virion assembly is at the plasma membrane of cells [110, 115, 
122].  
3.5. HIV-1 Gag protein association with lipid raft domains  
Until recently, questions still remained regarding the make-up or even existence of lipid rafts in anything 
other than an in vitro context [123]. However, a broad consensus has now formed suggesting that lipid rafts 
are highly dynamic regions of lipid membranes up to 200 nm in size which are rich in cholesterol and 
sphingolipids and serve to partition the membrane allowing it to serve as a platform to facilitate signalling 
and trafficking [124]. The association of assembling virions with regions of the plasma membrane that 
correspond to the current understanding of a ‗lipid raft‘ has been widely investigated in recent years, owing 
to the highly enriched lipid envelopes found in nascent virions, differing from that of the host cell plasma 
membrane [125] or bulk cellular membranes [126]. Biochemical studies added further weight to this theory 
when it was shown that altering the levels of cholesterol [127] in the membrane or replacing the myristic 
moiety of the matrix region with an unsaturated acyl analogue [128] perturb virion production. In the case of 
HIV Gag, it is the N-terminal myristate and the HBR of MA that are implicated in its association with lipid 
rafts. As already mentioned, the MA region within Gag interacts with the phospholipid PI(4,5)P2 which 
serves to promote membrane binding and Gag multimerisation. NMR studies have shown that as the MA 
region binds PI(4,5)P2 it can induce exposure of the myristate which is inserted into the inner leaflet of the 
membrane whilst sequestering the unsaturated 2‘ acyl chain of PI(4,5)P2, thereby providing a double anchor 
to the membrane [129]. It is clear then that the MA region within Gag is paramount for the formation of 
functional virions, with disruption of the ability of Gag to bind to the plasma membrane, either through 
altering the HBR or the myristate moiety, preventing virion formation. 
3.6. Antiretroviral therapy 
Currently therapy for HIV often takes the form of multi-drug HAART (highly active antiretroviral therapy) 
regimes which involves the prescription of three or four clinically approved antiretrovirals [130]. Typically 
this necessitates the use of two different classes with reverse transcription (RT) inhibitors and protease 
inhibitors (PI) being the two most commonly used. RT inhibitors can be segregated into two mechanistic 
classes, nucleoside reverse transcription inhibitors (NRTIs), which target the active catalytic site of the 
reverse transcriptase, and non-nucleoside reverse transcription inhibitors (NNRTIs), which target an 
allosteric site resulting in a conformational change of the active site. This use of combination therapy has 
been shown to successfully suppress viral loads within infected individuals for years at a time; however the 
virus is never eradicated as latent reservoirs remain [131],[132]. 
Moreover, even with the application of multi-drug HAART, resistance still occurs. This is largely due to the 
genetic diversity induced by the error prone nature of the viral reverse transcriptase enzyme leading to the 
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introduction of mutations, deletions or insertions. The genetic diversity is heightened further by the high 
rates of genetic recombination that can occur in infected cells. These two factors, coupled with the selection 
pressure exerted by the antiretroviral treatment leads to the emergence of multi-drug resistant (MDR) HIV-1 
isolates. 
In recent years, new treatments have become available to combat MDR isolates with the advent of fusion, 
entry and integrase inhibitors [133],[134]. The fusion inhibitor, T20, works through competitive binding to 
heptat repeat 1 (HR1) and thereby preventing HR1 binding to heptat repeat 2 (HR2), a process important for 
allowing fusion to occur [135],[136]. Maraviroc is a CCR5 antagonist preventing ‗R5‘ tropic strains of HIV 
from binding to target cells, blocking entry [136]. The development of integrase (IN) inhibitors took longer 
than other targets as many early attempts were either toxic or lacked specificity, however, in 2007 
Raltegravir was awarded FDA approval for clinical use [137]. Integrase inhibitors prevent the integration of 
the viral DNA into the host cell by preferentially binding to a viral DNA-IN intermediate step, preventing 
stand transfer (ST) of the viral DNA into the host cell. 
3.6.1. HIV-1 Gag as a potential antiviral target 
Even though the development of fusion, entry and integrase inhibitors is a fairly recent event, drug resistance 
has already been reported [138]. Development of new, potentially more robust targets is therefore required. 
One possible target is HIV-1 Gag, which currently no approved drugs target. Potential new antiretrovirals to 
target Gag could interfere with a number of different sites or stages of Gag processing, including, hindering 
the transport of Gag to the site of productive virus assembly, binding of Gag to cellular membranes, 
multimerisation of Gag monomers, cleavage of the Gag protein or budding and release of progeny virions.  
So far, targeting such steps in the virus lifecycle has resulted in varying degrees of success. The main focus 
has been on inhibitors that interfere with Gag-Gag interaction through binding to the CA region. The first 
such inhibitor was termed Capsid inhibitor peptide (CAI) and was reported by Sticht et al. [139]. CAI was 
shown to disrupt the interface between the CTD and NTD of CA, thereby weakening the hexameric lattice 
structure that forms [140]. However, CAI is not suitable as an inhibitor in cell based assays or in vivo trials 
as it is not cell permeable. This was addressed through the use of a technique called hydrocarbon stapling 
which increases the α-helical nature of the compound. The result was called NYAD-1 [141] which was 
shown to bind the same region of the CA-CTD as CAI and as a result, disrupted virus assembly.  
Maturation of the virus is essential for infectivity and requires cleavage of the Gag protein into the 
constituent sub-domains. Each of these cleavage sites is then a potential therapeutic target for small 
molecules that prevent cleavage and inhibit complete maturation. So far, only the CA-SP1 site has been 
successfully targeted by such a molecule, 3-O-(3‘,3‘-dimethylsuccinyl)betulinic acid (DSB), also referred to 
as PA457, which results in the accumulation of unprocessed CA-SP1 intermediates [142]. 
Another area which shows promise is the inhibition of efficient virion release. These inhibitors concentrate 
on the targeting of late domains found within the p6 region of Gag which are essential for release of newly 
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formed virions. Tavasolli et al. developed a method to screen for inhibitors of the p6-TSG101 interaction 
[143]. It was shown that this inhibitor was dependent on the late domain PT/SAP as use of a mutant PTAP 
late domain had no effect on virus release.  
Very little work has been carried out on the potential of interfering with the binding of Gag to the plasma 
membrane. As already stated, this process is dependent on the myristic switch mechanism and MA 
interactions with PI(4,5)P2. However, as myristoylation is a ubiquitous process within cells with many 
proteins reliant on lipidation to carry out their proper function, inhibition of host myristoyl transferases is 
likely to be toxic. However, a different antiviral inhibition strategy could be envisioned whereby only the 
myristoyl binding pocket on HIV matrix need be targeted to disrupt the myristoyl switch mechanism. After 
virion envelope/host membrane fusion, the viral capsid enters the host cell but remains bound to the inner 
leaflet of the fused membrane. This is because the capsid remains associated with the membrane bound 
matrix localised at the point of membrane fusion. Soon after this event, the membrane-bound matrix begins 
to diffuse laterally into the surrounding plasma membrane thereby reducing the localised concentration of 
matrix at the fusion point. This reduction of matrix concentration results in retraction of the myristate moiety 
out of the membrane and re-insertion into the myristate binding pocket on the matrix globular head [83], 
[144]. As a result, the matrix is no longer membrane bound and the attached viral capsid is now able to move 
away from the membrane and into the cytoplasm. Therefore the development of small molecules which may 
potential occupy the myristoyl binding pocket in matrix upon HIV entry, would result in there being no re-
sequestration of myristate and matrix would remain membrane bound. As a result the viral capsid would not 
be released and viral replication could be blocked. 
In a recent review of HIV Gag as a potential antiretroviral target Freed et al. state that MA may well prove to 
be a potential target if several issues can be overcome; Firstly, structural studies on the interactions of the 
MA region of HIV Gag with the gp41 sub unit. Secondly, structural studies of the interactions of HIV-1 Gag 
with the numerous host cell proteins implicated in trafficking Gag to the site of assembly and finally, the 
development of robust, cell based, high throughput platforms to screen for inhibitors that block the 
association of Gag with the plasma membrane or disrupt trafficking [145]. It is this last point that concerns 
the work undertaken in this thesis.  
3.7. Utilizing fluorescence to probe HIV-1 lifecycle & where to tag 
The most commonly employed strategy to label proteins of interest within live cells is to use fluorescent 
proteins (FPs). FPs are genetically encoded and therefore are highly specific, negating the problems of off 
target labelling and increased background associated with staining with synthetic dyes. This specificity of 
labelling position also allows for reproducible labelling so any effect of introducing the label can be 
repeated, understood and characterised. As such, FPs have been widely adopted in the study of HIV lifecycle 
and in particular the study of Gag protein dynamics and interactions [118, 146], [147], [148], [149]. The use 
of FPs typically place the tag at the C-terminus, but tags have also been placed in between the individual Gag 
domains, specifically the MA and CA regions, allowing expression of fluorescently labelled Gag in the 
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context of fully replication-competent HIV virions [116]. There are two main drawback of using FPs as the 
method of tagging, firstly, the size of the FP is 27 kDa, roughly half the size of the Gag protein. Therefore 
there are legitimate concerns over the potential of introducing artefacts due to the large size of the tag. It is 
often suggested that this may be overcome by co-transfecting a population of tagged Gag with a population 
of untagged Gag [116], however, a recent study demonstrated that Gag proteins tagged with YFP formed 
VLPs of almost identical size to VLPs comprised of untagged Gag and that, when co-expressed with 
untagged Gag, showed that there was no preference of incorporation of tagged or untagged Gag within the 
VLPs formed [81]. The second possible disadvantage is the maturation half time of the fluorescent protein 
chromophore, typically around 1 hour [150], during which, no information can be gathered regarding the 
position or interactions of the protein of interest.  
To overcome this, small dye based labelling systems have also been employed in the study of HIV, in 
particular biarsenical labelling [117], [151], [113]. Such labelling systems, however, possess different 
pitfalls, most notably the introduction of an extra labelling step and the non-specific labelling which may 
occur, resulting in a higher fluorescence background. Moreover, the limited spectral range of compatible 
dyes has meant that fluorescent proteins have been the method of choice to study the lifecycle of HIV.  
Here, the HIV Gag protein is tagged with either CFP or YFP at its C-terminus, which, as already discussed, 
is a well characterised labelling strategy that allows the monitoring of Gag-Gag interactions through the 
measurement of FRET from the CFP donor to the YFP acceptor. 
3.8. Host Cells to use 
If possible, employing cell lines that are the natural target cells (T cells and macrophages) of HIV is 
preferable. However there are issues when using such primary cell lines for microscopy assays. The main 
concerns are that such primary cells are grown in suspension, have high mobility and large nucleus 
(corresponding small cytoplasmic area to observe virion formation) all of which are undesirable properties 
for fluorescence microscopy assays. Use of adherent cells is preferable — particularly in microscopy — with 
HeLa cells (cervical cancer cell line) being the cell line of choice [152], even though they are not a natural 
target cell for HIV. Previous work has used HeLa cells which have been modified to express the natural 
receptors (CD4 & CCR5/CXCR4) to allow HIV to attach to them, facilitating the visualization of entry and 
transmission [153]. HeLa cells have therefore been used in the work presented here. However, it must be 
stressed that this is purely a model system. 
3.9. Investigating Gag-Gag interactions 
A variety of assay formats have been employed to investigate the multimerization of Gag proteins or the 
interaction of Gag proteins with host cell proteins, which may yield the possibility of identifying new 
therapeutic targets or shed new light on previously unknown steps in the production of progeny virions. 
Recently, a yeast two-hybrid screen of a human cDNA database showed that Filamin A, a non-muscle Actin 
filament cross linking protein, plays an important role in the trafficking of Gag proteins [154]. From this 
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initial screen Cooper et al. demonstrated the co-localisation of both proteins and how subsequent siRNA 
knockdown of Filamin A resulted in a reduction of virus release of approximately 60%.  
FRET was introduced in the previous chapter as a method of probing protein-protein interactions within live 
cells through the measurement of energy transfer from one tagged protein of interest to another. The ability 
of FRET to extract information on length scales <10 nm makes it ideal for investigating protein interactions, 
and as such, it has been applied to the investigation of Gag –Gag interactions. One of the first such examples 
of the application of FRET to a system of interacting Gag proteins came in 2003 where Larson et al. 
investigated the Gag protein of Rous Sarcoma Virus (RSV), another retrovirus, using two photon FRET and 
FCS measurements to confirm that Gag-Gag interactions occur in the cytoplasm, prior to trafficking to the 
plasma membrane [155]. Derdowski et al. were the first group to apply FRET techniques to the interactions 
of HIV Gag proteins, again in 2003 [156]. Here the authors present the potential of FRET as a technique for 
monitoring Gag-Gag interactions in cell based systems, showing that interactions between Gag proteins can 
be monitored on the plasma membrane of cells and, furthermore, showing in fluorometry based experiments 
that the interactions between TSG101 and Gag occur at the plasma membrane. 
Li et al. also used a FRET based approach to investigate the interactions between HIV-1 Gag proteins [157]. 
Using a large number of variants of fluorescently labelled Gag containing different mutations, the authors 
investigated the relative contributions of each domain on Gag-Gag interactions as read out by FRET. The 
findings of this paper suggest that there are three essential contributors to the interaction of Gag proteins; 
NC-RNA binding, CA-CA interactions and the interaction of the myristoylated MA domain with cellular 
membranes. 
In a similar fashion, Hogue et al. used a FRET based assay to answer two important unanswered questions of 
Gag assembly dynamics [146]. Firstly, identifying that it is the CACTD interface that is essential for 
multimerisation of Gag proteins and secondly, demonstrating that the role of NC to act as a scaffold through 
the binding of RNA and the role of micro-domains to promote Gag multimerisation are functionally linked. 
The authors used fluorescently tagged Gag proteins (CFP donor and YFP acceptor) to show that removing 
the CACTD completely removes the presence of FRET and that, in the presence of a fully functioning CACTD 
either NC or membrane binding ability was required to achieve Gag multimerisation at the plasma 
membrane. 
All the uses of FRET discussed above implemented intensity based spectral-ratiometric methods to measure 
FRET. The use of FLIM-FRET to investigate Gag-Gag interaction has been less widely employed, with its 
main uses being to investigate Gag protein interactions with other viral or host cell proteins. For example, 
Fritz et al. used TCPSC based FLIM to measure changes in the amount of FRET occurring between Gag 
labelled with the biarsenical label ReAsH and an HIV accessory protein, Vpr, labelled with GFP [158]. The 
authors were able to demonstrate that oligomerisation of the Vpr protein was a prerequisite for accumulation 
at the plasma membrane and that this oligomerisation was independent of the multimerisation state of the 
Gag proteins it interacted with.  
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3.10. The use of HIV-1 Gag protein as a model system 
Within this body of work, fluorescently labelled HIV-1 Gag proteins are expressed in HeLa cells to 
investigate the potential of using automatic FLIM-FRET technology to perform high throughput screening of 
potential compounds or siRNA libraries. As discussed, the HIV-1 Gag proteins aggregate at the plasma 
membrane of the cell forming large (~5000 Gag proteins) aggregates in the form of VLPs. Attaching a 
fluorescent protein to the C-terminus of the Gag proteins is already a well characterised method of 
monitoring Gag protein distribution. Here, the use of two, spectrally distinct fluorescent proteins which 
possess overlapping spectra allows for the transfer of energy (FRET) from donor to acceptor. The aim is to 
develop a robust assay based around this model system of protein aggregation to demonstrate the potential of 
automatic FLIM plate readers. 
3.11. Chapter conclusions 
This chapter has introduced the basics of HIV with particular attention paid to the Gag protein, which was 
shown to play an important part within the virus lifecycle. Current anti-retroviral treatments were described 
and the case for new therapeutic targets was outlined, with the HIV Gag protein highlighted as a potential 
target, specifically, the potential to interfere with the myristoyl binding pocket within the MA region of Gag. 
An introduction to previous research which used fluorescence based methods to investigate different aspects 
of the HIV lifecycle was given and a description of attempts to monitor Gag-Gag interactions was outlined, 
focussing on the use of various forms of intensity based FRET readouts. Overall, this chapter seeks to 
provide the biological groundwork to allow for the development of an exemplar assay to measure Gag-Gag 
interactions which is the subject of the rest of the thesis.  
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Chapter 4: Fully automated, optically 
sectioning, FLIM plate reader 
Chapters 2 and 3 have sought to provide a theoretical introduction to the tools and techniques that will be 
used for the rest of this thesis. This chapter now describes the application of a time gated method of 
fluorescence lifetime imaging in the context of an automatic, unsupervised FLIM plate reader. As already 
discussed, time gated techniques provide the necessary improvements in the speed of acquisition required for 
FLIM to be considered a viable tool for drug discovery. This chapter aims to outline and demonstrate time 
gated FLIM technology through the development and implementation of a cell based FRET assay, 
showcasing the abilities of the automated FLIM plate reader. The use of fluorescently tagged wild type Gag 
and fluorescently tagged mutated Myr(-)Gag serve as control samples defining the maximum and minimum 
FRET signals available. These plasmids are then used in a control plate to investigate the aggregation of 
HIV-1 Gag proteins and the available signal window around which a potential assay may be developed. 
Topics covered include: 
 An introduction to cell based assays 
 The development of an automated time gated FLIM plate reader 
 An outline of the positive and negative controls for the cell based assay 
 A demonstration of the FLIM plate reader on a control plate 
4.1. High content analysis and cell based assays 
Automated screening assays traditionally use non-cell, biochemical readouts, which provide a cheap, fast and 
easy method of screening large compound libraries. Initially, these typically take the form of yeast two-
hybrid (Y2H) screens, which are a form of protein fragment complementation assay used to screen for 
protein-protein interactions (PPIs). In a Y2H assay, a transcription factor is split into a binding domain (BD) 
and an activating domain (AD), that, when in their native state, bind to an upstream activating sequence 
(UAS) leading to transcription of the reporter gene, typically in the form of a fluorescence signal (see Figure 
4.1) [108]. To screen for PPIs, proteins of interest (P1 and P2) are inserted in between the BD and AD. If P1 
and P2 then interact, the reporter gene (for example LacZ) is transcribed leading to a fluorescence signal, 
whereas if there is no interaction between P1 and P2 the BD and AD cannot link together and no fluorescent 
signal is measured. 
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Figure 4.1: Schematic of the yeast two-hybrid screening system. (a)Binding domain (BD) and activating 
domain (AD) of transcription factor in their natural state bind to upstream activating sequence leading to 
transcription of the fluorescent reporter gene; (b) Protein 1 (P1) and Protein 2 (P2) are connected to BD 
and AD respectively. If P1 and P2 interact, the reporter gene is transcribed and the resultant fluorescence is 
read out.  
Although Y2H systems are relatively easy to set up and can be scaled up to high throughput sizes, there are 
issues surrounding high false positive and negative rates [159]. Moreover, as the readout of interaction takes 
place in the nucleus of yeast, it must be taken into account that these interactions are taking place outside of 
the protein‘s normal cellular environment and therefore may not have the pre-requisite post-translational 
modifications (e.g. phosphorylation) to be able to interact. Thus, Y2H are typically followed by, and used to 
direct, co-immunoprecipitation and/or pull-down experiments to confirm interactions [160].  
Investigating PPIs in a more endogenous, cellular, environment is therefore desirable; however, automating 
cell based assays leads to certain issues that need to be independently addressed for each assay, such as 
choosing between suspension and adherent cells, determining the appropriate range of passage numbers and 
elucidating the effects of various media components. That said, cell based assays are considerably easier and 
cheaper to implement than the use of animal models, which have limitations in terms of the assays that can 
be run and targets that can be imaged, as well as potentially suffering from difficulties with data 
interpretation [161] and potential ethical challenges. Cell based assays thus ultimately provide a reductionist 
approach to drug discovery, where the investigator assumes that each cell under investigation provides an 
independent measure of a compound‘s effect (or effects) on an entire living organism. The benefits of using 
such cell based assays over biochemical assays are, in essence, threefold. Firstly, providing a more 
physiologically relevant and self contained system to screen for potential compounds, secondly, allowing an 
early indication of cytotoxicity and finally, permitting a measure of compound penetration, which is 
particularly important if the desired target is an intracellular one.  
Cell based assays are now found at many stages of the drug discovery pipeline and are often run in parallel 
with traditional, biochemical assays. The growth of such assays was fostered by the development of the first 
automated fluorescence plate reader, which was reported in 1996 [162]. The FLIPR (fluorescent imaging 
plate reader) combined laser based illumination with an environmental chamber and automatic liquid 
handling for the first time to image population averages (i.e. a single value per well as the spatial resolution 
of this system was around 200 µm) in live cell-based assays [162]. 
Recently however, a number of more advanced automated fluorescence microscopy systems have come to 
market — the IN Cell Analyzer (GE Healthcare), the BD Pathway (BD Biosciences) and the ArrayScan 
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Infinity (ThermoScientific) are just three examples – that make use of auto-focusing and automatic stage 
movement to allow fluorescence microscopy images, comparable (i.e. in spatial resolution) to those obtained 
on a manual confocal microscope, to be acquired with minimum user intervention. These systems fall into a 
category termed ‗High Content Analysis‘ (HCA), which aims at automating the benefits of traditional 
microscopy systems to achieve throughputs that are beyond the capabilities of manual acquisition. Such 
HCA systems combine automated acquisition with sophisticated analysis routines and rely principally on 
fluorescence intensity images to look at relative distribution and co-localization of labels or perform intensity 
based Förster Resonance Energy Transfer (FRET) assays.  
There are numerous assay formats that can be implemented using HCA systems. Dudgeon et al. recently 
demonstrated the power of using such systems by devising a cell-based positional biosensor (PPIB) HCS 
assay to screen for disruptors of the interactions between p53 and hDM2 using the ArrayScan V platform 
(Thermo-Scientific) which monitored the co-localisation of p53-GFP and hDM2-RFP fusion proteins [163]. 
Upon ‗normal‘ binding of p53 and hDM2, images showed colocalised GFP and RFP fluorescence within the 
nucleus. However, upon disruption of the interaction, p53 remained located within the nucleus and the 
hDM2 shuttling partner redistributed to be cytoplasmic, resulting in green nuclei (p53-GFP) and red 
cytoplasm (hDM2-RFP). The authors fully characterised this cell based assay for PPIs, which provides a 
useful comparison for the assay developed here, since both are inter-molecular binding assays that aim to 
monitor the redistribution of proteins upon binding to each other. Dudgeon et al. reported a three day Z‘ 
factor of 0.56  0.08 and a signal to background ratio of 6.28  0.98, successfully demonstrating the 
robustness of the assay and then screening the LOPAC (library of pharmacologically active compounds) for 
potentially new inhibitors, identifying four such potential compounds. 
Another widely used intensity based fluorescent readout is the bimolecular fluorescence complementation 
assay (BiFC), which essentially relies on a ‗split‘ fluorophore, half of which is attached to one protein of 
interest and half to another protein of interest [164]. There are currently several fluorophores which can be 
used in a BiFC assay — including GFP [165] and YFP [166] — and BiFC has been used to investigate 
numerous interaction partners in a wide variety of cell types; for more information the reader is directed to 
two excellent reviews on the many uses of protein fragment complementation assays [164, 167]. The change 
from a ‗non-fluorescent‘ state prior to binding to a fluorescent one after binding results in BiFC assays 
having large signal to background ratios. However, for the two halves of the fluorophore to recombine, they 
must have a certain affinity for each other and thus, if they are over expressed it may lead to high levels of 
false positives, although strategies exist to mitigate such issues [168]. Moreover, the time taken for the 
maturation of the two halves of the fluorophore, typically at least an hour [164], makes BiFC assays 
unsuitable for monitoring dynamic or transient interactions. 
There is increasing interest in using FRET as a read out of bio-molecular interactions — owing to its strict 
distance dependence — and there are currently several implementations of FRET used in high content 
assays. Pollit et al. developed a cellular based, high throughput FRET assay to screen for Huntington‘s 
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disease (HD) therapeutics, making use of intensity based FRET measurements (using acceptor photo-
bleaching to test their constructs in non-neural cell lines and then spectral-ratiometric when using neural 
cells) to measure the level of protein aggregation [169]. The authors were able to identify a novel inhibitor 
that reduced polyglutamine aggregation in the cell-based assay and also had a marked effect when applied to 
a Drosophila model of polyglutamine disease [169]. Jones et al. [170] used a biosensor containing a Caspase 
sensitive linker (DEVD) tagged with both CFP and YFP to monitor apoptosis in situ. FRET measurements 
were performed by exciting the CFP donor and simultaneously measuring both CFP and YFP fluorescence 
emission. The FRET change was monitored by taking the ratio of donor to acceptor fluorescence (after 
appropriate background subtraction) for each well and averaging over repeat conditions and time points. This 
assay was applied to screen for compounds which activate the Caspase signalling pathway. In a similar 
approach, Takanaga et al. [171] developed an improved glucose FRET biosensor which use sugar sensitive 
linkers to induce conformational changes in the biosensor, leading to changes in FRET between the CFP 
donor and YFP acceptor. This sensor was applied in a small siRNA knockdown screen of glucose uniporters 
(GLUTs) to identify GLUT1 and GLUT9 as those most important in glucose uptake.  
Recently, the power of high throughput FRET measurements was demonstrated by Joseph et al. [172] who 
developed a novel high throughput platform that enabled real time, multi-parameter apoptosis detection in a 
number of cell lines. In this paper, the authors show how FRET — measured by calculating the ratio of 
donor to acceptor fluorescence emission under excitation of the donor only — can be used in conjunction 
with other readouts of cell death (Mitochondrial membrane potential (MMP) loss, chromatin condensation 
and mitochondrial superoxide generation) to understand the interplay of each signal and help to classify the 
action of different test compounds as well as shedding light on the kinetics of each compound. As an 
example, the authors monitored both DEVDase activity and chromatin condensation over time in HeLa 
SCAT3 cells which had been treated with a selection of 42 different compounds. It was shown that 12 hits 
displayed a gradual increase in both DEVDase activity and chromatin condensation, while 7 showed 
extremely rapid response in both readouts. It was demonstrated that these different response groups 
corresponded to different mechanisms of action of the added compounds, for example, the compounds found 
under the umbrella of ‗translation inhibitors‘ all showed a rapid (~12 hrs) effect on both DEVDase activity 
and chromatin condensation, whereas DNA Topoisomerase inhibitors, which directly inhibit the DNA, 
displayed a far quicker action on chromatin condensation, but with a slower action of DEVDase activity. 
Other studies make use of time resolved FRET (TR-FRET) commonly based on LANCE (Lanthanide chelate 
excite) technology (Perkin Elmer, Inc) whereby a lanthanide chelate donor, typically europium, is used to tag 
a protein of interest and, in the case of a europium donor, an allophycocyanin is used as an acceptor [173].  
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Figure 4.2: Schematic of LANCE TR-FRET assay (adapted from [174]). B: Biotin; E: Europium; P: 
Phosphate group; SA: Streptavidin. 
In the example shown in Figure 4.2, a streptavidin coated allococyanin bead binds to a biotinylated peptide. 
Upon addition of the kinase of interest (in the presence of ATP) and a europium labelled antiphosphopetide 
antibody, the target becomes phosphorylated and the donor labelled antibody binds to the phosphate group. 
Excitation at 340 nm allows energy to be transferred from the donor to acceptor by FRET and the 
(sensitised) signal is measured at 665 nm. The relatively large Stokes shift makes it possible to separate 
FRET signal from the donor signal through the use of spectral filters and enables direct excitation of the 
acceptor (and background fluorescence) to be separated from the FRET signal through temporal gating, 
owing to the long lived excited state of the europium. The above describes implementation of the LANCE 
assay within an in vitro context. Recently, this TR-FRET approach was also applied in a cell-based assay to 
investigate the distribution of EGFR/HER2 dimers [175]. This work by Gaborit et al. evaluated the in vitro 
effects of various targeted monoclonal antibody therapies including Cetuximab (anti-EGFR) and 
Trastuzumab (anti-HER2) illustrating how TR-FRET measurements can be made in cells and the results 
compared with results obtained by measuring the size of tumours observed during in vivo studies using 
xenografted tumour-bearing mice.  
As previously discussed, the most quantitative and robust method of monitoring FRET is by measuring the 
reduction in the fluorescence lifetime of the donor fluorophore. Despite the potential advantages of utilising 
FLIM within an HCA system, there are few examples. 
4.2. FLIM plate readers 
There are a few examples of automated FLIM systems in the literature using both time and frequency 
domain FLIM technology. Frequency domain and time domain FLIM can provide equivalent data, but there 
are performance trade-offs for specific implementations of both approaches. The first HCA instrument for 
unsupervised FLIM of multiwell plate sample arrays [176] used wide-field frequency domain FLIM in a 
non-sectioning microscope, demonstrating the potential of automated FLIM-FRET and the statistical 
analysis of FLIM array data. The authors also demonstrated the scalability of light microscopy, imaging both 
purified EGFP and Rhodamine 6G dye mixtures in a 1536 well plate and bacteria grown on a 9 cm x 14 cm 
rectangular preparation of agar (as well as cells in a 4-well Labtek chamber slide). Subsequently a wide-field 
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frequency domain FLIM plate reader has been applied to image post translational modifications (tyrosine 
phosphorylation) in situ – specifically uncovering components that transduce signals from epidermal growth 
factor receptors [177], illustrating the potential impact of FLIM HCA when combined with automated 
sample preparation. These wide-field frequency domain FLIM plate readers, however, did not benefit from 
optical sectioning, which can aid quantitative readouts by rejecting contributions from out-of-focus 
fluorescence.  
Recently a TCSPC based plate reader was reported that also enabled the acquisition of anisotropy images as 
a method of ‗fast screening‘ prior to TCSPC FLIM of potential ‗hits‘. This system used a Quadview 
polarisation resolved image splitter (Photometrics) to allow the simultaneous acquisition of parallel and 
perpendicular polarisation images in two spectral channels. From these four images the steady state 
anisotropy of the directly excited donor and sensitised emission of the acceptor were calculated and any 
potential ‗hits‘ were reimaged using TCSPC FLIM [178]. The reason behind using anisotropy imaging as a 
first pass screen stems from the limitations of TCSPC FLIM discussed earlier (section 2.6.2) which results in 
acquisition times ~12.5 hours (for 250 fields of view) although it should be noted, the authors state that with 
more sensitive detectors and new analysis methods based on Bayesian statistics [179], it is expected that 
TCSPC FLIM acquisition times may be reduced by a factor of 3. 
4.3. Automated time-gated fluorescence lifetime imaging plate reader 
Within the group of Prof. Paul French, an automated plate reading microscope has also been developed. 
Previously, Talbot et al presented the abilities of this system through application to dye samples, cell 
samples stained with Styo21 and cells transfected with EGFP-Raf-RBD and K-Ras-mRFP (both before and 
after stimulation with EGF). In each case, Talbot et al demonstrated the ability of the automated time-gated 
FLIM plate reader to quantify lifetime changes in a variety of experiments and highlighted the potential of 
such systems for the purposes of drug discovery [180]. 
The automated fluorescence lifetime imaging plate reader described in this chapter is based upon the system 
described by Talbot et al [180] and uses an Olympus IX81 frame with automatic dichroic cassette, objective 
turret and stage as well as the Olympus ZDC focus drive unit to allow automatic focusing. The motorised 
stage (Märzhauser Wetzlar GmbH, Scan Im) allows for software controlled sample movement, enabling 
whole plates (96-well, 384-well) to be imaged automatically and a Nipkow disk unit (Yokogawa, CSUX) 
allows optically sectioned images to be acquired (a schematic of the system may be found in Figure 4.3). A 
custom made (in-house) acquisition programme (Labview 7.1) allows the user to then set up fully automatic 
and unsupervised FLIM acquisitions to monitor, for example, PPIs within cells. 
The acquisition programme contains a ―pre-find‖ step which enables cells to be found prior to FLIM 
acquisition. This is a particularly useful step for sparsely labelled samples. Several ―pre-find‖ routines were 
implemented allowing the user to change the seek pattern — either spiralling out from the centre of the well 
or seeking around the edge of the well — or to use the larger FOV available in a low magnification (10 x) 
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objective to find labelled cells and thus speed up the ―pre-find‖ process. What follows is a discussion of the 
main components of the FLIM plate reader. 
 
Figure 4.3: Schematic of automated FLIM plate reader. FSCS: Fianium supercontinuum source; FW: 
Filter wheel; PD: Photodiode; GOI: Gated optical intensifier. 
4.3.1. Fianium Supercontinuum Laser source 
Time domain FLIM measurements necessitate the use of laser source capable of providing ultra short pulses, 
typically with pulse durations in the range of femtosecond to picoseconds. This requirement is satisfied here 
by using illumination from a commercially available supercontinuum laser source (SC400-6, Fianium UK 
Ltd) or using a frequency doubled Ti:Sapphire (Mai-Tai, Spectra Physics).  
The SC400-6 is capable of generating broadband, picosecond pulsed illumination from 400 – 1750nm at 
60MHz repetition rate with a spectral density of ~ 2 mW/nm. Fianium supercontinuum sources are based 
around a passively mode locked Yb-doped fibre laser that is fed into a high power fibre amplifier. The 
resulting light is coupled into a microstructured optical fibre where it undergoes highly non-linear effects — 
primarily four wave mixing, self phase modulation and stimulated Raman scattering — that result in spectral 
broadening, providing the user with a pulsed ‗white light‘ laser source from which the user can select 
radiation at the desired excitation wavelength through the use of spectral filters  
The Mai-Tai Ti:Sapphire is pumped with a 14 W Millennia (Spectra Physics) at 532 nm and allows fully 
tuneable excitation from 690-1040 nm, with pulse widths of ~100 fs at 80MHz repetition rate. The 
fundamental output beam from the Mai-Tai can be frequency-doubled by passing it through a critically 
phase-matched type I second harmonic generation (SHG) crystal, generating horizontally polarised SHG 
radiation and leaving the fundamental beam vertically polarised. The fundamental beam is then separated 
from the SHG using a prism with a highly reflective IR coating, and two further prisms are used to direct the 
SHG out of the doubler unit. 
4.3.2. Nipkow disk based optical sectioning  
The use of a Nipkow disk unit (CSUX, Yokogawa) provides multipoint confocal excitation through the 
scanning of many beams across the sample, instead of the single beam used in conventional confocal 
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microscopy. This allows far greater imaging speeds than traditional single point scanning or line scanning 
methods. 
The Nipkow disk is composed of an array of pinholes arranged in a spiral pattern that enables the full field of 
view to be sampled with each 30 degree rotation. Figure 4.4 shows the principle of a Nipkow disk, with a 
disk of pinholes arranged in an Archimedean spiral pattern to allow multipoint confocal scanning. 
 
Figure 4.4: Schematic diagram illustrating the workings of a Nipkow disk. (a) the pinholes within the 
Nipkow disk are arranged in a series of nested Archimedean spirals (here only three such spirals are shown 
for clarity); (b) a zoomed in area from the Nipkow disk illustrating how the pinholes rotate from the current 
position (green) to the new position (purple) as the disk spins. 
Traditionally the limiting factor with Nipkow disks was the low levels of light that could be transmitted 
through the pinhole array (as the majority of light is blocked by areas of the disk without pinholes) and as 
such they were not suited to low light experiments such as live cell imaging. However, with the 
implementation of a second disk containing an array of microlenses situated in between the exciting light 
source and the pinhole array, incident collimated laser light is now focused through each pinhole with 
approximately 70% efficiency [181]. 
(a) (b)
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Figure 4.5: The microlens array placed before the pinhole array focuses the collimated excitation light 
through pinholes. The fluorescence emission passes back through the pinhole array and is separated from 
the excitation light through use of a dichroic mirror place in between the microlens and the pinhole arrays. 
Collimated laser light from the excitation source is focused by the microlens array disk through the pinhole 
array disk. The multiple spots of light then pass through the tube lens and objective to the sample. 
Fluorescence from the sample is collected by the same objective and passes back through the pinhole array. 
The fluorescence is then reflected by a dichroic beam splitter, located between the microlens and pinhole 
arrays, to separate out the fluorescence from the excitation light. This allows the possibility of imaging a 
whole field of view up to 100 times faster than a traditional point scanning microscopes [182]. As well as the 
benefit of increased imaging speed, the use of a Nipkow disk reduces the peak excitation power, which is 
distributed between the multiple excitation beams. 
4.3.3. Time gating through use of a Gated Optical Intensifier 
The collected fluorescence is directed onto the photocathode of a gated optical intensifier (GOI), known as a 
high rate imager (HRI, Kentech Instruments). The use of GOIs to perform time-gated FLIM measurements 
has been widely demonstrated and such devices have been characterised for use in wide-field time-domain 
FLIM [183]. A basic schematic showing the workings of a single plate GOI is shown below in Figure 4.6. 
Each photon that strikes the photocathode has a certain probability of generating an electron — which 
defines the quantum efficiency of the device at a given wavelength. These photoelectrons are then 
accelerated across a micro channel plate (MCP) by an applied voltage. The resultant amplified signal is then 
converted back to an optical signal through the use of a phosphor screen and can be imaged onto a CCD 
camera. When the HRI is ―closed‖ a small positive voltage (32 V) is applied to the photocathode and when 
the gate is required to be ―open‖ a small negative voltage is applied, which accelerates any photoelectrons 
into the MCP. The HRI can therefore be thought of as an ultra-fast shutter in front of the CCD camera. 
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Figure 4.6: Schematic diagram of gated optical intensifier. Fluorescence photons are converted to 
photoelectrons at the photocathode and accelerated into the micro-channel plate (MCP) upon application of 
a negative voltage to the photocathode (gating voltage). These photoelectrons are amplified within the MCP 
and converted back to photons at the phosphor screen. 
The MCP contains an array of microchannels which amplify the incident electron signal by exciting cascades 
of secondary electrons, depending on the applied gain voltage. For all experiments undertaken in this work, 
the gain voltage was set to 750V. This voltage was selected as increasing the gain voltage minimises cross 
talk between adjacent channels and reduces the impact of CCD readout noise, but using a gain voltage that is 
too high restricts the available dynamic range as, for even modest signals, the high levels of amplification 
cause saturation within the CCD. For high repetition rate systems, as used here, the gating pulse is applied 
directly to the photocathode. Once the phosphor has converted the photoelectrons back to photons, they are 
relayed through the use of two camera lenses (Nikkor AF, Nikon) with focal lengths of 50 mm and 35 mm 
onto the CCD (Orca ER, Hamamatsu).  
4.3.3.1. Time gating electronics and gating strategies 
Performing time gated FLIM requires a trigger signal from the laser to define t0. This is obtained through the 
use of an electronic trigger signal taken directly from the laser source. The trigger signal is amplified and 
filtered and then passed through two delay lines. First, a ―slow‖ delay box (Precision Delay Generator, 
Kentech Instruments Ltd) allows the user to shift the decay in time (25 ps increments, over a range of 20 ns) 
to account for the relative optical and electronic path length difference. Secondly a ―fast‖ delay box (HDG, 
Kentech Instruments Ltd) is used to shift the gate relative to the trigger signal (picosecond increments).  
The positioning of time gates relative to the t0 position defines the delay time. By acquiring a series of 
images at different delay times it allows for the acquisition of several ―snapshots‖ of the fluorescence decay 
to be obtained and fitted, allowing the extraction of the fluorescence lifetime. The gating strategy used 
throughout this work (unless otherwise stated) employed nine gates, two of which were positioned before the 
peak, with the remaining seven sampling the fluorescence decay (as shown in Figure 4.7).  
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Figure 4.7: Typical arrangement of time gates for time-gated FLIM experiments 
Gates were positioned preferentially at the peak of the decay in order to adequately sample shorter decay 
components, allowing the possibility of fitting more complex models, with no gate placed more than three 
times the expected lifetime, as at these long delays the initial fluorescence has decayed to ~5% of its initial 
value and hence, sampling the decay at times greater than 3τ provides little to no advantage. 
4.3.4. Image processing 
Acquired data was processed using in-house software (FLIMfit), which uses a standard Levenberg-
Marquardt non-linear least squares (NLLS) fitting algorithm incorporating reference reconvolution, whereby 
the measurement of a short lifetime dye standard (DASPI) is used to account for the instrument response 
function (IRF) within the fitting algorithm (as discussed previously in section 2.6.4). 
4.4. Development of a FLIM cell-based assay to study HIV-1 Gag VLP 
formation.  
The following sections describe the initial stages of development for an automated cell-based assay to 
monitor the formation of HIV-1 Gag VLPs within cells. All plasmids used in this work were a kind gift from 
Dr. Edward  Murray at Pfizer Global Research and Development. Details of the specific steps used during 
the cloning are, unfortunately, unavailable. However, it is known that the Gag-YFP, Myr(-)Gag-CFP and 
Myr(-)Gag-YFP were sub-cloned from the Gag-CFP plasmid and therefore the Gag proteins expressed when 
using each construct were the same subtype.  
4.4.1. Protein preparation 
Plasmids were prepared using a commercially available MaxiPrep kit (Qiagen). The protocol is outlined 
below:  
4.4.1.1. Transforming bacteria 
Selective agar plates were prepared using imMedia ampicillin agar (Invitrogen). One sachet of imMedia amp 
agar (ampicillin concentration 100 µg/ml) was mixed with 200 ml filtered water in a 500 ml conical flask. 
t=0 Time (t)
log I(t)
t=3τ
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The agar media was then microwaved for 3 minutes until it began to boil at which point it was removed and 
cooled by placing in a bowl of cold water for 10 minutes. Once cooled, the agar was poured into 10 plates 
which were left to set and then dried in a 37°C incubator. 
One shot chemically competent TOP10 E.coli (Invitrogen) were thawed on ice. The DNA to be amplified 
was added (100 ng per E.coli tube) and the tubes were incubated on ice for 30 minutes. The bacteria were 
then heat shocked for 30 seconds and then replaced on ice for 2 minutes. SOC medium was added to each 
tube (250 µl), which were then incubated at 37°C with 225 rpm shaking for 1 hour, after which, 200 µl was 
spread onto a selective agar plate. The plate was inverted and incubated at 37°C overnight.  
4.4.1.2. Plasmid preparation 
A single colony of transformed bacteria was picked from the selective plate and placed into 5 ml of imMedia 
ampicillin liquid (Invitrogen) containing 100 µg/ml selective antibiotic in a 15 ml sterile falcon tube. The 
culture was incubated for 8 hours at 37°C with 300 rpm shaking, after which 200 µl of the starter culture was 
transferred into 200 ml of imMedia ampicillin liquid in a 1 litre conical flask and the resultant culture was 
incubated for a further 16 hours at 37°C with 300 rpm shaking.  
The bacterial culture was split into four 50 ml falcon tubes and harvested by centrifugation at 6000 g for 15 
minutes at 4°C and the supernatant was removed from the bacterial cell pellet. The pellet from the first tube 
was resuspended in 10 ml buffer P1 (50 mM Tris:Cl, PH 8; 10mM EDTA; 100µg/ml RNase A) and then 
used to resuspend the second pellet and so on until all four pellets were recombined into a single 50 ml 
sterile tube.  
The lysis of the bacteria was carried out by adding 10 ml buffer P2 (200 mM NaOH; 1% SDS (w/v)) to the 
resuspended bacteria and inverting the tube several times until the suspension turned a homogenous blue 
colour (due to the presence of the Qiagen lyseblue reagent) and was then left to incubate at room temperature 
for 5 minutes. 
The precipitation of the genomic DNA was achieved through addition of 10 ml buffer P3 (3 M Potassium 
acetate, PH 5.5) and the tube was inverted until a colourless suspension was left, indicating that the lysis 
buffer P2 was neutralised and the DNA efficiently precipitated. This suspension was then added to a 
QIAfilter cartridge and left for 10 minutes at room temperature. During this incubation a Qiagen-tip 500 was 
equilibrated by flowing 10 ml of QBT buffer (750 mM NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol (v/v) 
, 0.15% Triton X-100 (v/v)) through it. 
The lysate was forced through the QIAfilter through use of a plunger into the Qiagen-tip 500 which was left 
to clear by gravity flow, capturing the DNA in the filter within the tip. Once cleared the tip is washed twice 
with 30 ml of QC buffer (1 M NaCl, 50 mM MOPS, pH 7.0, 15% isopropanol (v/v)). The DNA is then 
eluted using 15 ml buffer QF (1.25 mM NaCl; 50 mM Tris-Cl, pH 8.5; 15% isopropanol (v/v)) into a 50 ml 
falcon tube. 
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Precipitation of the DNA out of suspension was achieved by adding 10.5 ml isopropanol alcohol, and the 
precipitate was centrifuged for 1 hour at 6000 g and 4°C. The supernatant was carefully removed and the 
DNA pellet washed with 10 ml 70% ethanol and centrifuged for a final time for 1 hour at 6000 g and 4°C. 
The supernatant was removed and the pellet air dried and resuspended in TE buffer (10 mM Tris-Cl, pH8.0; 
1 mM EDTA). The DNA concentration was then measured using a nano-drop and resuspended in TE buffer 
at a working concentration of 1µg/µl.  
4.4.2. Optimising the transfection protocol 
Following the standard protocol for use of Lipofectmine 2000 (Invitrogen) a plate was created to find the 
optimal conditions for growth and transfection of HeLa cells within 96 well plates. The parameters that were 
tested were: 
 Cell density. 
 Total amount of DNA. 
  DNA to Lipid ratio. 
The plating scheme is shown below in Figure 4.8, which provided 1 well per condition (cell number, DNA 
amount, DNA:Lipids). Judgements on this plate were made by eye, through viewing the plate on a Leica 
SP5 microscope with an epi-fluorescence lamp. It was found that the 7500 cells per well provided slightly 
over confluent cells in the centre of each well and therefore a slightly lower initial seeding density was 
necessary. Use of 100 ng DNA per well provided the healthiest looking cells, but cells that appeared slightly 
dimmer relative to the 200 ng and 300 ng per well treatments. As such, a total DNA amount per well of 
~150 ng was settled on. The testing of different ratios of DNA to lipid showed that a ratio of 1:2 provided 
the best compromise between transfection efficiency and cell toxicity. 
 
Figure 4.8: Optimisation plating scheme. (a) number of HeLa cells seeded per well; (b) total amount of 
DNA applied per well; (c) DNA to Lipid ratio, with white squares on the bottom row being lipid only toxicity 
test. 
4.4.3. Plate preparation protocol 
After optimisation of the cell transfection procedure, the following protocol was devised that provided large 
numbers of live, transfected cells. 
HeLa cells (passage number 14 – 35) were seeded in full growth media (Gibco DMEM + 10% FCS 
+0.5%Antibiotic) in a 96 well plate (µclear, Greiner) at a total of 6500 cells per well 24 hours prior to 
transfection, which resulted in cells being ~75% confluent at the centre of the well at the time of transfection. 
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Having cells ~75 % confluent provided the best compromise between achieving a high transfection 
efficiency (obtained when cells were highly confluent) and achieving easily distinguishable single cells, 
desired for imaging assays. Indeed, of all the parameters tested (DNA quantity, lipid to DNA ratio, 
transfection time etc) cell confluency had the greatest effect on the transfection efficiency.  
For each well, a total of 0.15 µg plasmid DNA was diluted into 25 µl of Optimem 1 (Gibco) in a sterile 
polypropylene tube and 0.3 µl of Lipofectamine 2000 (Invitrogen) was diluted into a separate 25 µl of 
Optimem 1 in a second sterile polypropylene tube. These mixes were both incubated for five minutes at 
room temperature before carefully adding the lipid mix to the diluted plasmid DNA. This was followed by a 
further incubation of 25 minutes at room temperature. Cells had the growth media removed and were washed 
once in phosphate-buffered saline (PBS) (Gibco, PH 7.4), ensuring that all residual PBS was removed by 
using a single channel pipette on each well independently. The cells then had 50 µl of Optimem 1 added to 
each well, followed by 50 µl of the transfection mix, added dropwise to the centre of each well. The plate 
was then incubated at 37°C, 5% CO2 for 6 hours, at which point the transfection mixes were removed, the 
cells were washed once in PBS (Gibco pH 7.4) and 100 µl DMEM (Gibco) containing no foetal calf serum 
(FCS) was added to minimise cell growth, preventing over confluence.  
After a further incubation of 24 hours at 37°C, 5% CO2, the cells were fixed for imaging through addition of 
100 µl of 4 % paraformaldehyde to each well. Cells were incubated at room temperature for 15 minutes and 
then washed twice with PBS. The cells were then kept in 100 µl PBS (per well) for imaging. 
Fixed plates were stored in a laboratory fridge at 4°C and it was ensured that plates were removed from the 
fridge at least two hours prior to imaging to allow the temperature of the plate to equilibrate. This is 
particularly important when performing lifetime based assays that use CFP as a fluorophore due to the 
temperature dependence of CFP [184].  
4.4.4. Defining the use of Myr(-)Gag and WT-Gag proteins 
The development of an assay to monitor the assembly and subsequent disruption of HIV Gag proteins 
requires maximum and minimum signal level conditions to be defined. As already discussed, myristoylation 
is an important step within the lifecycle of HIV, with both Gag and Nef relying on myristoylation to achieve 
membrane binding, which is a precursor to full and proper protein functionality. In the case of the HIV Gag 
protein, this functionality comprises the self-assembly of thousands of Gag proteins at the cell plasma 
membrane. Therefore use of a fluorescently tagged mutated protein which is unable to be myristoylated — 
through deletion of the first N-terminal glycine — provides a signal which defines a state of minimal 
aggregation. Likewise, use of a fluorescently tagged wild type Gag protein provides a signal defining a state 
of maximum aggregation. This is shown schematically below: 
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Figure 4.9: Schematic illustrating the differences between: (a) aggregating wild type HIV-1 Gag 
proteins and (b) non-aggregating Myr(-)Gag proteins. 
Addition of any compound which affects the ability of Gag to self-assemble — either through inhibiting the 
ability of Gag to form dimers and consequently trigger the myristic switch mechanism or through preventing 
myristoylation in the first place — should then fall between these two extremes. Therefore, it can be 
considered that the fluorescently tagged Myr(-)Gag protein acts as a positive control for the action of an 
inhibitor of Gag aggregation (i.e. low levels of FRET) and the fluorescently tagged wild type Gag protein 
acts as a negative control for the action of an inhibitor of Gag aggregation (i.e. high levels of FRET).  
4.4.5. Fluorescence background from microtiter plates and achievable signal to 
background. 
Greiner µclear 96 well plates were tested to ensure that the background signal from the plastic of the plate 
was not prohibitive to imaging. Myr(-)Gag-CFP transfected cells were plated in a Greiner µclear plate and 
several wells were left blank to obtain background measurements. There are four regions of interest to 
consider; firstly, the background signal obtained from a well containing just PBS with the laser shuttered. In 
this case the signal stems from the camera and GOI noise. Secondly, the background signal obtained from a 
well containing only PBS with the laser focused on the well which allows a measure of the plate 
fluorescence. Thirdly, a region away from transfected cells with the laser on to account for any additional 
background fluorescence caused during the preparation of the cells i.e. from fixing or transfecting. Finally, 
the region corresponding to the fluorescence signal to be measured i.e. transfected cells.  
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The brightness and contrast of the images were adjusted by performing the following procedure. Firstly, the 
background image (Figure 4.10 (a)) was loaded into ImageJ and the pixel values for the area shown in 
yellow were averaged to give a measure of the camera offset, which was found to be 193 DN. Then, the 
individual images were loaded into ImageJ and the brightness and contrast were adjusted so the highest value 
displayed was fixed to 4095 DN (the saturation point of the 12 bit CCD camera) and the lowest value 
displayed was fixed to 193 DN (the measured camera offset of the CCD camera). 
 
Figure 4.10: (a) Background image of well containing PBS with laser illumination off taken at the peak of 
the fluorescence decay; (b) same well as (a) with laser illumination on taken 6 ns from the peak of the 
fluorescence decay; (c) same well as (a) with laser illumination on taken at the peak of the fluorescence 
decay; (d) Sample image from the same plate taken at the peak of fluorescence decay. Colour scale indicates 
intensity from 193 to 4095. 
Figure 4.10 shows the differences seen in the background measurements. Part (a) shows the signal obtained 
from a well containing just PBS taken at the peak of the fluorescence decay, with the laser off, giving a 
average DN of 193. This signal is almost exclusively due to the camera offset. Part (b) shows the same well 
imaged with the laser on, but taken 6 ns away from the peak of the fluorescence (i.e. any fluorescence should 
have decayed away to almost 0). In this case the average DN was found to be 194, approximately the same 
as with the laser off. 
Part (c) shows the same well as parts (a) and (b) but taken with the laser on at the peak of the fluorescence 
decay. In this case the average DN is higher (207) than in parts (a) and (b) indicating that the plastic from the 
plate is fluorescent at the wavelength the experiment was performed at. Part (d) shows an example well 
(c) (d)
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containing cells taken at the peak of the fluorescence decay. Here there are two regions, region (1) 
corresponds to the background of the plate and was found to have a average DN of 208, similar to that of 
part (c) which indicates that the process of preparing the plate with cells (i.e. growth, transfecting, fixing 
etc.) does not increase the background levels of fluorescence. Region (2) corresponds to an area containing 
transfected cells. Here the average DN was found to be 2959, significantly higher than the background level.  
The signal (Figure 4.10 (d) region 2) to background (Figure 4.10 (d) region 1) ratio for this field of view was 
calculated to be 14:1. This analysis was repeated for a further 15 FOVs, which ranged from approximately 
10:1 to over 18:1. The 16 cells selected were derived from 4 separate plates, which were independently 
prepared and measured on different days. To account for the different integration times between plates, the 
average and standard deviation was obtained for each FOV on a given plate to provide an average and 
standard deviation for each plate and these average plate values were themselves averaged to report the 
overall variability in signal to background The results of this analysis are shown below and gave an average 
S/B (mean  standard error) of 13.4  2.3. 
 
Figure 4.11: (a) Plot illustrating signal (purple), background (green) and signal to background ratio 
(grey) for 16 cells selected from 4 plates; (b) example FOV used in signal to background calculations, where 
scale indicates signal to background ratio. (Scale runs from 0, black/blue to 18, white.) 
Figure 4.11 (a) demonstrates the variability in signal to background ratio for 16 separate cells. As before, the 
‗signal‘ region was defined as a region of cytoplasm of a transfected cell and the ‗background‘ region was 
defined as a region containing no cells from within the same field of view. 
From inspection of Figure 4.11 (a) it can be seen that the background levels are relatively stable with an 
average value (DN  standard deviation) of 221.13  5.09, corresponding to a relative standard deviation of 
2.3%. The background level is a combination of the camera offset (~193 DNs) and plate fluorescence and as 
such the slight differences between measurements can be attributed to the different integration times and 
laser powers used when imaging the 4 independent plates. In contrast, the signal from the cells varies 
considerably more as expected due to the variation in transfection efficiency and expression from cell to cell, 
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with the average value of 2984.56  534.64, corresponding to a relative standard deviation of 17.91%. 
Figure 4.11 (b) is an example field of view where the colour scale applied shows the calculated signal to 
background ratio for each pixel within the field of view to demonstrate the variability of expression from cell 
to cell. As such, it is important when analysing data acquired from the time-gated FLIM plate reader to set an 
appropriate intensity threshold to remove cells with a low S/B where the fluorescence from the plate will 
form a considerable fraction of the collected fluorescence signal.  
4.4.5.1. Accounting for the time varying nature of the background when making measurements 
using microtiter plates 
As shown, the transfection protocol developed allowed for significant numbers of highly expressing cells to 
allow for signal to background ratios of around 13:1 when making measurements at the peak of the 
fluorescence decay. However, section 4.4.5 also demonstrated that a fluorescence signal is also measured 
from the plastic of the microtiter plate and, as measurements are made at several points throughout the 
fluorescence decay of the transfected cells, a fluorescence decay originating from the plastic plate is also 
measured. This is referred to as the ‗time varying background‘ (TVB) and can be accounted for when fitting 
if an independent measurement of the TVB signal is made. 
This measurement was made using the same acquisition settings (filters, laser power, and integration time) 
used as when acquiring the data to image a well containing just the media used to image the cells i.e. for 
fixed cells in PBS, an empty well of PBS was used. The fitting software then adds the measured TVB as an 
extra fluorescence component in the model so only the fluorescence from the cells is fitted by the adjustable 
fit parameters. To demonstrate the effects of the TVB on the returned lifetimes and the ability of the fitting 
software to correct for them, simulations were performed. The architecture of these simulations are shown 
schematically in Figure 4.12 and comprise a time varying background area (region 1) and a desired signal 
area (region 2). The simulation programme adds the fluorescence decays of any areas that are overlapping 
such that the overlapped area (region 3) contains a contribution of both the desired signal and the TVB, 
which is the situation when making cell measurements. The signal region was set to contain a mono-
exponential decay with a lifetime of 3000 ps and the TVB was set to contain a mono-exponential decay with 
a lifetime of 800 ps which is approximately the fluorescence lifetime measured from the plastic of the 
microtiter plates. In all cases the shot noise added to the background image had a standard deviation of 2, 
comparable to that seen in measurements made with no sample present. The intensity signal-to-noise 
characteristics of such CCD-coupled micro-channel plate GOIs has been investigated previously by Mcginty 
et al. [183]. The authors demonstrated that for gain values of 420 – 1100 V the GOIs investigated display 
shot noise-like behaviour with an additional excess noise factor. This excess noise factor was found to 
decrease with increasing gain to such an extent that, for gain voltages typically used during an experiment 
(700 – 800 V), the excess noise factor is essentially negligible. 
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Figure 4.12: Schematic set up of single exponential decay simulation. Green area indicated the time 
varying background region and purple area indicates the signal region. The simulation adds together the 
fluorescence decays of the overlapping areas. 
The simulation programme allows the user to pick the number of photons in the peak of the simulated 
fluorescence decay. For the purposes of these simulations, 500 photons in the peak of the decay were used as 
it is estimated that each fluorescence photon emitted is amplified ~6 fold within the MCP of the GOI. 500 
photons therefore correspond to measured DN values at the CCD of ~3000 counts, comparable to the data 
acquired in experiments.  
The fractional contributions of the TVB and signal were then varied, keeping the total number of ‗photons‘ 
used constant. An IRF was simulated using the same simulation programme, setting the lifetime to 80 ps, the 
approximate lifetime of the reference dye DASPI used in all experiments. A region of the signal area 
containing no background (region 2) was segmented and the data was then fitted using the simulated IRF 
with a single exponential model, pixel-by-pixel. This gave a reference with which to compare the results of 
fitting the signal area containing a background contribution (region 3), which was fitted with a single 
exponential model, pixel-by-pixel, with and without the correction for the TVB. All results were then 
normalised and the histograms for this analysis are shown in Figure 4.13. 
Each plot within Figure 4.13 displays three histograms; the control histogram obtained from fitting a 3000 ps 
fluorescence decay containing no TVB shown in black; the histogram obtained from fitting a 3000 ps 
fluorescence decay with varying amounts of 800 ps TVB without the TVB correction shown in blue; and the 
histogram obtained from fitting a 3000 ps fluorescence decay with varying amounts of 800 ps TVB with the 
TVB correction shown in red. 
 
1 23
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Figure 4.13: Normalised histograms illustrating the effects of a background contribution to the fitted 
fluorescence lifetime and how the use of a measured TVB can correct the fitted lifetimes for (a)2.5% TVB 
contribution; (b) 5% TVB contribution; (c) 10% TVB contribution and (d) 20% TVB contribution. In all 
cases, the black curve shows the lifetime histogram for a single exponential decay containing no time 
varying background, the blue curve shows the lifetime histogram when a time varying background 
component is present but not accounted for and the red curve shows the same region when the TVB 
correction is used.  
It can be seen from Figure 4.13 that increasing the fractional contribution of the TVB without correction 
(blue histograms) leads to shorter measured fluorescence lifetimes when fitted with a single exponential 
decay, as expected. However, when the TVB correction is used (red histograms), the histograms appear 
overlapped with the single exponential control data (black histograms) indicating that the TVB correction 
adequately corrects for a background signal that varies over the timescale of the measurement. This 
correction is important when performing screening assays which will be run over several (~10s) plates as it 
allows direct comparison of the fluorescence lifetime measured from plate to plate which may have different 
signal to background ratios. 
Of course, the situation where a single exponential fluorophore is found in isolation is rare. Indeed, most 
fluorescent proteins exhibit more than one lifetime component, even when purified proteins are produced and 
analysed. This is the case for CFP [43], but is also true for GFP [185] and DsRed [186] among others. It is 
therefore interesting to investigate more complex decay profiles. To this end, the same analysis was 
performed on simulations containing either 2 or 4 exponential components as a model for CFP in isolation or 
CFP undergoing FRET with a YFP acceptor respectively.  
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Figure 4.14: Schematic set up of the multi-exponential decay simulations.(a)The two component 
simulation; Green area (region 1)indicated the time varying background region and purple area (region2) 
indicates the signal region. The simulation adds together the fluorescence decays of the overlapping area in 
region 3. (b) The four component simulation; Green area indicated the time varying background region 
(region 1). Region 2 contains a exponential decay with four components and region 3 contains an 
exponential with the same four components as region 2 added to the TVB from region 1. 
A double exponential decay was simulated containing lifetime components of 3500 ps and 1500 ps 
(comparable to the lifetime values of the CFP fluorophore used in this work [17]) in a 60/40 ratio. This decay 
was overlaid on top of a TVB signal that contributed 5% of the total photons in the resultant decay. The 
lifetime of the TVB was again set to 800 ps and the total number of photons in the peak of the decay was set 
to be 500. For the four component decay simulation (Figure 4.14 part (b)), two double exponential decay 
simulations were produced containing lifetimes of 3500 ps and 1500 ps (i.e. non-FRETing CFP donor) and 
3000 ps and 1000 ps (i.e. FRETing CFP donor) and were overlaid on top of each other to generate a four 
component decay (region 2). Again part of this four component decay overlapped with the TVB signal 
(region 1) to produce a four component decay with a TVB contribution (region 3).  
These decays were fitted with a single exponential decay model on a pixel-by-pixel basis, the results of 
which are shown below and demonstrate the ability to compensate for the TVB signal even in the presence 
of multiple decay components.  
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Figure 4.15: Normalised histograms illustrating the effects of a background contribution to the fitted 
fluorescence lifetime and how the use of a measured TVB can correct the fitted lifetimes for (a) a two 
component exponential decay containing 5% TVB contribution; (b) a four component exponential decay 
containing 5% TVB contribution; In all cases, the black curve shows the lifetime histogram for a single 
exponential decay containing no time varying background, the blue curve shows the lifetime histogram when 
a time varying background component is present but not accounted for and the red curve shows the same 
region (as the red curve) when the TVB correction is used. 
4.5. Application of FLIM plate reader to HIV-1 Gag VLP formation 
assay.  
The IX81 automated FLIM plate reader was applied to a plate containing various preparations of 
fluorescently labelled wild type and myristic negative Gag proteins to investigate the system‘s ability to 
make HCA-FLIM measurements on a biological assay. These proteins were used to define the positive and 
negative controls for the HIV-1 Gag aggregation assay, as defined previously in section 4.4.4.  
4.5.1. Acquisition settings 
The supercontinuum laser source (Fianium Ltd, SC400-6) was used for illumination with a 434/17 nm 
bandpass excitation filter (Semrock) allowing for CFP excitation. This light was coupled into a single mode 
fibre (Oz optics) and attached to the Nipkow disk unit (Yokogawa, CSUX), typically with ~8-9 mW power 
at the fibre output end. Excitation light then passed through the Nipkow disk (as described in section 4.3.2) 
and was imaged onto the sample using an Olympus 40x 0.6NA objective (Olympus, LUCPLFLN 40x). 
Fluorescence was collected through the same objective and separated from scattered excitation light through 
the use of a CFP/YFP dichroic (Semrock). Fluorescence was then imaged onto the front face of the GOI 
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(HRI, Kentech instruments Ltd) and relayed using a pair of camera lenses (Nikon) onto a CCD camera (Orca 
ER II, Hammatsu Inc) operating with 2 x 2 binning.  
The acquisition programme was set to acquire 4 fields of view per well, with an integration time per gate of 
0.3 s, resulting in a total acquisition time (including sample movement and auto-focusing) for the 248 fields 
of view of approximately 46 minutes, corresponding to a ‗per 96-well plate time‘ of 17.8 minutes (if only 
one field of view is taken per well). Total acquisition time scales of the order of tens of minutes per plate are 
sufficiently short to allow for automatic FLIM to be used as a method for screening small libraries of 
compounds or siRNA knockdown screens.  
4.5.2. Application of a single exponential fitting model 
Cells were transfected following the standardised protocol outlined previously (Section 4.4.3) and plated 
according to the plate map shown below (Figure 4.16 (a)). The lifetime data was analysed using the in-house 
fitting software to fit all pixels above an integrated intensity threshold of 1000, pixel-wise to a single 
exponential decay model, thereby providing an effective ―mean lifetime‖ per pixel. 
 
Figure 4.16: (a) Plating scheme for plate containing HeLa cell control samples transfected with varying 
combinations of fluorescently tagged Myr(-)Gag and wild-type Gag;(b) Fluorescence lifetime platemap 
showing the average lifetime value per well resultant from fitting a single exponential decay model, pixel-
wise, across all four repeat FOV within each well. Colour scale ranges from 2000 ps (blue) to 3200 ps (red).  
Figure 4.16 (b) is a false colour plate map of the average lifetime per well (calculated across all pixels above 
an applied intensity threshold and across all repeat FOVs). The plate was prepared such that higher levels of 
FRET were expected to be seen at the bottom of the plate. It can seen that the expected trend in effective 
mean lifetime is seen, with higher lifetimes (less FRET) observed at the top of the plate and lower lifetimes 
(higher FRET) at the bottom. Displaying the fitted data in the form of a plate map allows all the data to be 
viewed at once, enabling the user to easily identify any trends. It may be that this level of analysis is 
sufficient for the user‘s needs; however, as FLIM is an imaging technique, more detailed analysis can be 
obtained through use of the individual images.  
Figure 4.17 (a) and (b) present typical optically sectioned FLIM images of HeLa cells expressing 
Myr(-)Gag-CFP and Gag-CFP respectively. Inspection of the FLIM images indicates that higher levels of 
FRET (lower lifetimes) occur near the plasma membrane, as expected for VLP formation [110]. It can also 
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be seen that, as well as an increase in intensity at the plasma membrane due to the aggregation of HIV Gag 
proteins, there is a decrease in the observed fluorescence lifetime due to homo-FRET between CFP 
fluorophores within VLPs. 
Ordinarily, for a hetero-FRET experiment, the emission spectrum of the donor and the absorption spectrum 
of the acceptor typically have a much greater spectral overlap than the emission spectra of the acceptor and 
the absorption spectra of the donor. This results in the situation where the forward energy transfer rate (i.e. 
from donor to acceptor) is much greater than the reverse energy transfer rate (i.e. from acceptor to donor). 
However, in the situation where the Stokes shift is less than the width of the fluorescence spectrum — the 
case for many fluorescent proteins — energy can be exchanged between like fluorophores until emission of a 
photon; this is termed homo-FRET [187] or energy migration FRET (EM-FRET) [68, 188]. Homo-FRET is 
normally not detected when making fluorescence lifetime measurements as changes in the forward rate are 
matched by equal and opposite changes in the reverse rate when the two fluorophores are identical. 
However, it has been shown that the fluorescence lifetime of CFP is affected by homo-FRET [17, 68]. It has 
been postulated that the reason for the observed decrease in lifetime of aggregating CFP fluorophores is due 
to the complex CFP fluorescence decay profile corresponding to multiple excited states, one of which has a 
faster decay time but is not efficiently populated by laser excitation, although it may be efficiently populated 
by homo-FRET energy transfer [68]. 
 
 
Figure 4.17: (a) FLIM image of FOV containing HeLa cells transfected with Myr(-)Gag-CFP; (b) FLIM 
image of FOV containing cells transfected with Gag-CFP; (c) composite fluorescence lifetime histograms 
(from all pixels above the set intensity threshold, from all four FOV, across all repeat wells) for each 
plasmid preparation in the control plate (see plate map in Figure 4.16). 
Figure 4.17 (c) presents the composite histograms of CFP lifetime for each of the sets of repeat wells (i.e. for 
all pixels across all FOVs and repeat wells from each of the biological preparations). The composite 
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histograms display the expected lifetime shifts with the Myr(-)Gag-CFP cells presenting the longest lifetime 
and the cells expressing Gag-CFP + Gag-YFP presenting the shortest lifetime. When the Myr(-)Gag-CFP is 
co-expressed with Myr(-)Gag-YFP there is a small shift to shorter lifetimes due to the dimerisation of the Gag 
proteins in the cytoplasm. 
As discussed, the Gag-CFP cells display a shorter fluorescence lifetime to the cells expressing Myr(-)Gag-CFP 
due to the effects of homo-FRET between the CFP donor fluorophores. The observed lifetime shift between 
the non-aggregating Myr(-)Gag-CFP expressing cells and the aggregating Gag-CFP expressing cells is of the 
order of 325 ps, substantially more than the ~150 ps shift seen in previous studies of the effects of homo-
FRET on the lifetime of CFP [17]. It is possible that the reason for the larger than expected shift is a result of 
homo-FRET with multiple FRET acceptors present within the VLPs. 
The formation of VLPs at the cell membrane typically involves ~5000 Gag proteins organising into a 
spherical virion ~145 nm in diameter [189]. The Gag proteins within HIV-1, both in immature virions and 
VLPs, form a single, continuous but incomplete hexameric lattice with a spacing of 8 nm [190]. Based on 
this, it is possible to generate an estimate on the upper limit on the distances between the fluorescent protein 
tags by applying trigonometry as shown in Figure 4.18 (a). Taking the red circle in Figure 4.18 (b) as the 
centre and measuring distances from the centre of one fluorophore to the centre of another, this results in 
three fluorescent proteins being at most 8 nm away (orange circles, Figure 4.18 (b)), six fluorescent proteins 
being at most 13.8 nm away (green circles, Figure 4.18 (b)) and three fluorescent proteins being at most 
16 nm away (blue circles, Figure 4.18 (b)). Therefore, each fluorescently labelled Gag protein can be thought 
to FRET with at least three other fluorescent proteins.  
 
Figure 4.18: Arrangement of Gag protein lattice within VLPs 
8 nm
13.8 nm
16 nm
60 
8 nm
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It is interesting to compare these values with the theoretical calculation of the Förster radius (R0) as defined 
in equation 2-16 for different orientations of donors and acceptors (i.e. different κ2 values). This yields the 
following theoretical R0 values for CFP-CFP interactions and CFP-YFP interactions:  
 
κ2 CFP-CFP R0 (nm) CFP-YFP R0 (nm) 
0.66 3.31 5.07 
1 3.55 5.43 
4 4.47 6.84 
Table 4-1: Theoretical Förster radii for three different κ2 values (0.66 = randomly orientated; 1 = 
parallel alignment, side-by-side; 4 = collinear alignment) for CFP-CFP and CFP-YFP interactions. 
In situations where more than one acceptor is present there is an increase in the FRET efficiency, however, it 
has been shown that the increase is non-linear [191]. Instead of following a simple kinetic model of energy 
transfer, where the FRET efficiency for two acceptors is twice that of a single acceptor, Koushik et al 
showed that there is an ‗anomalous‘ amount of extra energy transfer [191]. It is not clear the exact reason for 
this extra amount of energy transfer, but it is clear that quantitative analysis of FRET experiments where 
more than one acceptor is present is considerably more complex than when a one to one stoichiometry is 
used, such as in the case of FRET biosensors. 
4.5.2.1. Application of image segmentation 
It is well known that HIV-1 Gag aggregates and forms VLPs on the plasma membrane when expressed in 
cells [110, 116, 192], findings which are in line with the images obtained here. Therefore it was investigated 
whether it would be possible to improve the available image contrast by selectively analysing just the regions 
where VLP formation is expected to occur.  
There are a number of different approaches possible when incorporating image segmentation in the analysis 
routine: segmenting whole cells allows the rejection of fluorescent cell debris created during the preparation 
of the plate, either through mechanical disruption (i.e. scraping the base of the well with a pipette tip) or 
biologically created debris (cells creating numerous VLPs and breaking apart). 
Organelle specific segmentation — in this case segmenting the plasma membrane — uses a priori 
knowledge, potentially derived from the acquired images, to select specific organelles to segment and 
analyse independently. Both of these segmentation approaches can be followed by either pixel-by-pixel 
decay analysis or by binning all the pixels from a segmented area together into a composite decay and fitting 
on a ―per-ROI‖ basis increasing the available signal to noise.  
The automatic image segmentation was performed using a routine developed in-house (MATLAB) that uses 
a size-tuned non-linear top-hat function [193]. This method transforms the image pixel by pixel, enhancing 
the brightness of a pixel if its close vicinity is also bright and its distant vicinity is dim. A user-defined 
threshold is then applied to the transformed image and the resultant binary image is smoothed using standard 
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MATLAB functions and spatially distinct regions are identified. These regions are then size-sieved to 
remove objects smaller than a user-defined threshold. To achieve segmentation of cell membranes, the cell 
segmentation masks are then eroded by a user-defined number of pixels (corresponding to the width of the 
cell membrane) and the difference between the two binary images provides a binary membrane mask to 
apply to the FLIM data prior to fitting. 
What follows is a comparison of these different segmentation and fitting methods to assess the relative 
merits of each. In all cases, the mean lifetime and standard deviation of each condition corresponds to the 
mean and standard deviation between wells (with each well containing 4 separate FOVs). 
 
Figure 4.19: Comparison of different image segmentation methods. (a) Application of simple intensity 
threshold vs application of cell segmentation algorithm to select whole cells; (b) whole cell segmentation 
fitted either pixel wise or by binning all pixels to a single decay for each cell; (c) binning all pixels to a 
single decay for either the whole cell, or just the cell plasma membrane; (d) a comparison of approaches 
outlined in (a-c).In all cases, error bars show the standard deviation between the eight repeat wells.  
Figure 4.19 illustrates the results obtained from different segmentation routines. Figure 4.19 (a) shows the 
comparison between applying just an intensity threshold and the application of the cell segmentation 
algorithm to select whole cells, where in each case a single exponential model was fitted on a pixel-wise 
basis. For the combinations of plasmid where we expect little to no FRET — Myr(-)Gag-CFP, Myr(-)Gag-CFP + 
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Myr(-)Gag-YFP — it can be seen that the two methods show very little difference. However, when the plasmid 
combinations that are expected to FRET (e.g. Gag-CFP + Gag-YFP) are compared, application of image 
segmentation results in slightly longer measured lifetimes. These differences arise due to inclusion of 
‗FRETing‘ cell debris when an intensity threshold is applied. The ‗FRETing‘ cell debris was due to the 
nature of this virus formation assay whereby the VLPs produced ‗bud‘ through the plasma membrane of the 
cells, eventually leading to the breakup of the cell itself and causing small particles of fluorescent cell 
membrane debris. This debris is formed of cellular plasma membrane with fluorescent HIV-1 Gag VLPs 
attached and therefore is bright and exhibits high levels of FRET. This cell debris is not included when 
image segmentation is applied as a size filter is used to remove particles below a certain size, leading to the 
larger shift in lifetime which is observed when the intensity threshold is applied.  
 
Figure 4.20: Example field of view from cells expressing Gag-CFP, either with (a) application of an 
intensity threshold; (b) application of image segmentation. The white box on both (a) and (b) indicates an 
example region which is selected for analysis when an intensity threshold is applied, but not selected when 
image segmentation is applied. Areas selected for fitting are shown in red. 
Figure 4.20 is an example FOV were cells were transfected with Gag-CFP and demonstrates the different 
regions that are selected when an intensity threshold is applied (part (a)) and when whole cell segmentation 
is applied (part (b)), where the regions highlighted in red are those that are included in the analysis. It can be 
seen that far less of the cell debris is selected when image segmentation is applied, as highlighted by 
comparing the two identical dashed areas in (a) and (b). Such FRETing cell debris will not occur within 
every assay, and can be considered a natural ―end-point‖ for a VLP/virion formation assay. The question of 
whether or not to include such debris within the analysis is then a matter for user to decide.  
Figure 4.19 (b) compares the results from applying the same cell segmentation algorithm to select whole 
cells, but fitting the results either pixel-wise or by binning to a single decay to obtain a single lifetime per 
ROI/cell. It can be seen that for all plasmid combinations, both fitting methods result in approximately the 
same average lifetimes and comparable standard deviations. The advantages of fitting on a per ROI basis are 
the increased speed of analysis and the increased signal to noise of each fit at the expense of sub cellular 
(lifetime) resolution.  
(a) (b)
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Figure 4.19 (c) shows the advantages of selecting just the plasma membrane as the ROI to fit and compares 
this against results obtained from whole cell segmentation, in both cases, fitting was carried out on a ―per-
ROI‖ basis as from Figure 4.19 (b) it was seen that little to no difference could be observed. It can be seen 
that membrane segmentation only has a noticeable effect for the constructs that are expected to aggregate, 
and hence FRET, at the plasma membrane of the cells, for which it increases the dynamic range of the assay.  
Finally Figure 4.19 (d) shows the comparison between all segmentation and fitting methods described. 
Application of the image segmentation routine to segment regions corresponding to cell plasma membranes 
resulted in the largest dynamic range, defined as the difference between the positive and negative control 
values (see table below). All differences were statistically significant at the p < 0.001 level. For this reason, 
and as the formation of VLPs is known to occur at the plasma membrane, it was decided that plasma 
membrane segmentation, as opposed to whole cell segmentation was the most useful form of segmentation to 
apply. It should also be noted that the use of an intensity threshold with no image segmentation provided 
greater contrast than segmenting whole cells, but less than segmenting just the plasma membrane regions.  
 Intensity Theshold Whole Cell Segmentation 
Plasma Membrane 
Segmentation 
Homo-FRET contrast 387  50 ps 352  60 ps 415  65 ps 
Hetero-FRET contrast 430  77 ps 397 87 ps 479  96 ps 
Table 4-2: Comparison of contrast generated from different segmentation methods. 
Figure 4.21 (a) shows an image segmentation mask generated by applying an automatic plasma membrane 
segmentation algorithm to the data to select regions where the VLPs are being formed and Figure 4.21 (b) 
shows the results, displayed in the form of box plots, of binning the time-resolved data for each of the (near 
membrane) ROIs independently and fitting each to a single exponential decay model. 
 
Figure 4.21: (a) Example of image segmentation algorithm selecting cell membrane regions; (b) box 
plots showing average lifetime ( SD) for each plasmid combination. 
Statistically different mean lifetimes are observed (significance level p < 0.05) for each of the plasmid 
combinations after application of an ANOVA test with multiple mean comparisons (Tukey‘s test) with the 
(a) (b)
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exception of Myr(-)Gag-CFP + Myr(-)Gag-YFP and Myr(-)Gag-CFP + Gag-YFP. As expected, the mean lifetime of 
wild-type Gag labelled with CFP decreases (by ~200 ps) due to FRET when co-expressed with the Gag-YFP 
acceptor construct compared to when it is expressed alone. The mean lifetime of the CFP attached to the Gag 
protein is itself lower than for the CFP attached to the mutated Myr(-)Gag, which does not form VLPs. The 
lower mean lifetime of the Gag-CFP can be attributed to homo-FRET between CFP fluorophores in the 
VLPs as well as to the different refractive index at the plasma membrane as previously discussed [17, 68].  
The mean lifetime of the Gag-CFP co-expressed with mutated acceptor protein (Myr(-)Gag-YFP) is again 
slightly lower than for the Gag-CFP only case. This is because, although the Myr(-)Gag-YFP does not 
contribute to VLPs at the plasma membrane by itself, it can still dimerise with the Gag-CFP protein in the 
cytoplasm and be ‗rescued‘ into VLPs, providing acceptors for hetero-FRET. Similarly, the mutated 
Myr(-)Gag-CFP does not form VLPs and so any FRET in these cells must arise from its dimerisation with 
Gag-YFP in the cytoplasm, with such dimers being brought into the VLPs. Finally, the cells expressing 
mutated Myr(-)Gag-CFP and Myr(-)Gag-YFP should not form VLPs but the mean CFP lifetime is slightly lower 
than for the cells expressing Myr(-)Gag-CFP alone due to FRET occurring when the Gag proteins form dimers 
or higher order multimers in the cytoplasm.  
4.5.3. Reproducibility of data 
The data presented in the previous section was taken from a single plate and demonstrates the application of 
the automatic FLIM plate reader to a plate containing control measurements. It is useful to know how 
reproducible the measurements are and therefore a second control plate was prepared. This plate was 
prepared with four different constructs (Myr(-)Gag-CFP, Myr(-)Gag-CFP + Myr(-)Gag-YFP, Gag-CFP and Gag-
CFP + Gag-YFP) plated vertically instead of horizontally, with details given in the figure caption.  
 
Figure 4.22: Comparison between two control plates. (a) Plate 1, as described previously (Section 4.5); 
(b) Plate 2, control plate containing HeLa cells transfected with Myr(-)Gag-CFP (column 4,) Myr(-)Gag-CFP + 
Myr(-)Gag-YFP (columns 6 & 7), Gag-CFP (columns 8 & 9) and Gag-CFP + Gag-YFP (columns 10 & 11). 
No cells were transfected in column 5. In both cases the colour scale runs from 2000 ps (blue) to 3200 ps 
(red). 
(b)(a)
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Comparison of the two plates in Figure 4.22 shows good agreement. Both Figure 4.22 (a) and (b) were fitted 
with a single exponential decay model with application of an intensity threshold to remove areas containing 
no cells. Figure 4.23 shows the average lifetime values (with the error bars being the standard deviation 
between repeat wells) for the four positive and negative control plasmids found for each plate.  
 
Figure 4.23: Comparison of the mean lifetimes ( standard deviation between repeat wells) per condition 
for the four positive and negative control plasmids. 
Slight differences can be seen between the average lifetimes of each plasmid when comparisons are made 
between plates. Application of a Student‘s t-test show that these differences are statistically significant at the 
0.05 level. It is notable that the standard deviation between repeat wells is smaller for plate 2. This is 
potentially due to plate 1 being one of the first plates prepared and therefore the protocol for preparing the 
plate was still being optimised. This also may account for the slight differences seen between plates.  
4.6. Conclusions 
This chapter has demonstrated the transfer of the HIV-1 Gag protein aggregation assay to a higher 
throughput context through the use of an automatic FLIM plate reader, providing for the first time an 
exemplar assay with which to investigate the merits of automatic FLIM-FRET measurements.  
A protocol was established and optimised enabling the transfection of HeLa cells within a 96 well plate. The 
protocol resulted in a sufficient transfection efficiency to allow for automatic imaging with transfected cells 
expressing the fluorescent HIV Gag proteins at levels that permitted the use of plastic bottom plates — with 
the average calculated signal to background ratio of the assay across four different plates found to be ~13:1 
— important for reducing costs and maintaining a healthy cell population.  
75 
 
The automatic FLIM plate reader was applied to a control plate containing rows of different plasmid 
preparations, each with 11 replicate wells (containing 4 field of view per well). The 248 fields of view were 
acquired in 46 minutes demonstrating the speed of the instrument, with TCSPC based measurements for a 
similar number of fields of view estimated to take over 12 hours (assuming 3 minutes integration time per 
FOV). This control plate was also used to investigate several ways of fitting the data and the effects of 
automatic image segmentation. Interestingly, applying the automatic image segmentation to select whole 
cells resulted in a reduction in the separation of positive and negative controls when compared to application 
of an intensity threshold. This was due to the inclusion of cell debris which demonstrated high levels of 
FRET being included in the intensity thresholded data, but not in the cell segmented data. Use of an image 
segementation routine that only selects plasma membrane regions provided the highest level of separation 
between positive and negative controls, but also resulted in slightly higher well to well variability. Next, a 
full characterisation of the assay using a known control compound is required. This is the subject of the next 
chapter.  
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Chapter 5: Disruption of HIV-1 Gag protein 
aggregation through use of an NMT inhibitor 
The previous chapter demonstrated the possibility of using an automated FLIM plate reader to achieve 
unsupervised imaging of samples and outlined the development of an exemplar assay which can be used to 
showcase the abilities of the imaging system. Within this chapter, this assay is developed further to allow the 
systematic disruption of the formation of VLPs through the use of an inhibitor of myristoylation. The assay 
is then fully characterised and dose response curves are generated by measuring the fluorescence lifetime of 
CFP donors. Topics include: 
 Introduction to N-myristoyltransferase (NMT) and NMT inhibitors 
 Characterising the HIV-1 Gag aggregation assay through use of a NMT inhibitor 
 Using the automatic, time-gated FLIM plate reader to generate dose response curves  
5.1. Myristoyl-CoA:protein N-myristoyltransferase and the myristoyl 
switch mechanism 
N-terminal protein myristoylation is ubiquitous within cells and refers to the process whereby a myristic acid 
moiety is irreversibly attached to the N-terminal glycine of a protein through the formation of an amide bond 
[194]. The process is catalysed by the myristoyl-CoA:protein N-myristoyltransferase and can result in a 
number of effects including promoting interactions with organelles or the plasma membrane and altering the 
affinity of protein-protein interactions [195].  
 
Figure 5.1: Schematic representation of the NMT catalytic cycle (adapted from [195]). 
Myristoylation of the HIV Gag protein is a vital step in production of progeny virions [196]. The Matrix 
(MA) region of Gag is responsible for membrane interactions through the myristoylated N-terminal domain. 
Current thinking is that the ability of MA to interact with the plasma membrane is determined by a myristoyl 
Binding of myristoyl CoA
induces conformational change
Binding of protein or 
peptide
Chemical 
transformation
Release of CoA
Release of 
myristoylated 
protein
N-myristoylatransferase
77 
 
switch mechanism [82-83], whereby monomers of Pr55Gag sequester the myristate, but upon aggregation the 
myristate moiety is forced out becoming exposed to the solvent. This results in an increase in hydrophobicity 
which drives the aggregated Gag molecules to the plasma membrane. This is supported by studies in which 
mutations that prevent myristoylation of the Gag protein have significant effects on virus assembly and 
release by stopping the association of Gag with the inner leaflet of the plasma membrane[196-197]. 
 
Figure 5.2: Matrix domain. (a) top view of MA. (b) side view of MA showing association with plasma 
membrane [198] 
After the formation of a budded and enveloped immature virion, the Gag is cleaved by protease and mature 
monomeric MA is released in the context of a mature virion. When this mature virion fuses with a host cell, 
the matrix monomers diffuse laterally through the lipid bilayer, and this reduced relative concentration of 
matrix causes the myristate to be re-sequestered, therefore allowing MA to disengage from the membrane 
and enter the cytoplasm. 
5.2. NMT Inhibitors 
Inhibitors of the NMT enzymes have been developed over the last decade to treat a number of diseases, most 
notably targeting several parasitic protozoa such as Trypanosoma brucei, commonly known as African 
sleeping sickness, and Plasmodium falciparum, the parasite which causes malaria [199]. These treatment 
routes concentrated on targeting species specific NMTs focusing primarily on modifications to the peptide 
binding pocket, which exhibits greater species diversity than the myristoyl-CoA site which is well conserved 
between species.  
In contrast, HIV uses the human host cell NMTs to add myristic acid to the Gag polyprotein as a pre-
requisite for virion (& VLP) formation at the plasma membrane. This poses the significant problem of 
having to inhibit an endogenous enzyme, which has obvious toxicity issues associated with it as 
approximately 150 human proteins are known to be myristoylated [200]. To date all mammals have been 
found to posses two isozymes of NMT, with each isozymes being highly conserved between species. For 
example, the human HsNMT1 and its mouse homologue share 97% sequence identity with a similar (96%) 
sequence similarity being seen between HsNMT2 and mouse NMT2 [201], suggesting that each NMT plays 
a specific role within mammals.  
78 
 
HsNMT1 and HsNMT2 share 77% sequence identity and as such, despite the potential issues of toxicity, 
several attempts have been made to exploit this sequence difference and investigate the possibility of 
selectively inhibiting one of these human NMT enzymes with the aim of disrupting the HIV lifecycle. 
However, the outcomes of these studies have been conflicting. Often these experiments investigated the 
relative affinities of Gag and Nef (an HIV accessory protein which also requires myristoylation to fulfil its 
function) proteins for each of the human NMT isozymes. Initially it was shown that Gag exclusively uses 
HsNMT2, whereas Nef uses both HsNMT1 and HsNMT2, with a preference for HsNMT1 [202]. A further 
study concluded that both Nef and Gag can bind to both isozymes, but that both isozymes show a higher 
affinity for Nef over Gag in vitro and in cell studies [203]. A subsequent study also showed how in cells, a 
reduction of the HsNMT1 isoform had negative implications for HIV assembly through the disruption of the 
Gag protein‘s ability to bind the membrane, but no such effects were seen for similar experiments which 
disrupted the HsNMT2 isoform [204]. Therefore, at the current time, it is not clear whether selective 
inhibition of a NMT isozyme will be a viable route for treatment of viral infections such as HIV. 
Nevertheless, preventing myristoylation of fluorescently labelled Gag proteins, such as those used in the 
previous chapter, should result in a decrease of FRET between donor and acceptors due to the reduction in 
the formation of VLPs. 
 
Figure 5.3: Chemical structure of NMT inhibitor DDD85646 
The NMT inhibitor used here (DD85646) acts on both human isozymes of NMT with similar efficacies, 
producing IC50s of 13.7  0.6 nM when acting on HsNMT1 and 14.4  0.8 nM when acting on HsNMT2 
[205]. As such it provides a useful method to perturb the aggregation of HIV Gag proteins through the 
prevention of myristoylation.  
5.3. Assay performance and assay characterisation 
Developing any assay, including those that are intended to be run as high content screens, requires assay 
validation to ensure signals are free from artefacts introduced in the process of preparing the samples, as well 
as possible edge and drift effects when imaging. In order to rule out these effects it is advisable to perform 
experiments which test the entirety of the assay protocol, from cell seeding through to the acquisition and 
analysis of data. It can be considered that there are two stages that need to be addressed; firstly, the 
optimisation of the signal to be measured relative to the background and minimisation of the variability in 
this signal from plate to plate; and secondly, the reproducibility of derived parameters (IC50, EC50, Ki etc.) 
from concentration dependent curves.  
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Section 5.3 outlines the first stage of this optimisation and validation process, which ensures that the signal is 
high enough and variability, both within a plate and from plate to plate, is low enough for the assay to 
produce useful data. The series of experiments involved a number of steps: 
 Testing the fluorescence of the compound DDD85646. 
 Ensuring that addition of the compound DDD85646 did not change the lifetime of the CFP 
fluorophore in any other way other than through a reduction in membrane binding. 
 Testing the variability of lifetimes across a plate to make sure that no bias was introduced during the 
preparation of the plates. 
 Testing the variability of lifetimes across multiple plates to check for day to day drift. 
5.3.1. Fluorescence of NMT inhibitor DDD85646 
Prior to any experiments, it is important to ensure that the compound itself is not fluorescent within the 
emission window of the assay (set by the emission filter 483/35 nm). Any intrinsic fluorescence from the 
compound needs to be properly accounted for and, if possible, minimised.  
To determine if the NMT inhibitor DDD85646 was fluorescent, a sample was excited at 430/5 nm using a 
spectrophotometer (Shimadzu, RF5301) and the fluorescence emission was detected over a 200 nm range 
from 450 to 650 nm. The NMT inhibitor was diluted to the maximum working concentration of 10 µM in 
PBS and the emission spectra was compared to the emission spectra of PBS measured under the same 
conditions, with the resulting spectra shown below in Figure 5.4. 
 
Figure 5.4: Emission spectra of PBS and 10 µM NMT inhibitor DD85646 
It can be seen that the emission spectra of PBS (Figure 5.4, purple) shows a flat profile around zero as 
expected. The 10 µM concentration of the NMT inhibitor shows a similar profile to that of the PBS, 
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oscillating around zero and demonstrating that the NMT inhibitor is not fluorescent when used under the 
proposed experimental conditions. 
5.3.2. Effects on the fluorescence lifetime of CFP upon addition of DDD85646  
As shown in the previous section, the NMT inhibitor DDD85646 is not intrinsically fluorescent when excited 
at the excitation wavelength of the CFP fluorophore (430 nm) and when used at experimental concentrations 
( < 10 µM). However, the addition of compounds to cells may still perturb the detected fluorescence signal, 
either by directly affecting the cellular environment (changing the local pH) or indirectly through inducing 
toxic effects within the cells which have been shown to effect the fluorescence lifetime of fluorescent 
proteins [206].  
To investigate whether adding the compound would perturb the lifetime of the CFP fluorophore by any other 
means than changing its ability to bind the plasma membrane, Myr(-)Gag-CFP was transfected into HeLa cells 
as described previously. Cells were incubated with three different concentrations of DDD85646 (10 µM , 
1µM and 0.1 µM columns 1-3 respectively) according to the protocol described later in this chapter (Section 
5.3.3.1). A final column (column 4) was used as a non-treated control. Myr(-)Gag-CFP was used as this 
plasmid possesses a mutation to prevent addition of the myristic acid moiety, and as such, addition of 
DDD85646 should have no effect on the Gag protein. Rather, any lifetime shifts measured would be due to 
the addition of the compound directly altering the lifetime of the CFP fluorophore itself. 
 
Figure 5.5: (a) Lifetime platemap of HeLa cells transfected with Myr(-)Gag-CFP and incubated with 
either 10 µM (column 1), 1 µM(column 2), 0.1 µM (column 3) or non-treated control (column 4); (b) Mean 
lifetimes ( Standard deviation between wells) for each column shown in (a) N.B. due to plotting on a semi-
log scale, the non-treated control is shown as a 1 x 10-4 µM dose, rather than 0. 
Inspection of Figure 5.5 shows that very little lifetime difference is seen between columns 1-4 (~32 ps). It 
can be noted that upon addition of high doses (10 µM ) a slight drop in lifetime can be seen. Application of 
an ANOVA test with subsequent multiple mean comparison (Tukey test) showed that no significant 
differences (at the p < 0.05 level) are seen between any doses, apart from when the 10 µM is compared to the 
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other doses. This slightly lower lifetime seen for the 10 µM dose of DDD85646 is indicative of possible 
cytotoxic effects where the compound is added at high concentrations, although no morphological changes 
were observed when the cells were viewed under bright field illumination. Therefore it was decided that 
doses over 10 µM should not be used to avoid perturbing the lifetime of the CFP fluorophore through 
inducing cytotoxic effects within the cells.  
5.3.3. Assay characterisation experiments 
The assay characterisation experiments were performed by producing three plates containing cells 
co-transfected with Gag-CFP and Gag-YFP which were made independently and imaged separately on 
different days to accurately replicate the situation of running a compound screen. These plates are prepared 
using a positive control compound (NMT inhibitor DDD85646 [205]), known to act on the target of interest, 
added column wise at three different concentrations —Low (~EC20), Medium (~EC25-EC75) and 
High(~EC80) — with the order of addition changing between the plates (e.g. Plate 1 has the compound 
added in the repeating pattern high, medium, low and plate 2 has the compound added in the repeating 
pattern low, high, medium etc).  
5.3.3.1. Plate Preparation 
HeLa cells were seeded and transfected (with Gag-CFP + Gag-YFP) according to the plating scheme shown 
below (Figure 5.6). A total of 6500 cells were seeded per well 24 hours prior to transfection in full growth 
media (DMEM (PAA) + 10% FCS +0.5% pen/strep) such that at the time of transfection cells were ~75% 
confluent at the centre of the well.  
 
Figure 5.6: Plating scheme for hetero-FRET assay characterization. HeLa cells were plated as shown, 
transfected with Gag-CFP + Gag-YFP and incubated with either 2 μM, 0.2 μM or 0.02 μM inhibitor. 
Transfections were performed according to the protocol described in section 4.4.3. The NMT inhibitor 
DDD85646 [205] was diluted in Optimem 1 from a 1.25 mM stock solution to 4 µM top working dose. This 
top dose was then serially diluted 1:10 to generate the medium and low doses required (with the further 1:2 
dilution resulting from the addition of the transfection mixes, see below).  
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Cells had the growth media removed and were washed in PBS (Gibco, PH 7.4), ensuring that all residual 
PBS was removed by using a single channel pipette on each well independently. Once this was achieved, 50 
µl of the inhibitor was added to each well, followed by 50 µl of the transfection mix, resulting in a further 
(1:2) dilution of the inhibitor. Washing and transfection was carried out on a per-condition basis i.e. cells 
found in columns that were designated to be medium and low dose were left in full growth media until the 
transfection of the high dose columns was completed. This avoids cells being exposed to the atmosphere for 
an unequal amount of time. 
The plate was then incubated at 37°C, 5% CO2 for 6 hours, at which point the transfection mixes and 
inhibitor were removed, the cells were washed (as described above) and 100 µl DMEM (Gibco) containing 
no FCS was added. The inhibitor was diluted into this DMEM as described above but at half the 
concentration, as there was no additional dilution step coming from the addition of the transfection mixes. 
Cells were then incubated at 37°C, 5% CO2 for a further 24 hours prior to fixing with 4% paraformaldehyde. 
Cells were washed (as described above) and 100 µl of 4 % paraformaldehyde was added to each well. Cells 
were incubated at room temperature for 15 minutes and then washed twice with PBS. The cells were then 
kept in 100 µl PBS (per well) for imaging. 
5.3.3.2. Assay characterisation parameters 
This section lists the definitions of parameters to be calculated when performing the assay characterisation 
experiments. There are a number of parameters to calculate for each of the plates that allow judgments to be 
made regarding the robustness of the assay and help to highlight problems in the assay protocol. These 
parameters are compared against acceptance criteria set out in the NIH assay guidance manual [207] to test 
the performance of the assay: 
 Mean (     : The arithmetic mean calculated across all repeat wells or by column or row for a each 
condition 
 Standard deviation (S): A measure of how much variability or dispersion occurs from the mean, 
calculated either between wells (column wise or row wise) or between a population of cells: 
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 Where n is the number of repeat wells and   is the sample mean.  
 Coefficient of variation (CV): A normalised, dimensionless measure of variation (which may also be 
referred to as the relative standard deviation when expressed as a percentage). The CV allows assays 
with differing read out values to be directly compared [208]: 
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 Coefficient of variation of the assay (CVassay): A similar quantity to the CV, but applied to the 
variation in the positive and negative controls of the assay rather than a particular condition [208]: 
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 Percentage activity: A measure of activity of the medium dose samples relative to the high and low 
dose: 
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 Signal Window (SW) and Z‘: Assay performance measures (APMs) that allow the calculation of a 
single number which defines the inherent performance of the assay based on the mean and standard 
deviations of the positive and negative control wells i.e. independent of the distribution of activities 
in the compound library: 
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Where (      and S are as defined previously and n refers to the number of repeat wells. Subscripts ‗high‘ and 
‗low‘ refer to the high and low dose of compound described in the previous section. It should also be noted 
that     
  quoted here is taken from the NIH assay guidance manual [207] which differs from the original 
publication by Zhang et al. [209]. The     
  described here uses the standard error of the mean, rather use of 
the standard deviation as published by Zhang et al. shown below: 
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Where           and            refer to the means of the positive and negative control wells respectively. For 
the purposes of the assay characterisation experiments performed in this section,     
  is used.  
Typically assay performance measures are used to both assess the potential for screening, and also act as a 
quality control (QC) test in production assays, with plates below a certain Z‘ or SW threshold being rejected. 
The cut-off points for determining the quality of the assay are, to a large extent, arbitrary. Ordinarily these 
values are reported as shown below [209]: 
SW Z’ 
Recommended >2 Excellent >0.5 
Acceptable >1 Acceptable 0<Z‘<0.5 
- Yes/No= 0 
 Unacceptable <1 Unacceptable <0 
 
Table 5-1: Accepted parameters for SW and Z' 
The SW and Z‘ are essentially measuring the same quantity; assay signal adjusted for assay variability. 
Therefore only one assay performance measure (SW or Z‘) need be applied for the duration of the assay, 
with the only requirement being that whichever one is picked is applied consistently. However Iversen et al 
have shown that use of the Z‘ factor provides a measure of assay performance which is less dependent on 
sample size [208], and as such it is the     
  factor that is used in this chapter. It should be noted that, 
although the     
  value is shown to be less dependent on sample size, there is still a direct correlation 
between the number of repeat wells used for the positive and negative controls and the confidence of the 
    
  calculation. Therefore, these values should be interpreted in the context of the particular assay in 
question, taking into account the number of repeat control wells. As an example Iversen et al. simulated a 
number of experiments with different maximum and minimum signals with a range of CVassay. They showed 
that for a low number of control wells on a plate the 95% confidence interval for a true Z‘ of 0.35 ranges 
from 0.02 to 0.71 (with a median of 0.4) and therefore recommended interpreting Z‘ values in relation to the 
number of control wells.  
5.3.3.3. Assay characterisation results  
The three replicate plates were imaged on three separate days (as stipulated in the NIH assay guidance 
manual) over a period of two weeks to mimic the day to day variation that would be seen in a screening 
assay. Data was obtained on the automatic IX81 FLIM microscope described previously in section 4.5.1. An 
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intensity threshold was applied to the data prior to fitting to remove signal from areas of the well containing 
no cells. The results from a single exponential fit, on a pixel-by-pixel basis, of the three characterisation 
plates are shown below. 
 
Figure 5.7: Plate variability and signal uniformity assessment. (a) & (b) plate map of mean well 
lifetimes (averaged over 4 FOV per well) from pixel-wise fitting to single exponential decay model and mean 
lifetimes plotted column-wise for each condition and row-wise for each condition for plate 1. (c) & (d) plate 
map and mean lifetime plots (column-wise and row-wise) for plate 2. (e) & (f) plate map and mean lifetime 
plots (column-wise and row-wise) for plate 3. White wells indicate that no cells were found by the auto find 
routine. Wells D6 and D7 were used for background and IRF. Error bars refer to standard deviations 
between repeat wells for each column or row. 
 
Inspection of the plate maps and plots indicates no systematic drift or edge effects are present, showing that 
both the protocol used to prepare the plates and the imaging system introduce no spatial bias with regards to 
position on the plate. Slight differences in the reported lifetimes per condition are observed between the three 
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plates for the high and medium doses of compound, but a consistent lifetime of around 2530 ps is seen for 
the low dose of the compound across all three plates. This indicates that the observed differences between 
the plates for the high and medium dose are most likely to be caused by pipetting errors made when 
manually preparing the plates, as any error in the initial dilution of the compound has far less effect at low 
concentrations. The assay protocol showed 30 ps variation across the three replicate plates for the low dose 
of inhibitor, enabling the running of dose response experiments over multiple days where the expected 
changes are of the order of hundreds of picoseconds.  
 
Figure 5.8: (a), (c) & (e) mean well lifetimes (averaged over 4 FOV per well) from pixel-wise fitting to 
single exponential decay model plotted per condition column-wise for plates 1, 2 and 3; (b), (d) & (f) mean 
well lifetimes (averaged over 4 FOV per well) from pixel-wise fitting to single exponential decay model 
plotted per condition row-wise for plates 1, 2 and 3. 
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Figure 5.8 illustrates the mean lifetimes per well plotted column-wise (a), (c) & (e) or row-wise (b), (d) & (f) 
for each dose condition. Plotting data in this way allows edge effects to be more easily noticed which 
manifest themselves as periodic structures within each condition. From the plots above, no noticeable 
periodic structures are seen with the exception of wells 1-8 and 72-80 in plate 2 (Figure 5.8 (c)). However, as 
this does not appear in either of the other plates, or in either of the other two dosing conditions on plate 2, 
this can be assumed to be an error introduced in the preparation of this particular plate. Overall, each plate 
shows reproducible lifetime results indicating little to no bias is introduced during the preparation or imaging 
of each plate. 
5.3.4. Plate to plate variability 
The final section of assay characterisation concerns itself with assessing the plate to plate variability, which 
is commonly large in high-throughput screens [210]. The same three plates used in section 5.3.3.3 were used 
here with comparisons being made between the average lifetime ( standard deviation) of each condition 
between the three plates. Figure 5.9 (a) illustrates the variability of each of the signals (high, medium and 
low doses) between plates. 
 
Figure 5.9: Plate variability and signal uniformity assessment. Plate variation between replicate plates 
described previously (section 5.3.3). Error bars represent the standard deviation between all repeat wells for 
a particular condition. 
The coefficient of variation of each signal (dose) is shown in Table 5-2. All CVs fall below 0.025, well 
below the acceptance criterion set out in the NIH assay guidance manual of a max CV for each signal of 0.2. 
Calculating the percentage activity of the medium dose relative to the high and low dose resulted in activity 
percentages of 73  9%, 75  9.6% and 76%  11.2% for plates 1, 2 and 3 respectively. This again compares 
well with acceptance criterion set out in the NIH assay guidance manual that the normalised medium dose 
signal should not vary by more than 15%. The Calculated Z‘ values for each plate were 0.75, 0.69, 0.65 all of 
which are above the recommended acceptance criterion of 0.4 [207].  
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 Mean  Standard Deviation (ps) Coefficient of Variation  
 High  Medium  Low  High  Medium  Low  
Plate 1  2892  21.18  2796  32.44  2532  37.87  0.007  0.012  0.015  
Plate 2  2935  33.23  2833  39.86  2522  53.12  0.011  0.014  0.021  
Plate 3  2964  31.66  2866  45.86  2552  63.65  0.011  0.016  0.025  
Table 5-2: Plate to plate variation for assay characterisation plates 
5.3.5. Assay characterisation summary 
Section 5.3 aims to characterise the HIV-1 Gag aggregation assay by following standardised guidelines set 
out by the NIH assay guidance manual. A summary of the calculated parameters, along with their 
recommended acceptance criteria is shown below: 
Parameter 
Acceptance 
Criterion 
Plate 1 Plate 2 Plate 3 
Z’ >0.4 0.75 0.69 0.65 
CVmax, CVmid, CVmin <20% 0.7%, 1.2% & 1.5% 1.1%, 1.4%, 2.1% 1.1%, 1.6%, 2.5% 
Normalised Smid <20% 9% 9.6% 11.2% 
Edge, drift, spatial 
effects 
None None None None 
Normalised mid-
signal 
< 15% change 
between plates 
73% 75% 76% 
Table 5-3: Summary of assay characterisation experiments showing the recommended acceptance 
criteria and the data from the three characterisation plates.  
It can be seen that the Gag aggregation assay developed here fulfils all the recommended criteria set out in 
the NIH assay guidance manual.  
5.4. Concentration dependent curves 
The previous section was concerned with confirming that the assay protocol was stable and introduces no 
variability. Once ‗hits‘ are identified by screening, the potential drug molecules undergo characterisation and 
modification through structure activity relationship (SAR) testing and concentration dependent curves are 
produced. From these curves it is possible to derive values such as the EC50, IC50 or Ki. Here the same 
inhibitor (DDD85646) is used to generate concentration dependent curves and to investigate the different 
analysis methods available when analyzing high content FLIM-FRET assay data, including application of 
image segmentation.  
5.4.1. How are the EC50/IC50 defined? 
Defining EC50 (or IC50) values is a fundamental part of pharmacology, referring to the concentration at which 
50% activation (or inhibition) is achieved. However, EC50 may refer to either absolute EC50 or relative EC50 
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depending on what this 50% value is measured relative to. This section aims to outline, in a practical sense, 
the different definitions and explain the differences between them.  
5.4.1.1. An ideal dose response curve 
The figure below shows the ideal case for a hypothetical dose response: 
 
Figure 5.10: An ideal dose response curve where purple points represent data and green points represent 
the control measurements. Here the positive and negative control measurements are shown at 2 and -4 on a 
log scale. This is for display purposes only. Typically these measurements are taken using a positive control 
for inhibition and vehicle only (i.e. no inhibitor) respectively.  
The purple points on Figure 5.10 represent the ‗data‘ (i.e. the dose response; measurements made on 
cells/purified proteins treated with varying concentrations of test compound).The green points are control 
measurements, with the point on left representing a blank measurement (a negative control measurement of 
inhibition) and the point on the right representing a positive control for inhibition. When fitting this curve 
there are three ways to treat such data and control measurements: 
 Fit just the data values and ignore the control measurements. 
 Average the control measurements to give single, fixed, value for the top and bottom plateau. 
 Include the control values in the fit, labelling them as ‗very high‘ and ‗very low‘ compound 
concentrations. 
In the ideal case above, these three methods will result in very similar outcomes as the dose response already 
contains top and bottom plateaus which are in line with the controls. In this case, the IC50 value is easily 
understandable as the value mid way between the top and bottom of the curve.  
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5.4.1.2. An ambiguous dose response curve 
There are situations, however, where defining the EC50 or IC50 values can be ambiguous. Below is the 
situation where an inhibitor does not reach 100% inhibition when measured relative to a known control.  
 
Figure 5.11: Defining the difference between relative and absolute IC50 values. An example of a partial 
inhibitor where the purple points represent the data and the green points represent the measured controls.  
This situation leads to two values that describe the curve, termed the absolute and relative IC50 (or EC50) 
values: 
 Absolute IC50 refers to the dose that induces a response half way between the absolute positive and 
negative control values.  
 Relative IC50 refers to the dose that induces a response halfway between the top and bottom plateaus 
of the fitted dose response function. 
It is the relative IC50 that is the most commonly reported as the absolute IC50 does not quantify the potency of 
the drug under investigation. As such, it is the relative IC50 that will be used throughout this thesis.  
5.4.1.3. Fitting dose response curves 
Typically dose response experiments are fitted with a four parameter logistic model: 
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Where A1 and A2 are the bottom and top asymptotes respectively, p is the Hill coefficient (slope of the curve) 
and Logx0 is the centre of the curve, such that: 
 
        
      5-9 
 
The Hill coefficient, p, allows a measure of co-operative binding. When the Hill slope is found to be equal to 
1, the system can be said to be following the law of mass action. If the Hill coefficient‘s is less than 1, it 
indicates that once a ligand has bound to its receptor or enzyme, that receptor/enzyme has a reduced affinity 
for other ligands. If the Hill coefficient is greater than 1 it indicates cooperative binding, whereby the binding 
of a ligand increases the affinity of the receptor/enzyme to bind other ligands. Fitting of dose responses was 
carried out in Origin 8.5 Pro using the four parameter logistic model as described above. 
5.4.1.4. Fixing parameters and comparing models 
It is often advisable to reduce models to their simplest form to avoid over parameterisation. Of course, this 
reduction in parameters needs to be weighted against the ability of the reduced parameter model to make 
accurate predictions. There are a number of methods used to assess the effects of fixing parameters in a 
particular model or comparing different models to fit the available data. 
One such method found within the Origin 8.5 Pro software used for fitting is to apply Akaike information 
criterion (AIC) which uses information theory to give a relative measure of the information lost when two 
different models are used to describe the data: 
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Where N is the number of data points, RSS is the residual sum of squares and K is the number of fitted 
parameters. AIC is based on Kullback-Leibler divergence (K-L) which is a non-symmetric measure of the 
difference between a real world probability distribution and a model distribution, telling us how much 
information is lost when the model distribution is used to summarise the real world distribution. Therefore, 
the smaller the AIC, the shorter the K-L distance and the closer the model is to the real world distribution.  
It is also possible to calculate Akaike‘s weight value, which is given by: 
 
92 
 
                 
         
            
 5-11 
 
Where ∆AIC is the difference in AIC values of the two models. The value of Akaike‘s weight can be 
interpreted as the probability that a given model is the correct one, allowing the quantification of how 
confident we can be in a given model relative to another model. 
5.4.2. Plate preparation 
HeLa cells were seeded and transfected following the protocol outlined previously (section 4.4.3). NMT 
inhibitor DDD85646 was added from 10μM (column 2) to 0.001μM (column 10), region A2 - D10 contained 
Gag-CFP transfected and treated cells (homo-FRET dose response) and region E2 - H10 contained Gag-CFP 
+ Gag-YFP transfected and treated cells (hetero-FRET dose reponse). Positive controls wells, containing the 
mutated forms of the HIV-1 Gag protein (Myr(-)Gag), were transfected in column 1. Wells A1 - D1 contained 
just Myr(-)Gag-CFP and wells E1 - H1 contained Myr(-)Gag-CFP + Myr(-)Gag-YFP, to account for the 
dimerisation of the Myr(-)Gag proteins within the cytoplasm. Column 11 contained HIV-1 Gag proteins treated 
with DMSO. Wells A11 - D11 contained Gag-CFP and wells E11 - H11 contained Gag-CFP + Gag-YFP. 
For plate map see Figure 5.12 (a). 
5.4.3. Acquisition settings. 
Acquisition settings were as described previously in section 4.5.1. 
5.4.4. Results for systematically disrupting the formation of HIV-1 VLP 
particles  
Figure 5.12 shows the result of applying a pixelwise single exponential fit. Figure 5.12 (b) is the lifetime 
platemap which reports the mean lifetime per well across the four repeat fields of view gathered within each 
well. Both the homo-FRET and hetero-FRET dose response display a gradient of lifetimes across the plate 
from left (high dose) to right (low dose). It can be seen from the lifetime platemap that the homo-FRET dose 
response (top half of plate) tends to a higher lifetime value than the hetero-FRET dose response (bottom half 
of the plate). This is expected due to the residual hetero- and homo-FRET that is expected to occur between 
Gag proteins in the cytoplasm, even at high inhibitor concentrations, with the residual hetero-FRET being 
more efficient than the homo-FRET and therefore resulting in lower fluorescence lifetimes observed within 
the positive control wells. As expected, the difference between the positive (column 1) and negative (column 
11) control wells for the hetero-FRET dose response show a larger separation (393 ps) than the 
corresponding control wells for the homo-FRET dose response (325 ps). This is due to the increased 
efficiency of energy transfer associated with hetero-FRET stemming from the larger overlap integral (J( )) 
as defined in section 2.7. It should be noted that no cells were found in wells F10, G10, E11 and F11, and far 
fewer cells than normal were found in wells G11 and H11, which may explain why the negative control 
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wells for the hetero-FRET dose response (rows E - H, column 11) show a higher average lifetime than wells 
treated with a very low dose of compound (rows E - H, column 9).  
 
 
Figure 5.12: (a) plating scheme for dose response. Top half of plate (purple) was used for the homo-
FRET assay and bottom half of the plate (green) was used for the hetero-FRET assay. Positive controls for 
both assays were plated in column 1 and negative controls for both assay were plated in column 11. The 
dose range spanned from 0.001 µM (column 10) up to 10 µM (column 2), as indicated; (b) fluorescence 
lifetime plate map showing the mean lifetime value per well when averaged over all pixels above the 
intensity threshold and across all four repeat FOV within each well, scale runs from 2000 ps (blue) to 
3000 ps (red); (c) Extracted dose response curves obtained from taking the average of the four repeat wells 
and standard deviation between repeat wells for each dose condition. Purple points represent data from the 
homo-FRET assay and green points represent data from the hetero-FRET assay. Data was fitted with a four 
parameter logistic model in Origin 8.5; (d) Same data as part (c) shown plotted as a percentage relative to 
the highest and lowest dosed wells. 
The calculated Z‘ values for this analysis were Z‘ = 0.62 for the homo-FRET assay and Z‘ = 0.45 for the 
hetero-FRET assay, although as already noted, the hetero-FRET negative control sample only contained two 
wells which resulted in a high standard deviation, and consequently, a decreases in the hetero-FRET Z‘. If 
instead the hetero-FRET data from column 9 is used as the negative control, then we obtain a Z‘ = 0.79, 
which should represent a lower limit on the true value. For quality control purposes, it is recommended that 
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Z‘ > 0.4 are used. This plate fulfils this quick QC check and therefore the dose response curves can be 
analysed. 
Figure 5.12 (c) shows the dose response plots for the homo- and hetero-FRET dose responses, generated by 
taking the average and standard deviation of the four repeat wells for each dosing condition. Data in (c) was 
fitted with a four parameter logistic model outlined in section 5.4.1.3. The IC50 value of DDD85646 was then 
found to be 46.1 nM (confidence interval 41.8 nM to 50.8 nM) and 28.3 nM (confidence interval 25.9 nM to 
30.8 nM) for the homo-FRET and hetero-FRET dose responses respectively. The fitted Hill-slopes were both 
close to 1(1.15 and 1.09 for the homo-FRET and hetero-FRET assays respectively). The effect of the drug 
action of the endogenous enzyme responsible for the addition of the myristic acid to the Gag protein should 
not be altered by use of a homo-FRET or hetero-FRET assay. Therefore it is interesting to note the difference 
in the returned IC50 values. The most probable reason for this discrepancy is the fitting programme‘s ability 
to define the lower plateau. From inspection of the graph in Figure 5.12 (c) it can be seen that the upper 
plateau is well defined with three data points, however the lower plateaus are less well defined leading to 
larger standard errors on the fitted parameters for the lower plateaus as shown below in Table 5-4. 
 Homo-FRET Hetero-FRET 
Upper plateau (ps  standard error) 2808.51  5.65 2715.96  6.61 
Lower plateau (ps  standard error) 2450.78  11.98 2170.59  17.54 
Table 5-4: Upper and lower fitted plateaus ( standard error on the fit) for homo- and hetero-FRET 
doses responses 
Figure 5.12 (d) shows the same data as in (c), normalised relative to the average values of the top and bottom 
doses, plotted as a percentage with the bottom and top plateaus fixed to 0 and 100%. Fitting data as 
percentage inhibition removes the vertical offset between the homo-FRET and hetero-FRET seen in Figure 
5.12 (c) and results in relative IC50 values of 39 nM and 35 nM respectively. These IC50 values are more 
similar to each other than was previously seen due to the fixing of the bottom and top plateaus at 0 and 100% 
respectively. 
The IC50 values derived from fitting to the four parameter logistic model are higher than those calculated by 
Gonclaves et al. using the same inhibitor [205] which were reported to be 13.7  0.6 nM when acting on 
NMT1 and 14.7  0.8 nM when acting on NMT2. This is to be expected as the experiments carried out here 
were performed in a cell based assay, rather than a biochemical assay and therefore the inhibitor must first be 
taken up by the cells, necessitating higher doses to achieve the same inhibitory effect.  
5.4.4.1. Four-parameter logistic vs. three-parameter logistic models 
The four parameter logistic model (4PL) is commonly used, however, it is possible to fix the value of the 
Hill coefficient (p), which turns the four parameter logistic model to a three parameter logistic model (3PL). 
It is then important to judge whether reducing the number of fitted parameters is justified. This is done 
through application of the AIC and calculation of Akaike‘s weights. 
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Figure 5.13: Comparison of 4 parameter logistic fit (Black) vs a 3 parameter logistic fit (red, p=1) for 
data shown in Figure 5.12. Error bars show standard deviation between the four repeat wells for each 
condition.  
Figure 5.13 shows the comparison of a three parameter and four parameter logistic fit to the data. Visually 
very little difference can be seen between the two models. Application of Akaike‘s information criterion 
resulted in the derived parameters shown in Table 5-5:  
 RSS N K AIC Akaike Weight 
4PL 1.84 9 4 15.71 0.011 
3PL 2.56 9 3 6.7 0.989 
Table 5-5: Use of AIC to compare four (4PL)- and three-parameter (3PL) logistic models. 
The 3PL model results in a lower AIC value, indicating that it is the better model (of the two tested) for the 
data. Use of the Akaike‘s weights shows that use of a 3PL model is around 90 times more likely to be correct 
relative to a 4PL model, therefore it is a 3PL model that will be used from now on. The use of a 3PL model 
resulted in slight lower IC50 values as shown below in Table 5-6.  
 Homo-FRET Hetero-FRET 
 
IC50 lower 
confidence 
limit 
IC50 
IC50 upper 
confidence 
limit 
IC50 lower 
confidence 
limit 
IC50 
IC50 upper 
confidence 
limit 
4PL IC50 41.8 nM 46.1 nM 50.8 nM 25.9 nM 28.3 nM 30.8 nM 
3PL IC50 38.6 nM 43.6 nM 49.3 nM 24.6 nM 26.9 nM 29.5 nM 
Table 5-6: Fitted IC50 values for homo- and hetero-FRET dose responses when a 4PL and 3PL fit are 
applied. 
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5.4.4.2. Application of image segmentation 
As in the previous chapter, it is possible to apply automatic image segmentation to regions of interest, in this 
case, regions corresponding to cell plasma membranes where VLPs are known to assemble. Membrane 
segmentation was applied to the dataset described above and all pixels from each cell membrane were binned 
together and fitted as a single decay such that a single average lifetime was reported per cell.  
 
Figure 5.14:  Comparison of dose response curves with and without the application of plasma membrane 
segmentation. Purple points show Gag-CFP with an intensity threshold applied. Green points show Gag-
CFP data with membrane segmentation applied. Orange points show Gag-CFP + Gag-YFP data with an 
intensity threshold applied. Blue points show Gag-CFP + Gag-YFP data with membrane segmentation 
applied. All data is shown with error bars representing the standard deviation between repeat wells and a 
corresponding three parameter logistic fit (red lines). 
Figure 5.14 illustrates the small differences seen between application of membrane segmentation and 
application of an intensity threshold. Membrane segmented data, both for the Gag-CFP only (homo-FRET) 
case and Gag-CFP + Gag-YFP (hetero-FRET) case, shows slightly lower lifetimes than the corresponding 
data with an intensity threshold applied for low doses of inhibitor. This is expected as for high doses of 
inhibitor, little Gag protein should bind the membrane. 
Application of membrane segmentation results in derived IC50 values of 31.6 and 25.6 nM for the homo-
FRET and hetero-FRET assays of respectively. It can be seen that the confidence limits of both the homo- 
and hetero-FRET assays overlap to a greater degree, which is expected as a change of acceptor fluorophore 
should not have any effect on the efficacy of the inhibitor 
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 Gag-CFP 
Gag-CFP + 
Gag-YFP 
 
 
 
Gag-CFP 
Membrane 
Segmented 
Gag-CFP + 
Gag-YFP 
Membrane 
Segmented 
Adjusted R2 0.994 0.998  0.992 0.985 
Lower plateau 
(A1) 
2437.3  12.5 ps 2149.7  13 ps  2408.9  15.7 ps 2111.4  32.8 ps 
Upper plateau 
(A2) 
2815  5.1 ps 2721.4  6.1 ps  2814.4  4.4 ps 2710.9  12.8 
Hill slope (p) 1 1  1 1 
IC50 upper 
confidence limit 
49.3 nM 29.5 nM  36.2 nM 31.3 nM 
IC50 43.6 nM 26.9 nM  31.6 nM 25.6 nM 
IC50 lower 
confidence limit 
38.63 nM 24.56 nM  27.6 nM 20.9 nM 
Table 5-7: Comparison of fitting parameters from data plotted in Figure 5.14. Errors refer to the 
standard error returned by the fitting software.  
5.5. Conclusions 
Chapter 5: described the implementation and characterisation of a cell based FLIM-FRET assay for HIV-1 
aggregation. The motivation behind this chapter was to develop an assay to a standard that is plausible for 
screening or drug development purposes in a pharmaceutical company and then demonstrate that the 
automatic FLIM-FRET plate reader is capable of providing sufficient contrast between treatments.  
To that end, an inhibitor of myristoylation in mammalian cells (DDD85646) was acquired from Dr. Edward 
Tate (Chemistry Department, Imperial College London). This inhibitor was then used to characterise the 
HIV-1 Gag aggregation assay, demonstrating that the standardised protocol used for the preparation of the 
plates and acquisition of the data introduced no spatial bias and resulted in robust, reproducible results within 
each plate and between multiple plates run over multiple days. 
In the final section, concentration dependent curves were generated, again demonstrating the system‘s ability 
to measure changes in the aggregation state of HIV-1 Gag proteins. Different dose response models were 
used to fit the data with small differences seen between a 4PL and 3PL model. Application of AIC showed 
that the 3PL model was more appropriate to the data. Use of the 3PL model resulted in IC50 values of 31.6 
and 25.6 nM for the homo-FRET and hetero-FRET assays of respectively. These values are ~2 times higher 
than those obtained by members of Edward Tate‘s lab [205]. These differences may be due to the effects of 
experiments being performed within cells which may require higher doses to achieve the same levels of 
inhibition as the inhibitor must pass through the cell membrane to bind to the NMT enzyme. 
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Chapter 6: Further development of HIV-1 
Gag aggregation assay. 
The previous two chapters have demonstrated the implementation of a high content FLIM-FRET cell based 
assay using an automatic plate reader developed in-house. This chapter concerns itself with investigating the 
potential to extend the assay further and focuses on four main areas: 
 Screening a number of different NMT inhibitors on a single plate. 
 Determining the best illumination method – Nipkow confocal or widefield illumination. 
 Optimising the ratio of donor to acceptor fluorophores for the hetero-FRET assay. 
 Extending the assay to use live cells. 
6.1. Using the automatic FLIM plate reader to test different NMT 
inhibitors 
The previous chapter showed how FLIM can be used to generate dose response curves by perturbing the 
aggregation of fluorescently labelled HIV-1 Gag proteins through use of a model inhibitor of the 
myristoyl-CoA:protein N-myristoyltransferase enzyme in mammalian cells. To demonstrate that time gated 
FLIM in an automatic plate reading microscope can be used to discriminate inhibitors of different potencies, 
the automatic FLIM plate reader was applied to image a plate containing three different modifications of the 
NMT inhibitor used previously and one compound with no known action on the NMT enzymes. These four 
inhibitors were a kind gift from the laboratory of Dr. Edward Tate, Imperial College London.  
As the homo-FRET dose response had consistently given higher Z‘ values, HeLa cells were transfected with 
Gag-CFP plasmid and doses of each inhibitor were applied following the standard protocol outlined in the 
previous chapter (section 5.4.2). A total of nine different doses of each inhibitor were added, allowing two 
repeat wells per condition. Myr(-)Gag-CFP was used as a positive control (column 1) and vehicle only dosed 
Gag-CFP was used as a negative control (column 11). A total of eight fields of view were acquired per well. 
Data was fitted with a single exponential decay model on a pixel-by-pixel basis and the fluorescence lifetime 
plate map showing the average lifetime per well (over all pixels above the intensity threshold across the eight 
fields of view) is shown below in Figure 6.1 (a). As expected, three of the inhibitors show an inhibitory 
effect (ICL13, ICL15 & ICL16) when incubated with cells expressing Gag-CFP. One inhibitor (ICL14) 
shows no effect at any dose tested. The Z‘ calculated for this plate was 0.51, in line with previous plates 
measured. 
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Figure 6.1: Testing different NMT inhibitors. (a) Fluorescence lifetime plate map showing average 
lifetime per well when averaged over 8 repeat FOVs. Column 1 contains HeLa cells transfected with 
Myr(-)Gag-CFP as a positive control for inhibition. Column 11 contains vehicle only Gag-CFP transfected 
HeLa cells as a negative control for inhibition. Dashed coloured squares indicate the four different 
inhibitors used from high dose column 2 to low dose column 10, scale runs from 2200 ps (blue) to 3100 ps 
(red). (b) Plots of percentage inhibition for each inhibitor relative to the average 10 μM dose of ICL13, 15 
and 16 and the and negative control column (column11). Points in black at 2 and -4 on the horizontal axis 
are the positive and negative control points respectively. Error bars refer to the standard deviation between 
the 16 repeat FOVs.  
Figure 6.1 (b) shows the data from (a) plotted as the percentage inhibition relative to the negative controls 
and the top (10 µM) dose. Ordinarily, the data would be plotted relative to the positive and negative controls, 
however inspection of the positive control data (column 1) showed relatively large heterogeneity between 
wells and showed lifetimes lower than those seen in wells dosed with high amounts of inhibitor. Ideally, this 
plate would have been reproduced and the heterogeneity that was observed between the positive control 
wells eliminated. However, due to time constraints this was not possible and therefore it was decided that use 
of the average lifetime value from wells dosed with the highest (10 µM) dose for compounds ICL13, 15 and 
16 would be used instead. The values obtained for the positive and negative controls are shown on Figure 6.1 
(b) as the points in black at 100 µM and 0.1 nM and the data were plotted as the mean and standard deviation 
between the 16 repeat fields of view rather than between the repeat wells as was done previously due to the 
fact that there were only two repeat wells per condition 
ICL13, ICL15 and ICL16 were fitted with a 3PL fit (i.e. fixed hill slope of 1, see section 5.4). The top and 
bottom plateaus were globally fitted across the three data sets. This was done to allow direct comparisons 
between the three inhibitors, which should all tend to the same values for the top and bottom plateaus, 
indicating maximum and minimum efficacy of the compound. The returned IC50 values for the three curves 
were then: 48 nM (confidence interval: 41 – 56 nM), 41 nM (confidence interval 34 – 50 nM) and 117 nM 
(confidence interval: 95 – 144 nM) for ICL13, ICL15 and ICL16 respectively. This highlights the FLIM 
plate reader‘s ability to discriminate the potency of different compounds which act on the same target of 
interest. Although only a small study, it is the first such screen using fluorescent lifetime technology in an 
automated high content context to generate multiple dose response curves and provides evidence that FLIM 
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can be applied to screen for and/or characterise useful therapeutic compounds as well as aiding in basic 
research. 
6.1.1. Varying the number of FOVs  
During data acquisition of the small inhibitor screen outlined above, 8 FOVs were taken per well, which 
were averaged to give a single lifetime value per well. However, the more FOV that are acquired per well, 
the longer the total acquisition time for the plate. Here, the effect of using different numbers of FOV per well 
was investigated in an attempt to ascertain the minimum number of FOVs that need to be acquired, whilst 
maintaining the robust nature of the data as measured through the Z‘ parameter.  
The data were fitted as described previously in section 6.1 with a single exponential decay model on a pixel-
by-pixel basis, with the difference that not all the data was used in every fit, i.e. different numbers of FOV 
were used, ranging from 1 to 8. The pre-find routine found 8 FOV for 74 of the 88 wells used in the plate. 
For the remaining 14 wells, the routine found less than the desired 8 FOV. This led to the situation where, for 
example, the effects of having 7 FOV per well were being investigated, but only 5 FOV for a particular well 
were available. Where this was the case, the maximum available number of FOV were used, i.e. in the 
situation described above, for the well with only 5 FOV per well, all 5 would be used in the case of 
investigating 7 FOV per well, and the same 5 FOV were used for the case of investigating 6 FOV per well.  
The fluorescence lifetime plate maps showing the average lifetime per well (over all pixels above the 
intensity threshold across the repeat fields of view) is shown below in Figure 6.2. Here, a selection of plate 
maps is shown corresponding to 1, 2 and 7 FOV being used per well for parts (a), (b) and (c) respectively. 
Visual inspection of these plate maps shows how the variability between wells increases as the number of 
FOV is decreased, comparing Figure 6.2 (a) and (c). Figure 6.2 (d) quantifies this change through calculation 
of the Z‘ parameter in each case (blue line). 
It can be seen that as the number of FOV used per well increases the calculated Z‘ increases until a plateau is 
reached around a Z‘ value of ~0.5. This plateau is probably due to the point at which biological variability 
between cells becomes dominant over shot noise and corresponds to using around 4-5 FOV per well, with 
little benefit gained by using more FOV per well. This result identifies that the use of 4 FOV per well is 
sufficient to maintain robust data. The limit on the achievable Z‘ may be increased only by modifying the 
assay itself, for example by improving the assay protocol even further to produce a more homogenous 
population of cells. It should also be noted that the value of the calculated Z‘ in the case of this plate is 
slightly lower than those of previous plates due to the heterogeneity of the positive control wells.  
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Figure 6.2: Fluorescence lifetime plate maps for the NMT inhibitor screen of HeLa cells transfected 
with Myr(-)Gag-CFP (Column 1) and Gag-CFP (columns 2-11) obtained from a single exponential fit for (a) 1 
FOV per well; (b) 2 FOV per well & (c) 7 FOV per well; (d) the effects observed when different numbers of 
FOV were used when processing the data. The purple points indicate the Myr(-)Gag-CFP positive controls 
(column 1 in (a), (b) & (c)), the green points indicate the Gag-CFP negative controls (column 11 in (a), (b) 
& (c)) with the values being shown on the left hand (purple) axis and the error bars displaying the standard 
deviation between repeat wells. The blue points indicate the calculated Z’ values for each plate, with the 
values shown on the right hand (blue) axis. 
6.2. Comparison of wide-field and Nipkow disk optically sectioned 
imaging 
The same plate was imaged using widefield illumination by removing the Nipkow disk unit and directing the 
light through a rotating diffuser wheel into the back port of the microscope in a Köhler geometry. The 
removal of the Nipkow disk unit removes the optical sectioning ability of the microscope and therefore 
fluorescence from out of focus planes is collected along with the light from the focal plane. Ultimately 
however, the test for which illumination geometry is preferable for the assay is the resultant contrast and 
reproducibility of results. While the contrast for optically sectioned images is expected to be higher, due to 
the reduction in out of focus light; this may be balanced by the reduction in detected signal. 
The total time to image both plates was the same (17.7 seconds per field of view). This was due to the 
necessity of overfilling the back port of the microscope when in widefield mode to obtain a uniform 
illumination at the focal plane, which by chance, led to the integration times for both widefield and sectioned 
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imaging to be equal. Therefore there was not the expected gain in imaging speed achieved from using 
widefield illumination. 
To minimise variability introduced by the user, the same plate was imaged with and without the Nipkow 
disk. In each case, the power was measured out of the objective using a power meter (Newport) and adjusted 
so the incident power was the same in each case (0.75 mW). Nipkow disk illumination was used first and 
eight FOV were pre-found and saved. These eight FOVs were then imaged with each illumination set up and 
the data was fitted to a single exponential decay model to provide the effective lifetime per pixel.  
 
Figure 6.3: NMT inhibitor screen performed with (a) widefield illumination and (b) Nipkow disk based 
optical sectioning. 
Figure 6.3 displays the resultant average lifetime per well across all pixels above an intensity threshold, 
averaged over the 8 repeat FOVs for using the widefield illumination (part (a)) and using the Nipkow disk 
illumination (part (b)). Very little difference can be observed between the two illumination methods, with the 
same trends in lifetime observed. The positive control column (column 1), which showed longer lifetimes 
towards the bottom of the column appears to be slightly more uniform when imaged with widefield 
illumination. This may be due to slightly different FOV being imaged as the plate was removed from the 
stage in between switching illumination methods. The widefield Z‘ value is consequently slightly higher than 
the sectioned Z‘ (0.62 vs 0.51). 
As outlined previously, data can be plotted relative to either the positive and negative control values or 
relative to high and low dose of inhibitor. Here, as previously, data is plotted relative to the negative control 
and the 10µM dose due to decreasing lifetime seen in the positive control column (column 1) when imaged 
with a Nipkow disk. The results are shown below.  
(a) (b)
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Figure 6.4: Dose response curves showing the differences observed between widefield illumination 
(green) and Nipkow disk based illumination (purple) for four NMT inhibitors; (a) ICL13; (b)ICL14; 
(c)ICL15; (d) ICL16.Error bars refer to the standard deviation between repeat wells. 
Figure 6.4 shows the data displayed in Figure 6.3 plotted relative to the highest dose (10 µM) and the 
negative control column (column 11). Data was fitted with a three parameter logistic model where the hill 
slope was set to 1. Little difference can be seen between widefield and optically sectioned data, with the 
obvious exception of ICL16 (part (d)) which displays a two-fold difference in calculated IC50 values. It is 
unclear why this one inhibitor showed such a large difference compared to the others. It must be noted that 
the bottom row of the plate contained far fewer cells than the top rows, and as such, not all eight FOV were 
acquired for rows G and H (ICL16 data), which may be the cause of this disparity. A table containing a 
comparison of the fitted IC50 values and their upper and lower confidence intervals is shown below: 
 ICL13 ICL15 ICL16 
 Upper IC50 IC50 Lower IC50 Upper IC50 IC50 Lower IC50 Upper IC50 IC50 Lower IC50 
Sectioned 57.7 nM 48.1 nM 40.4 nM 101 nM 75.3 nM 55.7 nM 109.1 nM 87.7 nM 70.4 nM 
Widefield 56.4 nM 46 nM 37.7 nM 85.3 nM 67.1 nM 52.8 nM 51 nM 45.8 nM 41.1 nM 
Table 6-1: Comparison of IC50 values and upper and lower confidence interval of IC50 values obtained 
when the same plate was imaged with and without the Nipkow disk. 
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It is also interesting to note that the use of sectioned FLIM produced slightly higher IC50 values than the use 
of widefield illumination, although when taking into account the confidence intervals of the fitted IC50 
values, ICL13 and ICL15 show little difference. The imaging time for the two illumination methods was also 
comparable, due to the necessity to overfill the back port of the microscope to achieve a uniform illumination 
at the focal plane, which removes a potential advantage of using widefield illumination.  
6.3. Investigating the use of different ratios of CFP to YFP 
The use of both Gag-CFP and Gag-YFP in a hetero-FRET readout leads to the potential for unequal 
expression of donor and acceptor within cells. The use of multiple acceptors for hetero-FRET readouts is 
now becoming increasingly popular, particularly in the design of biosensors [211]. Utilising multiple 
acceptors increases the amount of energy transfer as the excited donor can transfer energy to a number of 
surrounding acceptors at different orientations. Previously it was thought that this rate of energy transfer 
followed a kinetic formalism whereby an excited donor is able to transfer energy to multiple acceptors under 
the assumption that each donor-acceptor energy transfer is independent, in general following the form: 
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To test this generalisation, Koushik et al created a series of FRET standards based around a Cerulean 
(variant of CFP) donor and Venus (variant of YFP) acceptor, as well as use of an Amber fluorescent protein 
— Venus containing a single point mutation that prevents formation of the chromophore — as a control. 
These standards contained a single Cerulean donor and either two or three Venus/Amber acceptors. It was 
shown that providing an extra acceptor for FRET leads to more than twice the amount of FRET observed 
when using just a single acceptor, and was postulated that an extra energy transfer pathway must exist in the 
case of multiple acceptors [191].  
The HIV-1 Gag protein aggregation assay presented here raises the possibility of utilising multiple acceptors 
to increase the efficiency of energy transfer by increasing the ratio of acceptor to donor plasmid transfected 
into cells. The underlying assumption being that this change in ratio at transfection will lead to a change in 
the ratio of acceptors to donors expressed within cells, although it must be noted that unlike the work carried 
out by Kouishik and co-workers discussed above, the exact ratio of donor to acceptor expressed by each cell 
is unknown and the reported ratios refer to the relative amounts of Gag-CFP and Gag-YFP plasmids used 
during the transfection.  
To investigate the effect of multiple acceptors in the context of this particular assay, varying ratios of 
Gag-CFP donor and Gag-YFP acceptor were transfected into HeLa cells following the standard protocol 
outlined previously (section 4.4.3) whilst keeping the total amount of DNA per well constant. A total of 5 
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repeat wells for each donor acceptor ratio were prepared and a total of 8 fields of view were imaged per well. 
Data was fitted to a single exponential decay model to return the effective lifetime per well. As the ratio of 
acceptor to donor increases, the amount of available donor signal decreases since the total amount of DNA 
was kept constant. Therefore, to negate the effects of fitting artefacts introduced by low signal levels, the 
integration time of each condition was varied such that the peak gate approached the saturation point of the 
camera for each acquisition. This was a manual and inherently subjective process, and as such, the 
integration times presented here are only an indication of the increasing time required for imaging at 
different acceptor to donor ratios.  
 
Figure 6.5: (a) Fluorescence lifetime plate map showing the average fluorescence lifetime over 8 repeat 
FOVs per well for HeLa cells transfected with varying (1:1 to 1:7) ratios of Gag-CFP to Gag-YFP; (b) 
Mean lifetime ( SD between wells) of varying ratios of Gag-CFP to Gag-YFP taken from (a). 
Figure 6.5 shows the results obtained from varying the ratio of donor to acceptor at the time of transfection. 
It can be seen that increasing the amount of acceptor relative to the donor allows for reduction in the 
observed fluorescent lifetime of the Gag-CFP donor due to the presence of multiple acceptors. For all 
previous experiments a donor to acceptor ratio of 1:1 was used, however Figure 6.5 illustrates that it is 
possible to increase the lifetime change of the assay — by 110 ps in the example above — through the use of 
a higher acceptor to donor ratio. Altering the ratio of donor to acceptor beyond 1:4 does not provide any 
significant decrease in donor lifetime. With a view to minimising the integration required, a donor to 
acceptor ratio of between 1:2 and 1:3 would be the best compromise.  
It is interesting to note that the standard deviation between wells is much smaller for a 1:1 mixture of donor 
and acceptor than any other mixture. This is unexpected as, when there are high fractions of acceptor, each 
donor should be more likely to experience the same environment i.e. each donor should be completely 
surrounded by acceptors, therefore reducing the effect of a variable donor to acceptor stoichiometry. It is not 
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known why this is the case. The only difference between the preparations of each condition was that the 1:1 
preparation was made using a Gag-CFP + Gag-YFP DNA mix, whereas for the other preparations Gag-CFP 
and Gag-YFP DNA were mixed at the appropriate ratio, resulting in the need to pipette small quantities of 
DNA, particularly for the higher ratios of acceptor.  
6.4. Live Cell assay 
All previous work was carried out in fixed cells, which have advantages for running large screens as plates 
can be loaded into an automatic plate loading robot and run over the course of several hours or even 
overnight. However, the process of fixing cells causes cross linking of proteins and as such, may potentially 
perturb the fluorescence lifetimes measured. Therefore it is interesting to establish that the plate reader is 
able to perform live cell assays as well as assays in fixed cells. Moreover there is increasing interest from 
potential users of such systems, for example pharmaceutical companies, in the use of live cell assays and in 
vivo imaging [212]. Live cell assays also open up a raft of potential new measurements, enabling dynamic 
events to be monitored within cells. 
6.4.1. Important differences between fixed and live cell based assays 
To perform live cell measurements, a number of factors need to be addressed in order to prevent the 
introduction of artefacts into measurements. An environmental chamber (Solent Scientific) allowed the live 
cell assay to be conducted at 37° and buffered at 5% CO2, the same conditions used when culturing and 
transfecting the cells. The environmental chamber was allowed to equilibrate to 37°C for 24 hours prior to 
imaging to ensure that a stable temperature was achieved. Cells were placed into the environmental chamber 
30 minutes prior to measurements being made, to allow a stable temperature to be reached. Typically, once 
the cells were placed into the chamber, the time taken to set up the acquisition and perform the pre-find 
routine approximately accounted for this 30 minute wait. The plate was contained within a 5% CO2 enriched 
holder to minimise changes in PH, which can alter the fluorescence properties of fluorescent proteins [43]. 
6.4.1.1. Media used for live cell imaging 
The emission spectrum of several different preparations of DMEM were measured prior to imaging to 
identify which was most suitable as a live cell imaging solution. Ideally, a specialised, non-fluorescent 
imaging media can be prepared containing the necessary nutrients to maintain a healthy cell population 
during the course of the experiment, however, in this case, time constraints prevented this.  
Each sample was excited at 430/5 nm (the approximate excitation wavelength used for the imaging 
experiments) using a spectrophotometer (Shimadzu, RF5301) and the fluorescence emission was detected 
over a 250 nm range from 450 to 700 nm in 1nm steps.  
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Figure 6.6: (a) Fluorescence intensity of three different DMEM preparations and PBS control; (b) 
Zoomed in region of (a) corresponding to the emission filter used in imaging experiments (483/35 nm, blue 
box in (a)). 
Figure 6.6 (a) shows the spectra of three different preparations of DMEM along with a PBS control sample. 
All samples were background subtracted prior to analysis. DMEM preparations with and without phenol red 
were tested, the phenol red peak can clearly be seen (red dashed box) around 580 – 600 nm. This is 
sufficiently removed from the emission window of the imaging experiments (show as blue box) defined by 
the emission filter (483/35 nm). Figure 6.6 (b) shows the portion of part (a) corresponding to the emission 
window (465.5 - 500.5 nm). Surprisingly, the DMEM without FCS but with phenol red is the least 
fluorescent in the emission window, and therefore this media was chosen for imaging. Using this medium 
also simplifies the plate preparation protocol significantly as this is the same medium used to incubate the 
cells with the NMT inhibitors. Use of this medium as the imaging medium then saves an extra medium 
change and reduces use of the inhibitor.  
6.4.2. Background of live cell imaging media 
As the media used to image the cells during the live cell assay was different to that of the PBS used for the 
fixed cell assay, background measurements were again performed on the DMEM used for imaging. Analysis 
was carried out as previously described in section 4.4.5.  
Figure 6.7 (a) presents an example image of a well containing only the imaging media used for the live cell 
assay (DMEM), taken at the peak of the fluorescence decay. Figure 6.7 (a) represents the level of 
background fluorescence which was found to be 225 DN, higher than that of the plastic alone (see Figure 
4.10 (c)) as expected. Figure 6.7 (b) displays a FOV containing cells transfected with Myr(-)Gag-CFP. Region 
1 was used to measure the background signal, and was found to be 244 DN and region 2 was used to 
measure the signal from cells and was found to be 3133. These values give a S/B comparable to the fixed cell 
assay of ~14:1. 
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Figure 6.7: (a) Intensity image of well containing DMEM media used for live cell assay, yellow region 
indicates area of measurement; (b) intensity image of cells containing Myr(-)Gag-CFP from live cell assay 
plate. Region 1 indicates background measurement from plate and region 2 indicates measurement of cell 
intensity. In both parts (a) and (b) scale runs from 193 DN to 4095 DN.  
6.4.3. A Live cell, FLIM-FRET, VLP formation assay 
HeLa cells were transfected in the plating scheme shown in Figure 6.8 (a) with the homo-FRET (Gag-CFP 
only) dose response in the top half of the plate and the hetero-FRET dose response on the bottom half of the 
plate and Figure 6.8 (b) shows the corresponding fluorescence lifetime plate-map, with 8 FOVs acquired per 
well. As with the fixed cell assay described previously, the live cell assay shows longer lifetimes at higher 
NMT inhibitor concentrations. We also see an offset between the homo- and hetero-FRET positive control 
wells (column 1) due to the residual FRET between dimerising Gag proteins within the cytoplasm of cells.  
 
Figure 6.8: Live cell Gag aggregation assay within HeLa cells. (a) Plating scheme for dose response. 
The top half of plate (purple) was used for the homo-FRET assay (Gag-CFP) and the bottom half of the plate 
(green) was used for the hetero-FRET assay (Gag-CFP + Gag-YFP). Positive controls for both assays were 
plated in column 1 and negative controls for both assay were plated in column 11. The dose range spanned 
from 0.001 µM (column 10) up to 10 µM (column 2); (b) Fluorescence lifetime plate map showing the mean 
lifetime value per well when averaged over all pixels above the intensity threshold and across all 8 repeat 
FOV within each well. Scale runs from 1200 ps (blue) to 2200 ps (red). 
The fluorescence lifetime values measured for the live cell assay are considerably lower than those of the 
fixed cell assay. This is expected and is due to the temperature dependence of the CFP fluorescence lifetime, 
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which has been shown to vary by up to 50 ps per degree [43, 184]. This translates to an expected shift of 
~700 ps (assuming a lab temperature of 23°C) to lower lifetimes when compared to measurements made at 
room temperature using fixed cells. Comparing the positive control wells for the live cell assay above and 
the fixed cell assay run in the previous chapter (section 5.4.4), the decrease in lifetime due to the increased 
temperature at which the assay was performed were ~680 ps and 750 ps for the homo- and hetero-FRET 
assays respectively. 
The shift in fluorescence lifetime (i.e. the difference between the positive control average lifetime and the 
negative control average lifetime) seen for the homo-FRET live cell assay (~200 ps) is smaller than the 
corresponding lifetime shift seen for the homo-FRET assay run in fixed cells (~315 ps), whereas, in the 
hetero-FRET assay, the shift in fluorescence lifetime observed in live cells is larger than that seen in the 
corresponding fixed cell assay (530 ps vs 393 ps). It is unclear why this inconsistency is observed.  
The Z‘ values for the homo- and hetero-FRET assays were found to be 0.82 and 0.64 respectively, indicating 
good separation of positive and negative controls. These Z‘ values are higher than those obtained for the 
fixed cell assay, although only one live cell plate was measured. The higher Z‘ is potentially due to a number 
of factors. Firstly, it is unknown what effects fixing the cells will have on the measured fluorescence 
lifetimes. Performing fixation results in cross linking available proteins and thus could conceivably alter the 
measured lifetimes. Alternatively, as the cells were kept at a constant 37°C it is possible that this resulted in 
less lifetime heterogeneity than is observed when the cells were fixed and imaged at room temperature.  
As previously demonstrated, it is possible to fit concentration dependent data to dose response curves, with 
either three of four parameters. The average value per well was plotted against log [dose], with the error bars 
determined from the standard deviation between wells. Data was then fitted to a 3PL model (red) or 4PL 
(black), with the results shown below. 
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Figure 6.9: Live cell assay dose response fits from the data outlined in Figure 6.8. Purple data points 
represent the homo-FRET assay and green points represent the hetero-FRET assay, with 3PL fits shown in 
red and 4PL fits shown in black. Error bars show standard deviation between repeat wells. 
Visual inspection of the dose response curves shows there to be larger differences between a 3PL and 4PL fit 
when compared with the fixed cell assay. Comparing the two models, as shown in the previous chapter 
through use of the AIC value, showed that a 3PL fit was preferable but only marginally so (AIC values of 
18.2 vs. 21.7 for 3PL vs. 4PL) which translates to a 3PL model being approximately 5.8 times more likely to 
be correct when compared with a 4PL fit. 
6.4.3.1. Membrane segmentation of live cell assay data 
As previously demonstrated, the acquired lifetime data may be processed with the aid of automatic image 
segmentation to select organelles of interest. In the case of this assay the area most associated with viral 
assembly is the plasma membrane and therefore, plasma membrane segmentation was applied using the same 
algorithm discussed previously (section 4.5.2.1). Data was fitted to a single exponential decay model where 
all pixels from each cell membrane were binned together prior to fitting to give a single fluorescence decay 
per membrane and thus, a single lifetime value per cell. Analysis of the data in this way allows for the 
underlying variability in the cell population to be observed. Data was then plotted in the form of a histogram 
with a bin size of 5 ps from 1000 to 2400 ps (a total 280 bins) and a normal distribution model was overlaid 
onto the data.  
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Figure 6.10: Population histograms for (a) Homo-FRET and (b) Hetero-FRET assays. Each cell 
membrane was segmented and individually fitted to a single exponential decay model to result in a single 
fluorescence lifetime per cell membrane. The purple overlay indicates the approximate distribution of the 
negative control data from the homo-FRET assay in (a), an identical region is shown on (b), highlighting the 
effects of the unknown stoichiometry of the hetero-FRET assay.  
Inspection of the data in Figure 6.10 shows that the homo-FRET assay shown in (a) displays a tight 
distribution around the mean lifetime value for each condition. In comparison, the hetero-FRET distributions 
observed show significant broadening, leading to the stretched normal distribution profiles seen in (b). This 
stretching highlights the effects of the variable stoichiometry of the hetero-FRET assay. The identical purple 
overlay areas correspond to the approximate distribution of the negative control data from the homo-FRET 
assay in part (a). Use of this overlay in part (b) shows that, for the lowest inhibitor doses in the hetero-FRET 
assay, the data points that appear to be outliers correspond to the negative control data for Gag-CFP only 
transfected cells. This highlights the additional complications inherent within the hetero-FRET assay and 
shows how the use of just the Gag-CFP fluorophore allows for a cleaner interpretation of the data as well as 
simplifying the production of the plates and reducing reagent costs. 
6.5. Adapting a commercial plate reader to perform high speed FLIM-
FRET multiwell plate experiments 
All the work presented thus far has been performed on an Olympus IX81 microscope, customised to function 
as a plate reader. To further the case for using FLIM within the pharmaceutical industry, it is interesting to 
demonstrate that such technology works not only on standard inverted microscopes, but also within the 
context of commercially available plate readers.  
To this end, an InCell 1000 (GE Healthcare) was modified to perform high speed, automatic FLIM 
measurements [213]. This was achieved in the same manner as with the Olympus IX-81, through addition of 
a Nipkow disk unit (CSU-X1, Yokogawa) to provide optical sectioning and a GOI (HRI, Kentech 
Instruments) to enable time gating. As the InCell 1000 was already a plate reader, it came equipped with an 
automatic stage and optical autofocus unit, which were used and controlled by custom software, developed 
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in-house (Labview 7.1) with the acquisition software being developed by Dr. Sunil Kumar, Douglas Kelly 
and Dr. Clifford Talbot.  
To compare the two plate readers, two plates were produced following the protocol outlined in section 5.4.2. 
It was ensured that the same equipment (Nipkow Disk unit, GOI, filters, excitation source) was used on the 
two systems to perform both experiments and experiments were performed as described in section 4.5.1. The 
only exception was that the objective used on the InCell was a Nikon 0.7 NA 40x air objective and on the 
IX-81 an Olympus 0.6 NA 40x air objective was used. In both assays a total of 4 FOV were acquired per 
well and the exposure times for each assay were 1.1 s per gate for the InCell 1000 assay and 2.3 s per gate 
for the IX-81 plate reader assay. These exposure times were set by looking at a selection of FOV at the gate 
corresponding to the peak of the fluorescence decay and manually adjusting the integration time until, on 
average, a small fraction of pixels are saturating. It should be noted that this difference in exposure time is 
therefore probably due to differences in the sample as it was observed that cells over passage 35 appear 
significantly dimmer than those below passage 35. The passage number for the cells used in assay performed 
on the InCell (part (a)) was 27 whereas those cells used for the assay performed on the IX-81 plate reader 
were passage number 35.  
 
Figure 6.11: Fluorescence lifetime plate maps for the HIV-1 Gag aggregation assay showing the mean 
lifetime value per well when averaged over all pixels above the intensity threshold and across all four repeat 
FOV within each well for (a) Modified InCell 1000; (b) IX-81 Plate reading microscope. In both (a) and (b) 
4 FOV were acquired per well with the top half of each plate being used for the homo-FRET assay and 
bottom half of the plate being used for the hetero-FRET assay. Positive controls for both assays were plated 
in column 1 and negative controls for both assays were plated in column 11. The dose range spanned from 
0.001 µM (column 10) up to 10 µM (column 2), scale runs from 2200 ps (blue) to 3000 ps (red). 
Figure 6.11 shows the differences seen when the same assay was performed using the InCell 1000 (part (a)) 
or using the home built plate reading microscope (part (b), as described previously). The Z‘ values for the 
plate acquired on the InCell 1000 (part (a)) were found to be 0.58 and 0.32 for the homo-FRET and 
hetero-FRET assay respectively, compared to 0.62 and 0.45 for the homo-FRET and hetero-FRET assay 
performed on the home built plate reader. The slightly higher Z‘ for the home built plate reader indicates a 
slightly more robust assay; however the difference between the two plates is seen, not in the controls, but in 
the dose response data. It is clear from these plate maps that more variability is seen between wells when the 
(a) (b)
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InCell 1000 is used to acquire the data. This results in an increase in the standard deviations between wells 
and therefore a reduction in the certainty of the dose response fit.  
The source of this difference may stem from a number of difference areas. Firstly, the microscopes 
themselves are different and thus have different transmission efficiencies. However, even though the 
transmission efficiencies of each microscope body will differ, this can be ruled out as a source of the 
difference because the integration times were adjusted to achieve saturation on the peak gate for each plate. 
Therefore a comparable signal level was achieved for each plate, although there is a possibility that the 
longer integration times led to possible photobleaching of the CFP donor. Secondly, the autofocus units (and 
the autofocus software) differ between the two systems. The autofocus unit for the InCell is entirely 
controlled by the in-house acquisition software. It works through use of an IR laser diode which is focused 
through the objective onto the base of the plate. This results in two reflections, one from the plastic-air 
interface (the more intense of the reflections) and one from the plastic-sample interface. The software then 
decides which is the correct interface and adds a user defined offset to the focus position such that the focus 
is situated a constant distance above the plastic/sample interface. However, this in-house autofocus system 
appears less reliable in terms of finding the correct focus position than the ‗black box‘ Olympus version 
(ZDC). This may lead to the situation where varying amounts of plate fluorescence are being recorded in 
each FOV due to focusing at different points within the cells for the InCell case. If this is the case it would 
explain the increase in variability between wells, as the use of a time varying background to fit the data and 
account for the fluorescence decay arising from the plastic of the plate would not account for the varying 
fractions of this component from FOV to FOV.  
6.6. Conclusions 
This chapter has sought to extend the scope of the automated FLIM plate readers through the evaluation of 
the exemplar HIV-1 Gag aggregation FRET assay, investigating ways of extending and improving upon the 
original assay developed in previous chapters. It was shown that the FLIM plate reader can be applied to 
discriminate compounds of different potencies that act on the same target of interest and thus demonstrates 
the possibility of performing screening e.g. of small compound or siRNA libraries using such instruments. It 
was also shown that it is possible to perform the same assay in live cells utilising the environmental chamber 
of the microscope system. The extension of the Gag assay to live cells yielded data with higher Z‘ scores 
than the fixed version of the assay (0.82 vs ~0.62 and 0.64 vs ~0.45 for the homo- and hetero-FRET assays 
respectively).This improvement in the assay is evidence of the potential drawbacks of using fixed cells. This 
live cell assay also highlighted the advantages of using just a single fluorophore for this particular assay to 
negate the effects of unequal incorporation of plasmids as well as reducing the amounts of reagents used. An 
alternative approach to address this issue could be to clone both donor and acceptor into the same vector and 
thus ensure a more constant ratio of donors to acceptors. The optimum donor to acceptor ratio to use was 
also investigated and it was shown that expression of more acceptors leads to larger FRET shifts, increasing 
the available dynamic range of the assay, but at the cost of less donor signal and therefore longer integration 
times.  
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Comparison of the home built FLIM plate reader with the adapted InCell 1000 plate reader highlighted 
differences between the two plate readers in terms of the variability seen between wells. It was postulated 
that this may be a result of the different autofocus units, with the InCell 1000 being controlled by a home-
built autofocus unit that may lead to more variability due to different amounts of plate fluorescence being 
measured in each well. To investigate this further, it would be useful to perform Z stack measurements on 
both cells containing fluorescently labelled wild type and Myr(-)Gag proteins as well as on dye samples with 
known single exponential lifetimes to attempt to characterise the effects of variable incorporation of plate 
fluorescence and compare this to replicate experiments performed on the home built plate reader. 
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Chapter 7: Conclusions and outlook 
The focus of this thesis has been to investigate the potential of automated HCA FLIM technology for use in 
drug discovery by developing and evaluating an exemplar assay to demonstrate its capabilities and suitability 
for use within an industrial research environment.  
There is increasing interest, in particular from pharmaceutical companies, in identifying potentially new 
―difficult-to-screen‖ therapeutic drug targets, with around 60% currently thought to be cell surface associated 
[214]. Moreover, in excess of 50% of drug targets are thought to act on just four key gene families: class I 
GPCRs, nuclear gated ion channels , ligand-gated ion channels and voltage-gated ion channels, all of which 
are cell surface receptors, highlighting a clear disparity between the site of potential targets and the targets of 
currently available drug treatments. This is due, in part, to a lack of available methods which permit reliable 
screening of such ―difficult to screen‖ targets.  
The work contained within this thesis is designed to aid in the development of potentially novel drug targets 
by providing a method of monitoring changes in the fluorescence lifetime of a donor fluorophore 
participating in FRET. The use of FRET has become increasingly widespread, both in academic and 
commercial research settings, due to the ability of FRET to report on molecular interactions at nanometre 
length scales. It therefore provides a possible method of monitoring protein-protein interactions and 
unlocking a host of potential new drug targets allowing, for example, the probing cell signalling pathways  
During this thesis, fluorescence lifetime measurements were introduced as the most robust way to measure 
FRET within cell based assays, however, FLIM has yet to make a significant impact within pharmaceutical 
companies, in part, due to a lack FLIM platereader systems but also due to a lack of specifically designed 
cell based assays for use on such systems. Therefore, to address such problems, an assay was developed and 
characterised in a manner similar to that of assays currently in use within pharmaceutical companies which 
made use of a novel time-gated FLIM plate reader  
To achieve this required three key sections of work: firstly, chapter 4 discussed the optimisation of the 
plating, transfection and imaging parameters required to achieve a high level of signal to noise whilst 
maintaining viable cells; secondly, chapter 5 examined the use of an inhibitor to enable the generation of 
model dose response curves and finally, chapter 6 concerned the extension of the assay to explore the use of 
live cells, testing of other inhibitors, investigation of different illumination methods and optimisation of the 
donor to acceptor ratio. What follows is a final summary of the work undertaken within each chapter and the 
main results obtained followed by a discussion of the potential future directions the work may take. 
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7.1. An automated, time-gated FLIM microscope and its application to 
HIV-1 Gag interactions 
Chapter 4 described the automated FLIM plate reader, outlining the individual components that allow 
automatic, optically sectioned, time-gated FLIM images to be obtained, and then discussed the development 
of an exemplar FLIM-based assay optimised for use in microtiter plates. The automatic plate reader was 
based on an Olympus IX-81 frame with motorised dichroic cassette, objective turret and stage, as well as the 
Olympus ZDC focus drive unit which allowed automatic focusing. The motorised stage (Märzhauser Wetzlar 
GmbH, Scan Im) allowed for software controlled sample movement, enabling whole plates (96-well, 384-
well) to be imaged automatically, and a Nipkow spinning disk unit (Yokogawa, CSUX) allowed optically 
sectioned images to be acquired.  
To test the FLIM plate reader, a model assay based on the aggregation of HIV-1 Gag proteins was developed 
and optimised for use in microtiter plates. The variables of cell density, DNA concentration, DNA to lipid 
ratio and timings were all altered to achieve high transfection levels and the signal to background ratio of the 
plating protocol was tested indicating a typical signal to background ratio of ~ 13:1.  
The FLIM plate reader was tested on a plate containing various preparations of HIV-1 Gag proteins. 
Measurement of the fluorescence lifetime demonstrated that the different aggregation states of the HIV-1 
Gag proteins could be successfully distinguished from each other with a statistically significant difference in 
the fluorescence lifetimes of the donor-only and the donor + acceptor preparations. An interesting result from 
this plate was the difference observed in fluorescence lifetime between the aggregating (Gag-CFP) and non-
aggregating (Myr(-)Gag-CFP) donor-only preparations. This difference in fluorescence lifetime was attributed 
to homo-FRET between the CFP fluorophores, which exhibit complex multi-exponential fluorescence decay 
profiles [68]. A homo-FRET readout for monitoring the aggregation of HIV-1 Gag proteins can be more 
attractive than a traditional hetero-FRET readout due to the simplifications in preparing the plate and reduced 
costs — as less reagents need to be used — and the reduced variation in donor and acceptor expression.  
Chapter 4 discussed the application of different forms of image segmentation with the aim of improving the 
available image contrast. Three different image segmentation methods were used: firstly, an intensity 
threshold; secondly, a routine that selects whole cells and, finally, a routine that selects just the cell plasma 
membrane regions where the Gag proteins are known to aggregate. These image segmentation routines were 
combined with two different methods of fitting the resultant segmented images. Either by fitting 
pixel-by-pixel or by binning the pixels within each region to an individual (average) fluorescence decay 
profile and fitting to give a single fluorescence lifetime per region (per-ROI). It was demonstrated that 
membrane segmentation generated the highest degree of contrast (difference in fluorescence lifetime 
between the non-aggregating and aggregating proteins), with all methods producing statistically significant 
differences at the p=0.001 level (t-test).  
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Overall, the results presented in this chapter provided the basis on which to build a FLIM-FRET assay to 
monitor PPIs that is compatible with the automated FLIM plate reader.  
7.2. Development of a FRET based HIV-1 Gag aggregation assay 
Having established that it was possible to measure differences in fluorescence lifetime between aggregating 
and non-aggregating Gag proteins using the automatic FLIM plate reader, chapter 5 then discussed the full 
characterisation of the assay following NIH guidelines [207]. The aim of the work described in this chapter 
was to follow these guidelines to aid the development of an assay that would meet the standards expected by 
pharmaceutical companies, thereby validating the potential of using such technology to assay PPIs.  
To achieve this, an inhibitor of N-terminal myristoylation (acquired from Dr. Edward Tate, Imperial College 
London) was used. This inhibitor (DDD85646) targeted the endogenous NMT1 and NMT2 enzymes 
responsible for the co-translational addition of myristic acid to proteins and had been previously shown to 
work in vitro [205]. To establish that DDD85646 could serve as an inhibitor to characterise the FLIM assay, 
a number of checks were undertaken. First, it was demonstrated that the compound DDD85646 was not 
fluorescent at the wavelengths to be used during imaging, showing that when the excitation was tuned to 
430/5 nm and fluorescence emission was detected from 450 -650 nm, a 10 μM concentration solution of 
DDD85646 exhibited no more fluorescence emission than that of a sample of PBS. Second, it was shown 
that the DDD85646 did not alter the fluorescence lifetime of the CFP fluorophore by incubating varying 
concentrations of the compound with Myr(-)Gag-CFP, which cannot be myristoylated due to a mutation within 
the N-terminus. Finally, it was shown that the variability of the lifetime of ―dosed cells‖ between wells, 
across the plate and between replicate plates fell within the acceptable limits set out within the NIH 
guidelines [207]. To achieve this, three plates were prepared containing columns treated with either a high, 
medium or low dose of the compound, with the order of these columns altered between plates. Then, using 
the average lifetime value per well, the results from these plates were compared to the NIH guidelines and it 
was shown that there was no significant drift of lifetime values across each plate, either from top to bottom 
or left to right, and also that there was no significant drift from day to day. A statistical parameter was 
introduced, Z‘, which uses the relative variation and separation of the positive and negative control wells to 
provide a single value which describes the quality of the assay [209]. The three assay characterisation plates 
yielded Z‘ values greater than the acceptance criteria set out in the NIH guidelines.  
Once the stability of the assay had been established, the same compound was used to generate the first dose 
response curves ever to be read out using fluorescence lifetime (to the best of our knowledge). As it was 
shown in chapter 4 that it was possible to observe lifetime changes between highly aggregating CFP 
fluorophores as well as between CFP and YFP fluorophores, both hetero-FRET and homo-FRET versions of 
the assay were performed. Interestingly, calculation of the Z‘ parameter indicated that the homo-FRET assay 
(Z‘= 0.62) performed better than the hetero-FRET assay (Z‘ = 0.45). This higher Z‘ value was attributed to 
the unknown stoichiometry present within the hetero-FRET assay, whereby varying amounts of Gag-YFP 
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acceptors were expressed between cells leading to a larger spread in the observed lifetimes and hence a 
larger Z‘.  
Two different dose response models (3PL and 4PL) were fitted to the data to provide IC50 values for the 
inhibitor. It was shown through application of Akaike information criterion (AIC) that a 3PL model was 
more appropriate (AIC value of 6.7 compared to a AIC value of 15.71 for a 4PL fit) and application of the 
Akaike weights showed that the 3PL was approximately 90 times more likely to be correct than the 4PL 
model. The calculated IC50 values for the homo-FRET and hetero-FRET assays were found to be 31.6 and 
25.6 nM respectively, which is ~2 times higher than those obtained by members of Edward Tate‘s lab in 
biochemical solution phase measurements [205]. These differences are attributed to the effects of 
experiments here being performed within cells , which require higher doses to achieve the same levels of 
inhibition as the inhibitor must pass through the cell membrane to bind to the NMT enzyme.  
The development of this assay has provided a test case to showcase the use of high-speed, time gated FLIM 
technology within automated microscope systems. For the first time an assay has been developed specifically 
for use on such systems and has enabled the generation of the first dose response curves for which the 
readout is the fluorescence lifetime of the donor within a FRET system. This technology has many potential 
uses, both in industry, e.g. to perform screening of potential inhibitors of protein-protein interactions, and in 
basic research, e.g. enabling the evaluation of potential signalling networks through the use of siRNA 
knockdowns.  
7.3. Extension of the HIV-1 Gag aggregation assay 
Building on the work reported within chapter 5, chapter 6 described work carried out to extend the scope of 
the assay characterisation, including live cell imaging, ‗screening‘ of different NMT inhibitors and altering 
the ratio of donor to acceptor plasmids.  
7.3.1. NMT inhibitor screen 
The first series of experiments presented involved the use of a selection of NMT inhibitors of varying 
potencies in the format of a mock screen. In total, four compounds were used, three of which were known to 
have an inhibitory effect and one which was known to have no effect. The purpose of this was to investigate 
if the FLIM plate reader could discriminate different inhibitors of different potencies. As expected, three 
compounds showed an inhibitory effect, returning IC50 values of 48 nM, 41 nM and 117 nM for ICL13, 
ICL15 and ICL16 respectively, whereas ICL14 showed no effect.  
Data from this plate was also used to determine the minimum number of FOV required to be imaged per well 
by sub sampling the data prior to fitting. Eight different data sets were created containing either one to eight 
FOV per well that were then fitted in an identical manner. It was shown that, as the number of FOV used per 
well increased, the calculated Z‘ increased until approximately four FOV were used per well - which marked 
the beginning of a plateau of the calculated Z‘ value ~0.5. This plateau can be attributed to the point at which 
shot noise is no longer dominant and the variability seen is due to biological variability.  
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The same plate was also used to evaluate the performance of HCA FLIM using wide-field illumination and 
to then compare the relative merits of quasi-confocal and wide-field illumination configurations through 
comparison of the calculated Z‘ values. These were found to be 0.62 for wide-field illumination and 0.51 for 
Nipkow disk illumination. Comparison of the confidence intervals for the calculated IC50 values for wide-
field and Nipkow disk illumination were found to overlap for inhibitors ICL13 and ICL15 (with ICL14 
showing no inhibition with either illumination geometry), whereas ICL16 showed an approximately 2 fold 
change in the calculated IC50 value - from 45.8 nM when imaged wide-field to 87.7 nM when imaged using 
the Nipkow disk. The reason behind this discrepancy is not clear but may be due to the automated data 
acquisition identifying fewer suitable FOV for rows G and H (ICL16) than were for rows A – F. It was 
previously shown that the calculated Z‘ decreases with decreasing numbers of FOVs. The imaging of fewer 
FOV for these rows would lead to a larger degree of uncertainty in the fitted lifetimes and consequently, 
differences in the calculated IC50 values.  
7.3.2. Altering the donor to acceptor ratio 
For the hetero-FRET experiments reported throughout this thesis, the ratio of donor to acceptor used for the 
majority of experiments was fixed to 1:1, i.e. at the time of transfection, an equal amount of donor and 
acceptor plasmids were mixed prior to the transfection being performed. The reason for using a 1:1 ratio of 
donor to acceptor was purely to simplify the procedure. However, use of more than one acceptor for each 
donor unlocks the possibility of a greater efficiency of energy transfer [191]. It was therefore investigated 
whether increasing the ratio of acceptors to donors would allow for a greater separation of positive and 
negative controls. To achieve this, the total amount of DNA used was kept constant, as it has been shown 
that the number of Gag proteins incorporated into each VLP is directly related to the amount of Gag protein 
available (under the assumption that expression of Gag protein within cells is proportional to the 
concentration of the Gag plasmid used to transfect) [81]. For these experiments the ratio of donors to 
acceptors was changed from 1:1 to 1:7. When the average fluorescence lifetime over 5 repeat wells was 
calculated, it was demonstrated that the negative control lifetime could be decreased from ~2250 ps to 
~2140 ps through the use of more acceptors, with a minimum value for the lifetime being achieved at a 1:4 
donor to acceptor ratio. The alteration of the ratio of donors to acceptors (while keeping the total amount of 
DNA used constant) resulted in longer integration times as more acceptor (less donor and consequently, less 
signal per unit time) was used. A more optimal trade-off could be reached if this assay was to be 
implemented, with ~1:2 ratio of donors.  
7.3.3. Live cell Gag aggregation assay 
There is considerable interest in performing live cell assays and so it is useful to evaluate the potential of 
applying this FLIM Gag aggregation assay to live cells. All live cell measurements were performed at 37˚C 
with 5% CO2 and, as expected, produced lower fluorescence lifetimes than when experiments were 
performed at room temperature owing to the temperature dependence of the CFP donor fluorophore [43]. 
Interestingly, the use of live cells showed less well to well variability than using fixed cells at room 
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temperature (Z‘ = 0.82 .vs. Z‘= 0.62 for the homo-FRET assay and Z‘ = 0.64 vs. Z‘ = 0.45 for the 
hetero-FRET assay). This was possibly due to the use of the incubator chamber around the microscope, 
which may have provided a more consistent temperature, resulting in less heterogeneity between replicate 
wells. Alternatively, the different well to well variability may have also been a result of (unknown effects of) 
fixing samples on the fluorescence decay profiles of fluorescent proteins.  
Performing membrane segmentation allowed the visualisation of the population variability, providing an 
explanation of why the homo-FRET assay achieved higher Z‘ than the hetero-FRET assay. Here, cells were 
segmented to only select the cell membrane and all the pixels within each region were binned to a single 
fluorescence decay profile and fitted to a single exponential decay model to provide an average lifetime 
value per cell membrane. This data was plotted as histograms and showed the significant broadening of the 
population distribution when the assay was performed with both donor and acceptor fluorophores due to the 
unknown incorporation of donors and acceptors. This effect was shown by the purple area placed over Figure 
6.10 (a) and (b) which highlights those hetero-FRET cells that are most probably expressing a majority of 
Gag-CFP, leading to higher measured fluorescence lifetimes and, consequently, broadening the population 
distribution. Such effects could be eliminated by cloning both donor and acceptor into the same vector and 
potentially, using the information from section 6.3 to clone in two acceptors to maximise the efficiency of 
energy transfer. Alternatively, use of just the Gag-CFP plasmid was shown to provide a robust (homoFRET) 
readout of Gag VLP formation. 
7.3.4. Use of time-gated FLIM technology in a commercial plate reading 
microscope  
The final section of chapter 6 involved the comparison of the home built FLIM plate reader with a 
commercially available plate reader (InCell 1000, GE Healthcare) that was modified to perform time-gated 
FLIM measurements [213]. The calculated Z‘ values for the homo- and hetero-FRET assay were found to be 
0.58 and 0.32 respectively compared to 0.62 and 0.45 for the home built FLIM plate reader. This difference 
was postulated to be due to different autofocus units, resulting in a more heterogeneous incorporation of the 
background fluorescence from the plastic bottom of the plate in the data obtained from the modified InCell 
1000 instrument. To investigate this further, it is suggested that Z-stack measurements be made on a variety 
of samples including dye samples in solution, fluorescently labelled beads and cells expressing cytoplasmic 
fluorescent proteins to assess the reproducibility of both the autofocus systems over a number of plates.  
7.3.5. Future directions 
It is hoped that this body of work will stimulate further development of FLIM-FRET assays for the purposes 
of drug discovery. This sections aims to highlight some potential areas of future development using other 
novel technological advances. 
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7.3.5.1. 3D Cell culture 
Cells grown in 3D are able to mimic natural tissue and organs to a greater degree than traditional 2D cell 
cultures. Two dimensional cell cultures are grown on flat, rigid plastic surfaces which often lead to an 
unnatural spreading of the cells and the formation of attachments, or focal adhesions, which are potentially 
an artefact of 2D cell culture [215]. The use of 3D cell culture mediums, either using hydrogels or growing 
cells in cell spheroids to mimic tumour growth, are therefore a potentially valuable tool. Such 3D cell culture 
systems allow cells to form their full complement of cell-cell contacts within a 3D environment and have 
already been used within assays to demonstrate the different responses of 2D and 3D cell cultures to anti-
cancer drugs [216].Therefore, extending the development of FLIM based assays to encompass 3D cell 
cultures would potentially enable the identification of new targets of interest which would have be previously 
hidden by the artefacts of 2D cell culture. 
7.3.5.2. Advanced fluorescent labelling technology 
The development of genetically encoded fluorescent proteins as discussed in section 2.3.2 provided highly 
specific labelling of proteins and revolutionised the application of fluorescence microscopy. However, even 
with the continued development of new, improved variants of the original GFP, potential problems may still 
arise due to protein over expression. Expression of a fluorescently tagged version of the protein of interest 
yields a situation where the tagged and untagged proteins are in competition for the correct binding partner 
(assuming the protein of interest is endogenous to the cell line being used, which is not the case for the HIV-
1 Gag aggregation assay presented here.) New technologies that make use of artificially engineered 
nucleases enable genome editing in situ and have the potential to circumvent such issues. Techniques such as 
zinc finger nuclease technology (ZFN, which was recently commercialised by Sigma-Aldrich) or the use of 
TALENs allows the researcher to insert a gene of interest, for example a fluorescent reporter gene such as 
GFP, directly into the host cells genome, thereby tagging all endogenously translated proteins.  
The use of such technology is already highlighting differences in the dynamics and localisation of proteins 
when expressed at endogenous levels using ZFNs compared to previous studies where proteins were over 
expressed [217]. Such differences are of particular interest in the study of signalling pathways and therefore 
the incorporation of such technology into the development of future FLIM based assays may be potentially 
invaluable. Of course, the downside to such tagging methods is that as only the endogenous proteins are 
tagged, the available signal is reduced, and as such, the advantages of genome editing to cells must be 
weighed against the comparable loss in signal. Therefore, such technology may not be applicable to every 
biological system. 
7.3.6. Final remarks 
Overall, this thesis has been concerned with the development of a FLIM FRET assay and its implementation 
on a novel, automatic, high-speed, time-gated FLIM plate reader. This assay was developed to provide the 
first demonstration of a fully characterised FRET assay on an automated FLIM plate reading system, 
showcasing the potential of such systems for assaying protein-protein interactions for drug discovery and 
122 
 
basic research. Promising results have been presented with the assay shown to provide high Z‘ values — 
particularly for the homo-FRET assay — and robust shifts in fluorescence lifetime from positive to negative 
control wells. Thus the potential of automated fluorescence lifetime imaging systems to provide robust, 
reproducible data on time-scales that are compatible with HCA applications has been demonstrated. It is 
hoped that this work will stimulate further study and development of such systems within the pharmaceutical 
industry to tackle ―difficult-to-screen‖ therapeutic targets, particularly protein-protein interactions within 
cellular assays, thus leading to new potential drug targets.  
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